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Vertebrates are associated with trillions of bacteria, with the densest populations
residing in the large intestine. The symbiosis between vertebrates and their gut microbiota has resulted in important implications of the gut microbiome on host health.
Diet is an important factor that shapes gut microbiota composition, and because
of the interplay between host-microbiome-diet, dietary strategies that modulate gut
microbiome structure are deemed a relevant tool to improve host health. However,
gaps in knowledge exist with respect to these interactions, and it is essential to obtain
a mechanistic understanding of how these relations take place to develop successful
therapeutic strategies that target the gut microbiome.
In order to address these gaps, human trials were performed to assess the impact of
primary components of the human diet, resistant starches and whole grains, on the
gut microbiota. Overall, the impact of diet was temporal and varied across subjects.
Resistant starches substantially modulated the gut bacterial community of the subject population, especially increasing the abundance of Bifidobacterium adolescentis.
Ruminococcus bromii, Eubacterium rectale, and Parabacteroides distasonis were also
significantly enriched. Dietary incorporation of whole grains increased the proportions of Eubacterium rectale and acetogens such as Blautia wexlerae. Of note, whole
grains significantly improved inflammation and glycemic parameters. The shifts in
Eubacterium rectale correlated with glycemic improvements. Moreover, distinct abun-

dances of Dialister were determined among subjects that differed in terms of their
inflammatory improvement.
To gain mechanistic insight on the host-microbe-diet interplay, animal experiments
were conducted to evaluate the effects of grain sorghum lipids and plant sterol esters in the context of dyslipidemia. Significant and consistent alterations in gut
microbiota composition were detected in both experiments, especially involving shifts
in Coriobacteriaceae and Erysipelotrichaceae abundance, which displayed remarkable correlations to host cholesterol markers. Mathematical modeling of these associations revealed them to be inhibitory interactions, suggesting that changes in
host metabolism affected gut microbiome structure through an antimicrobial effect of
cholesterol, which was confirmed in vitro against selected gut microbes.
In conclusion, the studies presented in this dissertation allowed new insights on the
impact of diet on the gut microbiota and its consequences for health.
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Chapter 1
Introduction

2

1.1

Host-microbe symbiosis in the
gastrointestinal tract

The microbial community associated to the gastrointestinal tract1 (GIT) is characterized by a high population density, ample diversity and great complexity in terms
of interactions and dynamics. The gut microbiota (GM) is composed of a broad
repertoire of viruses, bacteria and to a lesser degree archea, fungi and yeasts2 , with
the bacterial cells in the GIT outnumbering our own cells by at least an order of
magnitude.
The relationship between vertebrates and their gut microbiota can be referred to as
a symbiosis. A symbiotic relationship is defined as a close and long-term association
among species (de Bary, 1879), and can potentially develop into mutually beneficial
interactions in which the members enhance their partner’s fitness. The mutualisitc
nature of the vertebrate/microbiome symbiosis is exemplified by the important role of
bacteria in their host’s biology. The gut microbiota contributes to nutrient provision
and energy storage, prevention of pathogen colonization (colonization resistance), and
the development of host physiology and immune functions (Gordon and Pesti, 1971,
Reddy et al., 1972, Savage, 1977).
The relevance of the GM in vertebrate biology is evidenced by the fact that several
species would not survive or would have impaired growth without a functional microbiome. For example, a herbivorous lifestyle based on fibrous plants would not
be possible as vertebrates do not possess the enzymes to digest cellulose and hemicellulose (Flint et al., 2008). Accordingly, some species, such as koalas and hamsters,
cannot even be reared germ-free (GF) (Stevens and Hume, 1998, Pollard, 1976).
1

For the purposes of this thesis, the main focus will reside on the small and large intestine
For the purpose of this thesis, the discussions will be centered upon the bacterial component
of the gut microbiota.
2

3
Even in vertebrates that do not have a strictly obligate relationship with the GM,
the important contributions of the microbiome in nutrient provision and resistance to
infections are still essential for the species’ success. The GM provides the host with
nutrients in the form of short-chain fatty acids (SCFAs) resulting from the fermentation of non-digested carbohydrates that are absorbed by the host. In the case of
herbivores (e.g.: ruminants), the bacterial contribution to the animal’s energy intake
is approximately 70%, and in omnivores such as humans is around 10% (Flint, 2011).
Acetate, propionate and butryrate are the principal SCFAs in the GIT, and have
different metabolic fates. Acetate and propionate are mainly taken up by the liver
where they undergo gluconeogenesis and lipogenesis (Turnbaugh et al., 2006), while
butyrate is the principal energy source of colonic epithelial cells (Louis et al., 2007).

1.2

Maintenance and control of microbial
populations in the gastrointestinal tract

Given the importance of the GM for vertebrate biology, the host must maintain and
control these bacterial populations to maximize the benefits of this symbiosis. The restricted enzymatic capability of humans to degrade complex carbohydrates allows for
non-digestible carbohydrates (NDC) to escape digestion and reach the large intestine
where they can be fermented by the resident bacteria (Flint et al., 2008). The GM
possesses a wide repertoire of enzymes to sense, capture and hydrolyze undigested
carbohydrates of diverse chemical structures (Martens et al., 2008), and it has been
estimated that approximately 10% of the bacterial microbiome encodes for enzymes
associated with the carbohydrate metabolism (Turnbaugh et al., 2009, Qin et al.,
2010), evidencing the importance of carbohydrate metabolic processes in the GIT. In
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addition, host-derived glycans represent a constant energy source for GIT bacteria
(Salyers et al., 1977). This nutrient rich environment provided by the host enables
the maintenance of the dense bacterial populations of the GIT.
In humans, the composition and density of the bacterial populations present in the
GIT are determined by the physicochemical characteristics of the different anatomical regions (Booijink et al., 2007). Factors including peristaltic motility, pH, redox
potential, host secretions (i.e.: bile acids, mucus, etc.), and available nutrients help
maintain and control the bacterial populations in the GIT (Booijink et al., 2007).
The low pH in the stomach severely restricts the bacterial density and diversity in
the organ. About 102-3 bacterial cells/ml of content are present in the stomach. Helicobacter pylori is considered the only true resident (autochthonous) bacterial species
in the stomach of humans (reviewed in Walter and Ley (2011)). The duodenum
harbors a low-density bacterial community of approximately 103-4 cells/g of content,
limited by the high concentration of bile acids, relatively low pH and a high transit
rate characteristic of the proximal small intestine. The increase in pH in more distal
regions and the reabsorption of bile acids allow a gradual increase of the microbial
load throughout the small intestine to reach densities of 108 cells/g of content in
the more distal sections. Bacterial restriction in these anatomical sites is considered
important as it reduces conflict for nutrients, and maximizes substrate absorption
by the host (Walter and Ley, 2011). Proteobacteria such as Escherichia coli and
Klebsiella and Firmicutes and Bacteroidetes genera (Enterococcus, Bacteroides, Ruminococcus, Dorea, Clostridium, Coprococcus, Weissella, and some Lactobacillus) are
autochthonous to the small intestine of humans (Walter and Ley, 2011). The ileocecal
valve provides a physical and anatomical separation from the harsh environment in
the small intestine and gives way to the largest bacterial reservoir in the human body,
the large intestine. Availability of the non-digested nutrients, anoxic conditions, and
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slow transit times in the large intestine allow for the presence of up to 1011 cells/g of
bacteria, and make the large intestine the primary site of bacterial fermentation.
The large ensemble of microorganisms in the GIT is in great proximity to the host,
and thus constitutes a constant threat of invasion. The host has therefore evolved
sophisticated mechanisms to keep the trillions of bacteria associated to the GIT in
check to ensure homeostasis (Hooper and Macpherson, 2010). A brief overview of
the main mechanisms involved in immune homeostasis in the GIT is provided due to
their importance in allowing the host-microbe mutualism to develop.
First, gut barrier function is achieved by mechanisms that prevent direct contact
between the gut microbiota and the host epithelium, and constitute the first line of
defense against microbial invasion. These mechanisms include the secretion of mucus,
antimicrobial products, defensins and immunoglobulins (Ig), in particular IgA. Goblet cells present in the intestinal epithelium secrete mucin glycoproteins that make
up the main constituent of the mucus layer. Mucins form a thick, viscous layer that
preovides physical, immunological and mechanical protection from bacterial invasion
(Johansson et al., 2008, Hooper and Macpherson, 2010). The importance of the mucus layer has been demonstrated in Muc2 deficient animal models, which develop
spontaneous intestinal inflammation (Johansson et al., 2008). This layer is organized
in two strata, an outer layer that is associated with bacteria, and an inner layer that
remains basically sterile (Johansson et al., 2008). It is thought that mucins in the
outer layer act as ‘decoy’ structures for bacterial attachment and thus contribute to
the shedding of intestinal bacteria (Lindén et al., 2009). The inner mucus layer is associated with secretory antibodies (mainly IgA), that are important to keep symbiotic
bacteria restricted to the intestinal lumen (Hooper and Macpherson, 2010, Macpherson et al., 2000). Dendritic cells sample for microorganisms in the GIT environment
and induce B-cell differentiation into plasma cells that translocate to the intestinal
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lamina propria and secrete IgA that is transcytosed across the intestinal epithelium
(Fagarasan and Honjo, 2003). The inner mucus layer is also associated with antimicrobial peptides that include defensins, lectins and cathelicidins, which have a direct
bactericidal effect. Antimicrobial peptides such as RegIIIγ have been proved crucial
to gut homeostasis (Vaishnava et al., 2011), as RegIIIγ(-/-) mice revealed increased
bacterial density associated to the epithelial surface and have an exacerbated immune
response.
These mechanisms illustrate only a small fraction of the great complexity of the hostmicrobe interactions, but allow a basic understanding of how immune homeostasis is
regulated in the GIT.

1.3

Bacterial diversity and function in the
gastrointestinal tract

1.3.1

Diversity of the gut microbiota

The advent of molecular techniques has enabled the analysis of the GM at unprecedented scales in terms of diversity, dynamics and function, and has revealed the
GIT ecosystem to be more complex than previously thought (Bohannan and Hughes,
2003).
The GM is known to have little diversity at higher taxonomic levels (e.g.: phyla)
which increases dramatically at lower taxonomical scales. Humans are associated
with six to eight bacterial phyla, the Bacteroidetes and Firmicutes (which constitute
>90-96% of the microbiome) (Mariat et al., 2009) and to a lesser extent Actinobacteria, Verrucomicrobia, Proteobacteria, Fusobacteria, Spirochaetes and Lentisphaerae
(Zoetendal et al., 2008, Rajilić-Stojanović et al., 2007). It is estimated that 500-1,500
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bacterial species are associated with the human GM (Eckburg et al., 2005, Qin et al.,
2010). While the stomach and small intestines are colonized by simpler bacterial populations, the large intestine of each individual is associated with at least 160 species
(Qin et al., 2010), and much greater number of strains.
The human GM is highly variable across individuals (β-diversity) at the lower taxonomic levels (Zoetendal et al., 2001, Stewart et al., 2005). Despite this marked
inter-individual variation, a bacterial phylogenetic core across humans has been identified. It includes between 60 and 90 bacterial species (Tap et al., 2009, Qin et al.,
2010, Willing et al., 2010), and it is estimated to represent over 40% of an individual’s microbiota in terms of abundance (Jalanka-Tuovinen et al., 2011). Additionally,
it has been recently proposed that although individuality across humans remains a
valid concept, three distinct microbiome structures (enterotypes) are distinguishable
among humans, each determined by one abundant bacterial genus (Ruminococcus,
Prevotella, or Bacteroides). However, the notion of discrete enterotypes has been
questioned, and instead enterotypes have been shown to follow a gradient (Wu et al.,
2011). The identification of a common bacterial core, and the possible existence of
enterotypes have important consequences to our conception of the GIT ecosystem,
as they could indicate the existence of keystone species necessary for community
assembly and maintenance. Moreover, functional redundancy in the GIT has been
proposed, suggesting that although we might harbor different species, bacterial functions are shared across individuals (Turnbaugh et al., 2009).
Some of the key members of the human GM will now be discussed. One of the most
dominant phyla in the human GIT is the Bacteroidetes, which is mainly comprised of
members of the Bacteroides and Prevotella genera, with at least twenty-five species
of this phylum being identified as core members of the GM (Gerritsen et al., 2011,
Willing et al., 2010). The Bacteroidetes become particularly established in the GIT
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with the incorporation of solid foods to the infant diet (Koenig et al., 2011). The
other dominant bacterial phylum associated to the GIT, the Firmicutes, is mainly
constituted by bacteria in the Clostridia clusters XIVa and IV, which are dominated
by the genera Clostridium, Eubacterium, and Ruminococcus. Approximately fifty-five
species of this phylum have been identified to be present in over 50% of humans, and
thus considered part of the human core (Gerritsen et al., 2011, Willing et al., 2010,
Tap et al., 2009). The Actinobacteria are a minor phylum in adulthood, and Bifidobacterium adolescentis, Collinsella aerofaciens and Bifidobacterium longum have
been determined to be core human species (Willing et al., 2010, Tap et al., 2009).
Archeal species in the GIT are not numerically dominant but are prevalent across humans and have important implications for gut the ecosystem (Dridi et al., 2009). The
two most dominant archeal species are Methanobrevibacter smithii and Methanosphaera
stadtmanae (Dridi et al., 2009, Gill et al., 2006, Mihajlovski et al., 2008). These
methanogenic organisms can convert hydrogen, carbon dioxide and formamate into
methane, constituting an additional electron sink in the GIT food-web, and allow
further energy harvest from nutrients (Samuel et al., 2007).

1.3.2

Traits of bacteria that colonize the large intestine:
The gut microbiota is enzymatically equipped to
forage dietary and host derived glycans

The capacity of the GM to derive energy from undigestible dietary compounds is
possible through the great enzymatic repertoire of gut microbes that allow them to
degrade a wide array of substrates. Different members of the GM have distinct substrate utilization strategies that enable them to occupy the available niches. Some
bacteria are considered generalists, they can ferment a wide diversity of substrates

9
thanks to possessing a large repertoire of genes that encode enzymes involved in substrate utilization. This is the case of the symbiont Bacteroides thetaiotaomicron, one
of the best described gut organisms in terms of carbohydrate. This organism is one of
the core species of the human GIT (Qin et al., 2010), and its vast enzymatic potential
for carbohydrate degradation have made it a model organism to study carbohydrate
utilization in the GIT. Bacteroides thetaiotaomicron has 163 SusC and SusD paralogs (enzymes that bind and import starch), 226 predicted glycolytic enzymes and
15 polysaccharide lyases (Sonnenburg et al., 2005). The opposite strategy is held by
microbes that specialize on the utilization of specific substrates, as they possess fewer
genes that encode for substrate utilization (Ze et al., 2012). Ruminococcus bromii has
been identified to be a specialist in starch degradation in the GIT (Ze et al., 2012).
Parabacterides distasonis is also considered a specialist, and has the enzymatic capability to degrade host glycans, and superior capacity to degrade pectin (Xu et al.,
2007). However, not all bacteria in the large intestine are equipped to utilize a large
range of complex carbohydrates, but instead rely on shorter carbohydrates released
by other bacteria or fermentation end-products. Methanogens for example rely on
by-products of bacterial fermentation (H2 , acetate, formate and CO2 ) for their growth
(Stecher and Hardt, 2008), which allows them to indirectly subsist on a wide range
of dietary substrates. Specialists and generalists play differential roles in the complex
food web of the GIT (Ze et al., 2012). Specialists are usually the primary degraders of
the undigested nutrients and are keystone species for utilization of substrates in the
GIT. Generalists can maintain stable populations with a wider range of substrates
(Xu et al., 2007).
Expression of gene clusters that encode proteins involved in carbohydrate utilization
is tightly regulated in response to nutrient availability, and allow the gut bacteria to
adapt to the ever changing substrate sources in the GIT (Sonnenburg et al., 2010).
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Members of the Bacteroidetes and the Firmicutes have been shown to regulate gene
expression according to the substrates present in the environment (Sonnenburg et al.,
2006, Scott et al., 2011b). Moreover, Bacteroides thetaiotaomicron can further adapt
its metabolism to forage host-derived glycans when deprived of dietary carbohydrates
(Sonnenburg et al., 2005).
Trophic and syntrophic interactions in the GIT generate complex food webs among
GM members (Stecher and Hardt, 2008). Primary degraders can utilize the NDC and
release oligo and monosaccharides that can be utilized by secondary degraders. This
seemingly inefficient substrate utilization is key to maintain diversity in the GIT, as
more organisms can benefit from NDC. Moreover, primary and secondary degraders
can generate SCFAs (acetate, butyrate, propionate, succinate, lactate and formate)
and gases such as CO2 and H2 (Stecher and Hardt, 2008), that can serve as substrates
for other bacteria. A schematic representation of these processes is presented in Figure 1.1. The versatility of enzymes synthesized by gut commensals to utilize diverse
carbohydrates, coupled with their ability to sense the nutritional environment and
adapt to it, do not only constitute a fitness advantage for the organisms, but have
important consequences in the ecology of the GIT, as they enable persistence and
stability in this ecosystem.
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Figure 1.1: Food webs in the gastrointestinal tract. Trophic interactions in the
gastrointestinal tract between members of the gut microbiota.

1.4
1.4.1

Ecology of the gastrointestinal tract
Characteristics of gut ecosystems: stability, resilience
to perturbations, colonization resitance, and
individuality

As described above, the GIT is colonized with highly adapted microbes that possess
specialized traits to succeed in the gut, and a phylogenetic core comprised of 6090 phylotypes has been identified. These organisms occupy available niches, which
preclude the establishment of incoming organisms due to competitive exclusion, an
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important trait that characterizes the GIT (Hardin, 1960, Kassen and Rainew, 2004).
The GIT is a dynamic ecosystem, continuously exposed to exogenous (i.e.: diet, antibiotics) and endogenous (i.e.: bile and gastric acid) factors that greatly condition
the GM composition. However, the gut ecosystem is remarkably resilient and resistant to environmental disturbances, most GM alterations are temporary and the
bacterial community returns to pre-treatment conditions shortly after treatment cessation (Davis et al., 2011, Wu et al., 2011, Dethlefsen et al., 2008, McFarland, 1998,
Jernberg et al., 2010). Homeostatic forces make the GM a stable ecosystem, which
is another important feature of the GIT (Franks et al., 1998, Vanhoutte et al., 2004,
Zoetendal et al., 1998, Jalanka-Tuovinen et al., 2011),
Despite the presence of an autochthonous core, the human gut microbiota is characterized by a high degree of individuality in membership and community structure
(β-diversity) (Eckburg et al., 2005, Turnbaugh et al., 2009). The factors driving βdiversity are still not completely understood. Humans are born with a sterile GIT
that is successively colonized with dense microbial populations until climax, adult-like
communities stabilize (Koenig et al., 2011). This process appears to be ‘chaotic’, due
to a lack of common temporal patterns of diversity between individuals (Palmer et al.,
2007), but the process nevertheless results in remarkably stable climax communities.
What are the host and environmental factors that favor personalized populations in
the gut, and how are the niche environments specifically created or otherwise influenced by host, microbial, environmental and stochastic factors?
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1.4.2

Ecological factors that govern the gut microbiome
assembly

The most current theory in community ecology includes three perspectives by which
communities assemble: (i) Deterministic niche-related, (ii) neutral, and (iii) historic
processes (Cavender-Bares et al., 2009, Emerson and Gillespie, 2008). It is likely that
all three factors are involved in shaping the assembly of the gut microbiota, but recent observations suggest that their relative importance may differ. The first view of
community assembly asserts that communities form according to niche-related, deterministic processes guided by local ‘environmental filters (Cavender-Bares et al., 2009,
Emerson and Gillespie, 2008). Such processes select for members that possess specific traits that allow competitive exclusion of other members competing for resources
(Hardin, 1960, Kassen and Rainew, 2004). There is strong empirical evidence or the
importance of deterministic forces in the assembly of the gut microbiota, which might
be exerted through such factors as gut physiology, immune responses, and diet (Ley
et al., 2008, Ochman et al., 2010, Rawls et al., 2006). Using quantitative genetics, we
have recently shown that host genetic factors have a clear measurable contribution to
the relative abundance of bacterial genera (Benson et al., 2010). However, host genetic factors were shown to account for only 26% of the variation between individual
mouse gut microbiotas, leaving a substantial portion to be explained by other factors. Similarly, although the microbiotas of genetically identical human monozygotic
twins are statistically more similar than those of unrelated individuals, they are still
remarkably different, and the microbiotas of dizygotic twin pairs are almost as similar
(Turnbaugh et al., 2009). These findings indicate that environmental and stochastic
factors impact colonization history (Dethlefsen et al., 2006).
Neutral Factors are unlikely to significantly contribute to β-diversity among indi-
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viduals. The neutral model for community assembly does not appear to predict
community composition in fecal samples (Sloan et al., 2006), and the assumptions
made by the Neutral Theory that ecological communities are open to additional
colonists, continuously changing, and have non-equilibrium assemblages of species
(Cavender-Bares et al., 2009, Emerson and Gillespie, 2008) are in clear contradiction
to microbial communities in the human gut, which are temporally stable, resilient to
perturbations, and resistant to colonization (Costello et al., 2009, Dethlefsen et al.,
2008, Stecher and Hardt, 2008). However, although Neutral Processes are probably
negligible, unpredictable and stochastic events are nevertheless important as they do
impact colonization history (Dethlefsen et al., 2006).
The third model of community assembly emphasizes the role of historical factors in
how communities assemble (Cavender-Bares et al., 2009). In this view, historical
patterns of dispersal, which can only be described in probabilistic terms, influence
the interactions within the community and matter more than environmental filters.
Especially differences in immigration order will affect community assembly as organisms alter niches for themselves and other organisms, thereby shaping the physiochemical properties of the habitat and species interactions. Importantly, Benson and
co-workers observed several sets of taxa that were highly positively correlated across
the nearly 700 mice (Benson et al., 2010). Collectively, these positive correlations
imply that these taxa co-assemble into the microbiota, which then begs the question
of how the microbiota would configure if one or more of these organisms were absent.
The historical perspective of community assembly opens the door for an evolutionary
perspective of community ecology (Cavender-Bares et al., 2009, Emerson and Gillespie, 2008). It challenges the classical assumption in ecology that the traits of the
members within a community are static over ecological time-scales, and that communities assemble mainly by ecological fitting in which new members that evolved
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elsewhere fit themselves into the open spots within a community. In contrast, both
old residents and new arrivals can adapt to niches that are open or newly arise during
community assembly, a process referred to as in situ evolution (Cavender-Bares et al.,
2009). Bacteria have many unique features that favor rapid evolution over ecological time-scales: short generation times, high population levels, rapid mutation rates,
phenotypic plasticity, and high levels of gene flow. Therefore, colonization order and
history and in situ evolution could have a central role in the establishment of the
human gut microbiota.
Many characteristics of gut microbiota can be explained when we assume a combination of niche-related and historical processes during community assembly. For
instance, unpredictable events during assembly would result in differences in community structure in individuals, while in situ evolution would ensure highly adapted
phenotypes even in the absence of reliable modes of transmission. Gene flow within
members of the community would lead to phenotypic plasticity and functional redundancy among microbial lineages, with the consequence that microbiomes in adult
humans are variable in composition but conserved in functional traits (Turnbaugh
et al., 2009).

1.4.3

Environmental factors that are likely to impact
assembly of the gut microbiota

Given the importance of the microbiota for host physiology and function, the impact
of colonization history and immigration order during community assembly is highly
relevant as these factors are likely to affect the final composition and functionality of
the microbiota, with consequences for health.
Several factors associated with a Westernized lifestyle have been identified to affect
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the composition of the gut microbiota. Importantly, these factors are likely to introduce hurdles to symbiont transmission and disrupt community assembly in the GIT.
Mode of delivery is the first aspect that conditions the GM composition and assembly
(Dominguez-Bello et al., 2010), and is highly relevant as nowadays a large percentage
of infants are born by caesarean sections. The neonate is born sterile, and bacterial
colonization starts immediately after birth (Koenig et al., 2011). During the passage
through the birth canal the neonate becomes associated to the gut microbiota present
in this environment. Caesarean section born babies cannot acquire these microbes
and instead, are exposed to mostly environmental and probably skin associated microbes from people in contact with the new born, including non-maternal sources
(Dominguez-Bello et al., 2010). Caesarean section born babies have been reported to
have a delayed colonization of important GM members such as bifidobacteria, lactobacilli and Bacteroides (Grönlund et al., 1999).
The feeding regime at the lactation period is another factor of significant importance
in the establishment of the GM early in life. Differences in the GM composition have
been observed between breast-fed and non-breast-fed infants (Roger et al., 2010, Fallani et al., 2010, Palmer et al., 2007). In addition, the use of antibiotics can cause
severe disruptions in the GM assembly process (Dethlefsen et al., 2008, Cotter et al.,
2012).
Interestingly, epidemiological studies have linked several environmental factors that
are likely to affect gut microbiota assembly to many chronic human diseases with an
metabolic or immunological etiology (Bach, 2002). For example, cesarean sections
and early administration of antibiotics have been linked to higher rates of allergies,
autoimmundiseases, and obesity later in life (Kozyrskyj et al., 2007, Marra et al., 2009,
Verhulst et al., 2008, Penders et al., 2007, Bager et al., 2008, Negele et al., 2004). In
addition, several studies have revealed that breast feeding prevents the development
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of future atopic and allergic diseases, and that these events are related to an altered
microbiota (Penders et al., 2007, Wang et al., 2008, Sjögren et al., 2009). Breast
feeding has also been associated with decreased risk of childhood obesity (Kalliomäki
et al., 2008).
Because these diseases are associated with modern lifestyle habits, and their occurrence is less in developing countries, they are often referred to as Western diseases
(Graham-Rowe, 2011). It is striking that virtually all these diseases have been recently linked to the gut microbiota, which led to the intriguing hypothesis (microbiota
hypotheisis) that many chronic human diseases might be caused by a disruption of
the symbiosis between humans and their gut microbiota (Noverr and Huffnagle, 2004,
Blaser and Falkow, 2009). This hypothesis suggests that lifestyle in industrialized societies has introduced profound changes to the human environment (e.g., diet, antibiotics, hospital deliveries, hygiene, etc.) from the conditions to which we have evolved
to and that are likely to have occurred too abruptly for the human microbiome to
adjust to them. Most importantly, all of these factors impair the transmission of
bacterial symbionts and are therefore likely to impact community assembly resulting
in altered gut microbiota composition throughout life. Such aberrations of the gut
microbiota induced through lifestyle factors could be relevant to the etiology of several complex human diseases whose occurrence has markedly increased in developed
countries.
Given these associations, it is essential that we develop a mechanistic understanding
of intestinal microbial ecology, and identify bacterial populations in the gut that are
associated with diseases. In the coming sections, the association between the gut
microbiota and disease will be discussed.
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1.5

The gut microbiota in disease

In recent years the GM has been implicated in the etiology of several complex human
diseases, mostly with an immunological or metabolic etiology. Diseases that are now
associated with the microbiome include inflammatory bowel diseases (IBD), type 1
diabetes (T1D), rheumatoid arthritis (RA), multiple sclerosis (MS), dyslipidemia, insulin resistance, type 2 diabetes (T2D), colon cancer, allergies, coronary heart disease
(CHD) and obesity (Berer and Krishnamoorthy, 2012, Bäckhed, 2011). Host genetic
factors have been identified in the predisposition to disease, but do not completely
explain disease manifestation.
The evidence for a contribution of the gut microbiota to Western diseases is three
fold. First, virtually all the environmental changes associated with Western diseases
(C-sections, antibiotics early in life, formula feeding, clean living conditions, low fiber
foods, etc.) are likely to disrupt assembly of the microbiota, as they prevent efficient
symbiont transmission (see above). Second, animal models are often protected from
disease when animals remain GF. Third, aberrations in the gut microbiota are associated with virtually all of these diseases, both in humans and in animal models.
Table 1.1 summarizes the diseases that have been associated with the gut microbiota,
and some of the main findings that link pathophysiology with the gut microbiome.
Because of the scope of the research presented in this thesis, this discussion will focus
on the importance of the gut microbiota in obesity and related metabolic disorders
(type II diabetes, CHD).
Although the diseases associated with the gut microbiome show very different etiologies, there seems to be a common link between them: the interaction of the microbiome with the host immune system. As mentioned, the gut microbiota is important
for the correct development of host immune functions (Graham-Rowe, 2011). The ab-
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sence of specific microbes in early life, coupled with a genetic predisposition to disease,
might cause dysfunctional immune reactions that underlie disease (Berer and Krishnamoorthy, 2012, Graham-Rowe, 2011). In addition, the assembly of a microbiome
enriched in microbes that induce inflammation and/or other pathologic immune reactions (e.g. induction of Th17 response) might contribute to disease (Atarashi and
Honda, 2011). Moreover, the interrelationship between the microbiota and the immune system might also underlie diseases such as colon cancer or metabolic disorders.
Inflammation is a major early contributor to the development of colon cancer, and
it is likely caused through gut bacteria (Rubin et al., 2012, Carbonero et al., 2012).
In addition, obesity and related metabolic disorders (e.g. insulin resistance) are associated with what is referred to as a ‘metabolic inflammation’, and there is strong
evidence that this inflammatory response is not only caused by gut microbes but also
has a causative role in pathophysiology (Kern et al., 2001, Gregor and Hotamisligil,
2011, Lee et al., 2009).

1.5.1

A role of the gut microbiota in obesity

1.5.1.1

The impact of the gut microbiota in the host’s energy
metabolism

The contribution of GM to host energy metabolism extends beyond energy provision
to the host from undigested dietary nutrients, but is also manifested through their
regulation of several metabolic pathways that induce energy storage in the host.
SCFAs signaling of G-coupled receptors GPR41 and GPR43 modulate host energy
metabolism (Murphy et al., 2010). GPR41 is involved in the production of several gut peptides, peptide YY (PYY), ghrelin and glucagon-like peptide 1 (GLP1),
which are involved in the modulation of insulin secretion, the host’s lipidome, glu-
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cose metabolism and food intake (Cani et al., 2007, Samuel et al., 2008). Signaling
of GPR43 by acetate has been associated to improved immune capacity of the host
to prevent infection by enteropathogenic Escherichia coli, which has been attributed
to promote enhanced gut barrier epithelial function (Maslowski et al., 2009, Fukuda
et al., 2011).
Bile acid represents another example of diet-host-microbiome interactions. Primary
bile acids (BA), cholic and chenodeoxicholic acids, are synthesized in the liver from
cholesterol. Their amphipathic nature allows them to emulsify the dietary lipids in
the small intestine to facilitate their absorption. Bacteria can further process primary
bile acids through deconjugation and dehydroxylation reactions, generating secondary
bile acids (Ridlon et al., 2006). These modifications alter the hydrophobicity of BA
with consequences to their lipid solubilization capacity and absorption, and condition
their metabolic fate (Nicholson et al., 2004). Moreover, the gut microbiota composition can significantly impact the BA pool, consequently affecting the host lipidome
(Martin et al., 2007, Velagapudi et al., 2010). Microbiota generated lithocholic acid
has been shown to activate G-coupled receptor TGR5, which induces GLP-1 secretion
in colonocytes affecting pancreatic function and glucose metabolism (Thomas et al.,
2008, Reimann et al., 2008). TGR5 has futher effects on brown adipose tissue where
it increases energy expenditure through production of triiodothyronine (Watanabe
et al., 2006). Conversely, bile acids can modulate the GM composition (Islam et al.,
2011).
There are additional mechanisms through which the gut microbiota affects the host’s
energy metabolism. GF animal experiments have revealed that the association of the
host with the GM suppresses the expression of angiopoietin-like protein 4 (Angptl4),
a strong repressor of lipoprotein lipase (LPL) therefore increasing adiposity in the
host (Bäckhed et al., 2004). Apart from suppressing LPL activity, Angptl4 has also
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been suggested to regulate fatty acid oxidation in the skeletal muscle by affecting
the expression of carnitine palmitoyl transferase-1 (Cpt-1) and medium-chain acylCoA dehydrogenase (Bäckhed et al., 2004). The GM has been further implicated in
the downregulation of AMP-activated protein kinase (AMPK) in hepatic cells and
in skeletal muscle (Bäckhed et al., 2007). AMPK is an enzyme implicated in host
cellular energy homeostasis. AMPK can sense the cellular energy state and inhibit
anabolic pathways while stimulating catabolic ones in conditions of energy depravation. The presence of the GM downregulates AMPK activity, causing the host to
increase its energy storage (Bäckhed et al., 2007). Increased glucose uptake in the
small intestine has also been observed in microbiota-associated mice, and although
the mechanisms by which this takes place are not known, it contributes to dietary
energy harvest (Bäckhed et al., 2004).
The ability of the GM to ferment non-digested nutrients that would otherwise represent wasted energy, allow the microorganisms to harvest energy for their own growth
and survival, and also provide the host with additional energy sources. The above
mentioned mechanisms illustrate diverse forms in which the GM impacts the host
energy metabolism that extend beyond increased energy harvest. This increased capacity for energy harvest and storage could have once been a beneficial trait conferred
by the gut microbiota for our ancestors when food was scarce and not as readily available as today. The large food supply and the lack of physical exercise characteristic
of Westernized societies have turned this into a disadvantage.

1.5.1.2

Associations between the gut microbiome and obesity

In the past 50 years ‘Westernized’ societies have experienced a dramatic rise in the
prevalence of obesity (Gregor and Hotamisligil, 2011). Both genetic predisposition
and an excessive caloric intake contribute to the manifestation of obesity (Cani and
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Delzenne, 2009). The fact that GF animals have been shown to be protected from
developing obesity and insulin resistance (Bäckhed et al., 2004, Caesar et al., 2012),
coupled with observations indicating that conventionally raised animals have 40%
more adipocity than their GF counterparts despite a lower feed intake (Bäckhed
et al., 2004) have prompted research to investigate the links between the GM, obesity
and metabolic aberrations. It must be noted that some studies have shown contradicting results as to the contribution of the GM to obesity. Fleissner and co-workers
(2010) concluded that GF mice were not protected from diet-induced obesity, and
undermined the role of Angplt4 as a host-microbe mediator of fat storage. Nevertheless, GM transplantations from obese to GF animals have indicated that the obese
phenotype can be transferred (Turnbaugh et al., 2008, 2006, Vijay-Kumar et al.,
2010). A further link between obesity and the GM was suggested through a genetic
mouse model with impaired sensing of GM commensals. Toll-like receptors (TLRs)
are pathogen-sensing receptors of the innate immune system (Vijay-Kumar et al.,
2010). In this study, researchers showed that Tlr5 deficient mice have an altered GM
composition, and that transplantation of Tlr5-/- GIT contents to GF mice transferred
milder features of the metabolic aberrations and obesity, which the researchers concluded could be attributed to an altered GM composition.
Further associations between the GM and obesity have stemmed from observations
that ascribe a dysbiotic microbial phenotype to obesity (Table 1.1). First, obese
individuals have been shown to harbor a less diverse microbiota than normoweight
individuals (Turnbaugh et al., 2009). In addition, both animal experiments and comparisons between humans have revealed that obesity is associated with a decrease in
the abundance of the phylum Bacteroidetes (Ley et al., 2005, 2006). These shifts were
linked to an increased dietary energy harvest capacity with increases in the Firmicutes/Bacteroidetes ratio (Turnbaugh et al., 2006), and suggested that this bacterial
dysbiosis can cause obesity. However, the importance of dysbiosis in obesity has been
questioned. Increased abundance of Bacteroidetes has not been detected in several
human studies. In addition, Bacteroidetes did not correlate with body mass index
(BMI) (Duncan et al., 2008, Schwiertz et al., 2010). A possible explanation to these
conflicting results is that Bacteroidetes abundance may not be conditioned by obesity
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but by energy intake and diet (Furet et al., 2010, Ley et al., 2006). Employment of
different methodologies and differences between the human cohorts among studies
may also explain the differences encountered between studies (Flint, 2011).
Although the importance of dysbiosis is unclear, the microbiota clearly contributes
to host nutrient utilization. This trait was likely shaped during co-evolution and
beneficial throughout most of human evolution when diet was limited. An increased
capacity for energy harvest and storage could have once been a beneficial trait conferred by the gut microbiota for our ancestors when food was scarce and not as
readily available as today. However, the large reliable food supplies of often energy
dense foods and the lack of physical exercise characteristic of Westernized societies
have now turned this once mutualistic trait of our bacterial symbionts into something
many would prefer to avoid.
Table 1.1: Dysbiosis in microbiota associated diseases.

Pathology

Study population

Obesity

Main findings
Dysbiosis

Bibliography

in

obese

versus normoweight
12 Obese

↑ Bacteroidetes

2 Normoweight

↓ Firmicutes

23 Obese/overweight

↓ butyrate producing

14 Normoweight

Clostridia

(Ley et al., 2006)

(Duncan et al., 2008)

cluster

XVIa
25 Obese/overweight chil-

Composition at in-

(Kalliomäki

dren

fancy prior to obesity

2008)

et

al.,

development
24 Normoweight children

↓ Bifidobacteria
↑ Staphylococcus aureus

20 Obese

↓ Bacteroidetes

(Armougom et al.,
2009)

Continued on next page
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Table 1.1 – continued from previous page
Pathology

Study population

Main findings

20 Normoweight

↑ Lactobacillus

31 Monozygotic twin pairs

↑ Actinobacteria

Bibliography

(Turnbaugh

et

al.,

2009)
23 Dizygotic twin pairs

↑ Firmicutes

46 Mothers of twins

↓ Bacteroidetes

3 Obese

↑ Prevotellaceae

3 Normoweight

↑ Methanogens

(Zhang et al., 2009)

3 gastric bypass surgery
33 Obese

↑ Bacteroidetes

(Schwiertz

et

al.,

2010)
35 Overweight

↓ Firmicutes

30 Normoweight
30 obese

↓ Bacteroides/

13 Normoweight

Prevotella

T2D

(Furet et al., 2010)

Dysbiosis in T2D versus control

Type

1

18 diabetic

↓ Firmicutes

18 healthy

↓ Clostridia

dia-

Dysbiosis

betes

in

(Larsen et al., 2010)

T1D

control
4 future T1D

↓ Firmicutes

4 controls

↑ Bacteroidetes

Rheumatoid

Dysbiosis in RA ver-

arthritis

sus control
51 RA patients

↓ Bifidobacteria

(Giongo et al., 2011)

(Vaahtovuo
2008)

Continued on next page

et

al.,
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Table 1.1 – continued from previous page
Pathology

Study population

Main findings

50 fibromyalgia

↓

Bibliography

Bacteroides-

PorphyromonaPrevotella
cont.

↓ Eubacterium rec-

(Vaahtovuo

tale

2008)

-

Clostridium

et

al.,

coccoides
↓ Bacteroides fragilis
Inflammatory

Dysbiosis in IBD ver-

bowel disease

sus control
68 CD patients

↑ Enterobacteriaceae

61 UC patients

↓ Firmicutes

61 controls

↓ Bacteroidetes

27/63 CD patients

↓ Faecalibacterium

8 UC patients

↑ Adherent/invasive

(Darfeuille-Michaud

Escherichia coli

et al., 2004)

↑ Adherent/invasive

(Baumgart

Escherichia coli

2007)

(Frank et al., 2007)

16/102 controls
13 ileal CD patients

8 colon CD patients

et

al.,

↓ Faecalibacterium

7 controls
10 Twin pairs with CD

↓ Faecalibacterium

8 Healthy twin pairs

↓ Roseburia

(Willing et al., 2010)

↑ Enterobacteriaceae
↑

Ruminococcus

gnavus
68 CD patients (in remis-

↓

sion)

prausnitzii

84 Unaffected relatives

↓ Dialister invisus

Faecalibacterium

Continued on next page

(Joossens et al., 2011)
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Table 1.1 – continued from previous page
Pathology

Study population

Main findings

55 controls

↓

Bibliography

Bifidobacterium

adolescentis
↑

Ruminococcus

gnavus
12 CD patients

↓ Firmicutes IBD

6 UC patients

↑ Bacteroidetes IBD

5 controls

↑ Enterobacteriaceae

(Walker et al., 2011b)

CD

1.5.2

The gut microbiota triggers low-grade inflammation
associated with obesity and metabolic disorders

Obesity is associated with a cluster of metabolic disorders related to insulin resistance, dyslipidemia and the development of type 2 diabetes and cardiovascular disease (CVD) (Cani and Delzenne, 2009). Obese humans are characterized by increased
levels of circulating and adipose derived proinflammatory cytokines and biomarkers
of inflammation, including interleukin-6 (IL-6) and tumor necrosis factor-α (Kern
et al., 2001). This phenotype has been demonstrated to be reversible with weight loss
(Dandona et al., 1998), and to contribute to the development of the obese related
pathologies (Gregor and Hotamisligil, 2011, Lee et al., 2009). A contribution of the
GM to the development of low-grade inflammation has been determined (Cani et al.,
2007). High-fat (HF) diet induced obesity animal models have been employed to
investigate the relation between diet-microbiome-host in their connection to obesity.
It was determined that a HF diet in association with the GM can trigger inflammation, and that the inflammatory response of the host antecedes the onset of obesity
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and insulin resistance, as TNF-α levels were significantly increased before weight
gain or insulin insensitivity was observed (Ding et al., 2010). Animal experiments
based on this model conducted by Cani and co-workers (2007) determined, first,
that lipopolysaccharides (LPS) induced metabolic endotoxemia. LPS are molecules
present in the outer membrane of Gram-negative bacteria that serve as recognition
factors by the host immune system and can act as endotoxins and induce pronounced
immune responses in the host. Second, the researchers demonstrated that continuous
subcutaneous infusion of bacterial LPS caused weight gain and insulin resistance,
independent of a HF diet. Another piece of evidence supporting for a GM induced
low-grade inflammation, is that antibiotic treated obese mice presented lowered LPS
and TNF-α expression, weight loss and an improved glycemic profile (Cani et al.,
2008, Membrez et al., 2008). Recent research has indicated that bacterial LPS instigates accumulation of macrophages in white adipose tissue, but not obesity or
impairment of the glucose metabolism (Caesar et al., 2012).
The increased plasma levels of LPS linked to HF diets have been attributed to
chylomicron-facilitated absorption of LPS enhanced by increased ingestion of fatty
acids (Caesar et al., 2010). An alternative or complementary mechanism through
which plasma LPS is thought to be increased, is by the paracellular transport of LPS
through tight junctions of the intestinal epithelium (Caesar et al., 2010). Decreased
levels and increased interspersion of tight junctions proteins occludin and ZO-1 have
been reported in obese mice (Cani et al., 2009).
These studies depict the link between obesity and the gut microbiota as highly complex. Moreover, despite connections between GM and obesity being identified that
suggest the causation of metabolic disorders by gut bacteria, the extent of the contribution of the GM to the development of these diseases remains unclear.
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1.5.3

Implication of the gut microbiota in metabolic
disorders and cardiovascular disease

Obesity is associated with an increased risk of cardiovascular disease (CVD) (Gregor
and Hotamisligil, 2011). As mentioned above, several lines of research have evidenced
a contribution of the GM to obesity, thus generating a higher risk of CVD events.
Interestingly, the connection between the GM and CVD extends beyond the link between obesity and CVD. Dietary phosphatidylcholine has been determined to increase
the risk of CVD with the GM as a mediator (Wang et al., 2011). Choline is released
from phosphatidylcholine by host enzymes. The GM further processes choline into
trimethylamine (TMA), which is absorbed by the host and converted into trimethylamine N-oxide (TMAO). Wang and colleagues (2011) demonstrated that bacterial
action on choline directly impact plasma TMAO concentrations. In atherosclerotic
prone animals TMAO is associated with arterial plaque development and increased
risk for CVD, which can be reversed upon treatment of the animals with antibiotics.
A study conducted in humans did not detect differences in the GM composition of
atherosclerotic patients compared to healthy subjects (Koren et al., 2011), suggesting
that choline metabolism into TMA is an ubiquitous trait of the GM, and that no specific bacterial population is associated with it. However, supplementation of specific
bacteria (Lactobacillus rhamnosus and Lactobacillus paracasei) to humanized mouse
models decreased hepatic TMAO levels, suggesting that specific bacteria can impact
host-choline metabolism.
To further illustrate the complexities between microbe-host interactions, current research has highlighted the involvement of the GM on yet another metabolic disorder,
non-alcoholic fatty liver disease (NAFLD). NAFLD is a metabolic liver condition associated with obesity and insulin resistance. This asymptomatic state can develop
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into non-alcoholic steatohepatitis (NASH), which can lead to cirrhosis. The mechanisms by which the GM was linked to NAFLD and NASH involve the inflammasome.
The inflammasome is a multiprotein oligomer that is expressed in myeloid cells as
part of the innate immune system, and can take several configurations depending on
the activator that initiates its assembly. Upon activation, the inflammasome triggers the maturation of inflammatory cytokines IL-18 and IL-1β. Inflammasomes can
sense and regulate GM composition. Henao-Mejia and co-workers (2012) established,
first, that genetic mice lacking functional inflammasomes harbored a dysbiotic GM.
Second, that co-housing of inflammasome impaired mice (Asc-/- , Casp1-/- , IL-18-/- or
Nlrp3-/- ) with wild type mice resulted in the transmission of the NASH phenotype to
the wild type mice to a comparable extent. Next, the authors established that TLR
knockout mice were resistant to NASH development due to co-housing with inflammasome impaired animals, indicating the sensing of microbial factors is needed for
the progression of disease.
Dysbiosis has also been observed in individuals with type-2 diabetes (T2D). T2D
patients have been reported to have increased abundance of Bacilli and Betaproteobacteria, and decreased proportions of Clostridia (Larsen et al., 2010).

1.5.4

The importance of dysbiosis

Although GF animal experiments have provided strong evidence indicating that the
GM is involved in the etiology of diseases, the importance of dysbiosis is often much
less clear. Most importantly, the directionality of the association between dysbiosis
and disease has not been elucidated. As described above, the dysbiosis associated
with obesity might be caused through the differences in the dietary habits between
obese and lean subjects. In addition, IBD causes similar aberrations in the gut micro-
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biome (e.g. increased Enterobacteriacea) than acute inflammation or inflammation
associated with other diseases (for example transplant rejection (Oh et al., 2012),
suggesting that some features of dysbiosis are a response and not a cause of inflammation. It is possible that the physiological and immunological changes associated
with metabolic disorders related to obesity affect the GM composition, but this is
much less understood. In this thesis (Chapter 5), evidence is presented that indicates
that the host cholesterol metabolism shapes the composition of the gut microbiota.

1.6

Impact of dietary habits on the gut
microbiota in relation to health

1.6.1

Effects of dietary habits on the gut microbiome

1.6.2

Dietary regimes in early infancy

Diet is a primary factor that shapes GM composition (Flint, 2011). Human milk contains over two hundred different oligosaccharides (Zivkovic et al., 2011) that provide
nourishment to the infant and the GM (Harmsen et al., 2000). Human milk oligosaccharides especially support the growth of Bifidobacterium spp. and Bacteroides spp.
(Marcobal et al., 2010, Xiao et al., 2010). The dietary regime at the lactation period
determines differences in GM composition between breast-fed and formula-fed infants.
Non-breast fed infants are characterized by a decreased abundance in bifidobacteria,
the association with different bifidobacteria species than breast-fed infants, and have
increased proportions of Bacteroides, Clostridia and Proteobacteria (Roger et al.,
2010, Fallani et al., 2010).
The most striking example of the impact of diet on the GM composition is weaning
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and incorporation of solid foods to an infants’ diet, which drive the most dramatic alterations in the gut bacterial community that healthy individuals experience in their
lifetime. During this period, the GIT environment is exposed to ‘novel’ carbohydrates
that induce marked changes in GM structure, especially a decline in the abundance
of bifidobacteria and an expansion of Bacteroidetes (Koenig et al., 2011).

1.6.3

Diets high in non-digestible carbohydrates, fat or
protein have differential impacts on the gut
microbiota

The impact of dietary habits on microbiome structure has been indirectly provided by
studies investigating the GM composition of individuals living in Westernized versus
non-Westernized societies. Yatsunenko and co-workers (2012), compared the gut microbiome of people from Malawi, US metropolitan areas and Venezuelan Amerindians,
while De Filippo and colleagues (2010) investigated the GM of children in Burkina
Faso and Europe. These studies revealed important differences in the conformation
and function of the GM. Notably, although genetic, cultural, geographical and lifestyle
factors are bound to impact the gut microbiome and differentiate GM composition,
both studies identified diet as a key feature driving the differences observed. An
overrepresentation of Xylanibacter (a xylan and cellulose degrading organism) was
observed in Burkina Faso children, while this genus was undetected in European children (De Filippo et al., 2010). In addition, SCFAs concentrations were significantly
higher in the feces of the African children, evidencing a greater carbohydrate intake
and metabolism in the GIT (De Filippo et al., 2010). Yatsunenko and co-workers
(2012) determined that US gut metagenomes were enriched in catabolic enzymes of
simple sugars, sugar substitutes and host glycans, whereas Malawians and Amerindi-
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ans who have a cassava and maize rich diet had an abundance of α-amylase encoding
genes (Yatsunenko et al., 2012). In addition, genes encoding for glutamate synthase,
characteristic of herbivores, were overrepresented in Malawians and Amerindians,
while US individuals had an overabundance of glutamine degrading enzymes, a trait
of carnivores (Muegge et al., 2011). Also, the presence of enzymes implicated in the
bile acid metabolism was greater in US microbiomes, potentially reflecting higher lipid
consumption in Western diets (Yatsunenko et al., 2012). Interestingly, a point of convergence between the studies was the higher abundance of Prevotella in individuals
of Malawi, Burkina Faso and the Venezuelan Amerindians compared to Westerners.
The rumen associated Prevotella ruminocolla has been described to possess particular
xylanase activity (Kabel et al., 2011). A genome search using the Integrated Microbial Genomes (IMG) platform of the Joint Genome Institute (JGI) revealed that the
human gut commensal Prevotella copri has two β-1,4-xylanases and a predictive xylanase encoding genes, two pectinmethylesterases and five endoglucanases encoding
mainly for cellulase activity. These findings portray the aptitude of Prevotella as
primary carbohydrate degraders, and help explain why this organism is more abundant in diets rich in complex carbohydrates. Concordantly, a recent study found that
long-term carbohydrate rich diets were associated with higher Prevotella proportions
in the GIT and favored the Prevotella-dominant enterotype (Wu et al., 2011).
Several studies have documented that not only carbohydrates but also dietary proteins and lipids have an effect on the gut microbiome. Most of the knowledge we have
on the effect of a HF diet on GM composition has stemmed from animal models of
obesity in which a HF-diet is used to develop the obese phenotype. This has caused
difficulties in segregating the effects of the HF diet per se, and the potential contributions of a higher body fat and inflammation on the microbiome. A few studies
have tried to unravel these confoundiing factors, and have concluded that the effect
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of a HF diet prevails over the microbial alterations caused by the obese phenotype
(Ravussin et al., 2012, Murphy et al., 2010). A HF driven expansion of Firmicutes
has been consistently described in several studies (Hildebrandt et al., 2009, Murphy
et al., 2010, Ravussin et al., 2012), and members of the Clostridiaceae family were
determined to be the most affected (Hildebrandt et al., 2009). Increased abundance
of Proteobacteria with HF diets has also been reported (Hildebrandt et al., 2009).
Abundance of Bacteroidetes, on the other hand, has been shown to both increase and
decrease depending on the study (Hildebrandt et al., 2009, Ravussin et al., 2012).
Concomitant with compositional changes of the GM, metabolic changes have also
been ascribed to HF diets. Hildebrandt and colleagues (2009) determined that genes
involved in amino acid and carbohydrate metabolism decreased in abundance, and
those implicated in membrane transport increased. Genes involved in sugar transport have also been determined to be increased in HF diet regimes (Hildebrandt et al.,
2009, Turnbaugh et al., 2008).
High protein consumption has also been determined to affect the GM composition and
metabolism. Overall, a Bacteroides dominated microbiota is associated with protein
intake (Wu et al., 2011). In addition, a dietary regime high in protein and low in carbohydrates was identified to cause significant decreases in the Roseburia/Eubacterium
rectale group concurrent with a decreased proportion of butyrate in the SCFA pool
compared to subjects on a high-protein moderate-carbohydrate diet (Russell et al.,
2011). However, a higher supplementation of peptides to an NDC-rich medium is associated with increased butyrate production and proportions of Roseburia/Eubacterium
rectale.
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1.6.4

Impact of diet-induced alterations of the gut
microbiota on health

As popular wisdom holds: ‘We are what we eat’. Epidemiological research has
strongly linked dietary habits to disease, and some of these links might be due to
the gut microbiota.
The benefits of a low fat diet in terms of obesity and metabolic disorders do not only
originate through a decreased fat absorption by the host with consequent reduction in
fat deposit, insulin resistance and dyslipidemia, but also stem from a reduction in the
systemic inflammation associated with impaired gut barrier function and increase of
plasma LPS elicited through dietary fat. High fat diets have been shown to increase
permeability of the gut, and higher gut permeability is associated with obesity in
humans (Cani et al., 2009).
Another disease that is determined to have the GM at the intersection between diet
and disease is colorectal cancer, the fourth most common cause of cancer related death
(Jemal et al., 2011). Diet has been determined to be the most important contributing
factor to the etiology of this disease, as it is estimated that 80% of colorectal cancers
are diet related, and that a diet high in fats and proteins (especially of animal origin)
and low in carbohydrates is detrimental (Willett, 1995). The GM has been implicated
in the development of colorectal cancer in several ways. First, bacterial fermentation
of dietary proteins leads to the formation of toxic compounds such as ammonia,
amines and indoles, which have been linked to carcinogenesis (Hughes et al., 2000).
Second, NDC ingestion is deemed beneficial for the prevention of this disease as its
fermentation by-products, SCFAs, are deemed protective. Butyrate promotes apoptiosis in colonocytes and regulates gene expression (Csordas, 1996, Tazoe et al., 2008,
Heerdt et al., 1994). Moreover, bacterial fermentation of plant derived carbohydates
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has been shown to release protective phenolic compounds with anti-carcinogenic capacity such as ferulic acid derivatives (Hamer et al., 2008, Russell et al., 2011). For
these reasons, diets rich in whole grains and fiber have been included in dietary recommendations, and researchers have questioned the value of long-term diets high in
protein and low in complex carbohydrates (Russell et al., 2011).
An additional benefit of NDC in the context of IBD, and particularly Crohn’s disease,
is the enhanced butyrate concentrations and expansion of Faecalibacterium prausnitzii
populations given its association to decreased rate of relapse after surgery (Sokol et al.,
2008). Despite these promising associations, dietary interventional trials with FOS in
CD patients have failed to stimulate Faecalibacterium prausnitzii populations in the
GIT (Benjamin et al., 2011).

1.7

Dietary strategies to modulate the GM

The interest in the modulation of the gut microbiota to promote human health dates
back more than a century when Metchnikoff hypothesized that reducing the number of ‘putrefactive’ bacteria in the GIT could improve gastrointestinal health and
prolong life (Metchnikoff, 1908). The increased understanding of the critical role of
the gut microbiota in human health and the aberrations in the GM linked to several complex diseases have intensified the interest in dietary strategies that modulate
the gut ecosystem. Many studies have shown that dietary strategies can be used
to modulate the GM, suggesting that aberrations or imbalances associated with disease could be corrected and host health improved. These dietary strategies have
focused primarily on probiotics and prebiotics, and more recently on synbiotics (a
combination of pro- and prebiotics). Probiotics are live microorganisms that when
administered in adequate amounts confer health benefits to the host (FAO/WHO,
2001). A prebiotic is a selectively fermented ingredient that allows specific changes,
both in the composition and/or activity in the gastrointestinal microbiota that confers benefits upon host well-being and health. Prebiotics are defined as ‘selectively
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fermented ingredients that allow specific changes, both in the composition and/or
activity in the gastrointestinal microbiota that confer benefits upon host well-being
and health’ (Roberfroid, 2007). Several prebiotics are now widely commercially used
in foods, including inulin, fructooligosaccharides (FOS), and galactooligosaccharides
(GOS). Moreover, there has been increased interest to use dietary fibers (including
resistant starch), other NDCs, and whole grains to modulate the gut microbiota. In
this section an overview of the main NDCs used to impact GM composition and the
main effects observed in in vivo human trials is presented (Table 1.2).
Table 1.2: Impact of non-digestible carbohydrates in in vivo
human trials.

NDC

Number of

Treatment Daily

subjects

duration

dose

8

15 days

15 g

Method

Outcome

Bibliography

Culture

↑ Bifidobacteria

(Gibson and Rober-

FOS

froid, 1995)
↓ Clostridia
↓ Bacteroides
↓ Fusobacteria
12

25 days

4g

Culture

↑ Bifidobacteria

(Buddington

RK,

1996)
8

5 weeks

8g

FISH

↑ Bifidobacteria

(Menne

and

Guggenbuhl, 2000)
40

7 days

2.5-10 g

Culture

↑ Bifidobacteria

(Bouhnik

et

al.,

2006)
Inulin
10

9 days

9g

FISH

↑ Bifidobacteria

DGGE

↑

Eubacterium

rectale group
Continued on next page

(Harmsen, 2002)
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Table 1.2 – continued from previous page
NDC

Number of

Treatment Daily

subjects

duration

dose

39

4 weeks

2.5 g

Method

Outcome

Bibliography

Culture

↑ Bifidobacteria

(Bouhnik

et

al.,

2007)
30

2 weeks

5 or 8 g

FISH

↑ Bifidobacteria

(Kolida et al., 2007)

12

7 days

36, 71,

Culture

↑ Bifidobacteria

(Ito et al., 1990)

Culture

↑ Bifidobacteria

(Bouhnik

GOS

143 mg
8

21 days

10 g

et

al.,

1997)
30

4 weeks

2.4 g

8

1 week

2.5,

5,

Culture

↑ Bifidobacteria

(Gopal et al., 2003)

Culture

↑ Bifidobacteria

(Bouhnik

7, 10 g
18

3 week

et

al.,

2004)
↑ Bifidobacteria

2.5, 5,

DGGE

10 g

Pyroseq. ↓

(Davis et al., 2011)

Bacteroides

group
Resistant
starch
46

4 weeks

22 g

DGGE

↑ Ruminococcus

(Abell et al., 2008)

bromii
14

3 weeks

22 g

qPCR

↑ Ruminococcus

(Walker

bromii

2011a)

Pyroseq. ↑

et

al.,

et

al.,

Eubacterium

rectale
↑ Oscillibacter
Arabinoxylans
63

3 weeks

3 or10 g

FISH

↑ Bifidobacteria

(François
2012)

Continued on next page
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Table 1.2 – continued from previous page
NDC

Number of

Treatment Daily

subjects

duration

dose

20

3 weeks

10 g

Method

Outcome

Bibliography

qPCR

↑ Bifidobacteria

(Cloetens

et

al.,

2010)

1.7.0.1

Dietary non-digestible carbohydrates affect the gut microbiota
composition and function

One of the main carbohydrates that reach the large intestine are resistant starches.
Starches are the main storage carbohydrates present in plants, a fraction of which is
denominated resistant starch (RS) in virtue of its resistance to amylases in the small
intestine, and can be fermented by bacteria in the large intestine. Over 50% of gut
bacterial isolates have the ability to degrade starches in vitro (Salyers et al., 1977,
Walker et al., 2011a). Despite this, not many bacterial species have been determined
to be enriched in in vivo dietary human trials with RS. The main species identfied to
respond to RS diets are Eubacterium rectale and Ruminococcus bromii (Abell et al.,
2008, Walker et al., 2011a).
Fructans are another type of plant storage carbohydrates, and include inulin and
their shorter chain counterparts fructooligosacchrides (FOS). Consumption of inulin
has been notable for stimulating bifidobacteria (Scott et al., 2011a). Moreover, inulin
and FOS enhance butyrate production in the GIT and butyrate producing species such
as Faecalibacterium prausnitzii (Ramirez-Farias et al., 2009). Galactooligosaccharides
(GOS) are another class of carbohydrate regarded for its bifidogenic potential. GOS
were determined to elicit an important bifidogenic response in 50% of individuals and
to have a dose-response effect in some persons (Davis et al., 2011).
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Another important source of carbohydrates in the large intestine are plant cell wall
polysaccharides, which include a wide variety of carbohydrates such as pectin, cellulose and xylans. Most of the bacteria reported to degrade these polysaccharides
belong to the Firmicutes phylum. Xylan utilizers include Roseburia intestinalis and
Butyrivibrio fibrinisolvens (Rumney et al., 1995), while Faecalibacterium prausnitzii
and Eubacterium eligens are pecting degraders (Lopez-Siles et al., 2012, Salyers et al.,
1977).

1.7.1

Mechanisms by which non-digestible carbohydrates
induce specific changes in the gut microbiota

By definition, prebiotics specifically support the growth of a specific bacterial species
in the GIT. Clearly, as described above (section ’Traits of the gut microbiota’ ), substrate specificity exists to some degree within the gut microbiota (i.e.: inulin is utilized
by bifiodbacteria and the Eubacterium rectale clostridial group). For example, the
prebiotic inulin is only utilized by a restricted group of gut microbes. In addition,
recent research, including research described in this thesis (Chapter 2), showed that
even carbohydrates such as resistant starches, which are utilized by many gut microbes, induce remarkable specific alterations to the gut microbiome. However, it
is now generally recognized that most prebiotics are not as selectively fermented as
previously proposed. It is therefore evident that more complex competitive and cooperative interactions between the gut microbiome define the effect of NDC on gut
microbiota composition.
Cross-feeding in the GIT involves the utilization of partial breakdown products from
primary degraders by secondary utilizers, as well as the use of fermentation byproducts such as SCFAs. Flint’s group has nicely evidenced these co-operative inter-
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actions in in vitro experiments in which co-culturing of Ruminococcus bromii with
Bifidobacterium adolescentis, Eubacterium rectale or Bacteroides thetaiotaomicron led
not only to an increased utilization of RS2 and RS3 than the respective mono-cultures,
but even favored the growth of Eubacterium rectale (Ze et al., 2012). Flint and colleagues have also performed in vitro assays showcasing the relevance of cross-feeding
between bacteria. Eubacterium halii and Anaerostipes caccae cannot grow on RS in
pure culture, but are able to grow if Bifidobacterium adolescentis is present in the culture (Belenguer et al., 2006). These syntrophic associations are possible through the
utilization of Bifidobacterium adolescentis-generated lactate by Eubacterium halii and
Anaerostipes caccae. Moreover, these co-operative networks result in the production
of butyrate by Eubacterium halii and Anaerostipes caccae with positive consequences
to host health. Another important by-product of bacterial fermentation implicated
in cross-feeding networks is hydrogen. For many bacteria, hydrogen constitutes an
end product of fermentation. However, a few members of the GM are specialized in
hydrogen utilization as an energy source. Acetogens, methanogens and sulfate reducers can utilize hydrogen produced by other bacteria and add another link to the GIT
energy network.
These observations allow us to hypothsize that nutrient utilization in the GIT is determined by the composition of the GM as a whole, and dependent on competitive
and co-operative interactions between its members. Moreover, these considerations
imply that predicting the modulation of the GM by dietary substrates is a rather
difficult task from an in vivo context. Further obstacles may arise when one considers the potential effect of the food matrix and the interaction with other nutrients
present in the diet in view of predicting modulatory outcomes of the GM by diet.
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1.8

Open questions

The evolved dependence of mammals with their GM to ensure its own development
suggests the profound importance of the correct establishment of the GM for the
host to achieve homeostasis throughout life. Our modern lifestyle has challenged this
symbiosis, with consequences to our health. In order to restore this symbiosis, a clear
understanding of the mechanisms that control GM assembly and composition need
to be understood. Dietary strategies constitute one of the most effective tools to
modulate the microbiome composition and function. The work presented in this dissertation focuses on dietary strategies to modulate the GM, their impact on health,
and the interrelationship between diet, the microbiome and health.
Animal experiments constitute an important tool to gain mechanistic insight into
how diet exerts metabolic and microbiome modulations, and to determine how these
entities interplay. Two animal experiments are presented as part of this dissertation
in which the impact of dietary lipids (grain sorghum lipid extracts and plant sterol
esters) was examined in the context of dyslipidemia. GM and metabolic alterations
as a result of the dietary intervention were investigated. The data revealed that the
observed shifts in GM composition were most likely a response to host metabolic
changes that affected the GIT environment, namely, cholesterol concentrations in the
GIT were determined to impact bacterial populations in the GIT.
Although animal experiments are key to gain a mechanistic understanding of the
host-microbe interactions, human trials are necessary as a direct extrapolation cannot be made from animal experiment investigations. In another set of experiments,
the impact of resistant starches and whole grains was evaluated in human subjects.
The studies conducted determined the impact of these dietary components on the
GM in terms of dynamics, individuality of response, and their association with host
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metabolic and immune markers related to metabolic disorders. Significant alterations
in GM composition were observed in both studies, and an anti-inflammatory effect of
whole grains was detected.
An important contribution of these studies was the use of massive parallel sequencing
technology in the characterization of the GM, which permitted an overall communitywide perspective on the effects of diet on the microbiome. Moreover, dietary components that had not been previously investigated in terms of their impact on the
GM were used in these studies: grain sorghum lipid extracts, plant sterols esters, and
chemically-modified resistant starch.
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and F.R. Bornet. The capacity of nondigestible carbohydrates to stimulate fecal
bifidobacteria in healthy humans: a double-blind, randomized, placebo-controlled,
parallel-group, dose-response relation study. Am. J. Clin. Nutr., 80:1658–1664,
2004.
Y. Bouhnik, L. Raskine, G. Simoneau, D. Paineau, and F. Bornet. The capacity
of short-chain fructooligosaccharides to stimulate faecal bifidobacteria: a doseresponse relationship study in healthy humans. Nutr. J., 5:8, 2006.
Y. Bouhnik, L. Raskine, K. Champion, C. Andrieux, S. Penven, H. Jacobs, and

46
G. Simoneau. Prolonged administration of low-dose inulin stimulates the growth
of bifidobacteria in humans. Nutr. Research, 27:187–193, 2007.
Chen SC Witherly SA Buddington RK, Williams CH. Dietary supplement of neosugar
alters the fecal flora and decreases activities of some reductive enzymes in human
subjects. Am. J. Clin. Nutr., 63:709–716, 1996.
R. Caesar, R. Fak, and F. Bäckhed.
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2.1
2.1.1

Abstract
Background

To systematically develop dietary strategies based on resistant starch (RS) that modulate the human gut microbiome, detailed in vivo studies that evaluate the effects of
different forms of RS on the community structure and population dynamics of the gut
microbiota are necessary. The aim of the present study was to gain a community wide
perspective of the effects of RS types 2 (RS2) and 4 (RS4) on the fecal microbiota in
human individuals.

2.1.2

Methods and Findings

Ten human subjects consumed crackers for three weeks each containing either RS2,
RS4, or native starch in a double-blind, crossover design. Multiplex sequencing of
16S rRNA tags revealed that both types of RS induced several significant compositional alterations in the fecal microbial populations, with differential effects on
community structure. RS4 but not RS2 induced phylum-level changes, significantly
increasing Actinobacteria and Bacteroidetes while decreasing Firmicutes. At the
species level, the changes evoked by RS4 were increases in Bifidobacterium adolescentis and Parabacteroides distasonis, while RS2 significantly raised the proportions
of Ruminococcus bromii and Eubacterium rectale when compared to RS4. The population shifts caused by RS4 were numerically substantial for several taxa, leading
for example, to a ten-fold increase in bifidobacteria in three of the subjects, enriching them to 18-30% of the fecal microbial community. The responses to RS and
their magnitudes varied between individuals, and they were reversible and tightly
associated with the consumption of RS.
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2.1.3

Conclusions

Our results demonstrate that RS2 and RS4 show functional differences in their effect
on human fecal microbiota composition, indicating that the chemical structure of
RS determines its accessibility by groups of colonic bacteria. The findings imply that
specific bacterial populations could be selectively targeted by well designed functional
carbohydrates, but the inter-subject variations in the response to RS indicates that
such strategies might benefit from more personalized approaches.

2.2

Introduction

The gastrointestinal microbiota is of profound importance for the human host, affecting its metabolism, immune functions, and physiology with implications to health
(Gordon and Pesti, 1971, Nicholson et al., 2005). Not only are these microbial populations involved in the prevention of gastrointestinal infections and stimulation of the
immune system, but recent research has indicated a role of the gut microbiome in complex diseases such as colon cancer, obesity, type 2 diabetes, and inflammatory bowel
disease (Cani et al., 2007, Flint et al., 2007, Tannock, 2008). The implications of these
cohesions cannot be overstated; if the gut microbiota influences health, it stands to
reason that dietary factors which influence species composition and metabolic characteristics of the gut microbiota are strong candidates for disease prevention and
intervention. Dietary components that are resistant to human digestion are considered the most significant source of nutrients for colonic bacteria, and they thus offer
a promising tool for the modulation of the gut microbiota (Louis et al., 2007).
Resistant starches (RS) are starches or products of starch degradation that escape
digestion and are not absorbed in the small intestine of healthy individuals (Asp,
1992). RS are classified into four categories according to the features that render it

72
undigestible. RS type 1 is physically inaccessible starch whereas RS type 2 (RS2) is
native granular starch consisting of ungelatinized granules. RS type 3 is retrograded
amylose, and finally, RS type 4 (RS4) is chemically modified to achieve undigestibility.
Several studies have shown RS have the potential to improve health, with one of the
primary benefits being maintenance of healthy blood sugar levels (Behall et al., 2006,
Nilsson et al., 2008). Though resistant to digestion in the small intestine, bacterial
species that reside in the colon are capable of utilizing RS as a substrate. These fermentations lead to an increase of short chain fatty acids (SCFA), especially butyrate,
and a reduction of secondary bile acids, phenol, and ammonia (Louis et al., 2007,
Nugent, 2005). These metabolic effects are likely to underlie some of the documented
health benefits of RS, which include the prevention of colon cancer development and
colitis in animal models (Bauer-Marinovic et al., 2006, Le Leu et al., 2007, Moreau
et al., 2003, Toden et al., 2006).
Several studies have been performed to characterize the potential of RS to induce alterations in the composition of the gut microbiota. Increases in bifidobacteria (Conlon
and Bird, 2009, Drzikova et al., 2005, Kleessen et al., 1997, Wang et al., 2002) and
Bacteroides (Lesmes et al., 2008) as well as decreases in enterobacteria and Bacteroides (Silvi et al., 1999) have been reported. Unfortunately, most studies have
been performed in either in vitro systems or animal models (Crittenden and Playne,
2006). To our knowledge, there were two previous studies that have used culture
independent methods to characterize the effect of RS in humans in vivo. Abell and
coworkers, who used denaturing gradient gel electrophoresis (DGGE) to study the impact of RS2 on the human gut microbiota and revealed an enrichment of phylotypes
related to Ruminococcus bromii (Abell et al., 2008). Walker et al. (2011) detected
an enrichment of bacteria related to Eubacterium rectale and Ruminococcus bromii
when RS3 was consumed by overweight individuals (Walker et al., 2011).
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Recently, the ecological study of the human gastrointestinal microbiota has gained
enormous momentum through the development of high throughput multiplex sequencing of 16S rRNA tags (Robinson et al., 2010, Hamady and Knight, 2009). This technique has been extremely valuable, for example, in the characterization of the human
microbiota in terms of lean and obese physiological states, impact of antibiotics, and
the importance of delivery mode at birth (Dethlefsen et al., 2008, Dominguez-Bello
et al., 2010, Turnbaugh et al., 2009). Pyrosequencing has significant advantages over
other molecular techniques currently used to study microbial communities. First,
unlike probe based techniques such as fluorescence in-situ hybridization (FISH), pyrosequencing allows the determination of the entire phylogenetic spectrum of the
bacterial populations in one single analysis. Second, it further allows an immediate
taxonomic characterization and the flexibility to analyze the communities at different taxonomic levels. Third, pyrosequencing has a markedly increased dynamic range
when compared to more traditional fingerprinting techniques such as DGGE (Hamady
and Knight, 2009).
The goal of the present study was to obtain a community wide perspective of the
impact of RS on the composition of the human gut microbiota. We were further
interested to compare RS4 and RS2 in this respect because most emphasis in the
literature has been placed on the latter substrate. To achieve our goal, we conducted a placebo-controlled, double-blind crossover trial with 10 human subjects and
performed a comprehensive characterization of their fecal microbiota by using a combination of approaches, including pyrosequencing of 16S rRNA tags (Figure 2.1).
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Figure 2.1: Experimental design used in this study. Subjects (n = 10) participated in a 17-week double-blind crossover design, in which 3 dietary treatments were
assessed: 100 g of crackers containing either native starch or 33 g of RS2 or RS4.
An initial baseline period was proceeded by 3-week periods of each dietary treatment
in succession interspersed by 2-week washout periods, and a final washout period.
Weekly fecal samples were collected throughout the entire study.

2.3

Materials and methods

The human trial of this study was approved by the Institutional Review Board of
the University of Nebraska (IRB Approval Number: 2008038840EP), and written
informed consent has been obtained from all subjects.

2.3.1

Preparation of RS crackers

Three types of crackers, containing either RS2 (Hi-Maize 260, National Starch and
Chemical Corp., Bridgewater, N.J., USA), RS4 (Fibersym RW, MGP Ingredients,
Atchison, Kansas, USA), or native wheat starch (Midsol 50, MGP Ingredients, Atchison, Kansas, USA), were prepared at the American Institute of Baking International
(Manhattan, Kansas). Fibersym RW is a chemically modified phosphorylated crosslinked type 4 RS prepared from wheat starch (RS4) (Woo and Seib, 2002). The
crackers containing RS were formulated to both contain 33 g of fiber in the form of
RS per 100 g of crackers, calculated based on the proportion of total dietary fiber
(true RS) in Hi-Maize 260 (60%, dry basis) and Fibersym RW (85%, dry basis), us-
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ing native wheat starch to account for the different RS contents of Hi-Maize 260 and
Fibersym RW. The formulations of all three types of crackers are shown in Table 2.4,
and the baking conditions of dough are presented in Table 2.5. The amount of RS
in the final products was confirmed using the AOAC 991.41 method, which measures
total fiber (and the most reliable method to measure RS4). This analysis revealed
that the amount of fiber per 100 g of crackers after processing was 4.53 ± 1.4 g for
the control crackers, 33.2 ± 4.2 g for the RS2 crackers and 30.5 ± 3.5 g for the RS4
crackers.

2.3.2

Experimental design of human study

A double-blind, crossover study was performed starting with 13 healthy human subjects. None of the subjects had been on antibiotics or on a vegetarian diet within
three months prior to the start of the study or throughout its duration. Three subjects stopped their participation for reasons unrelated to the study. Thus, the study
was completed by ten subjects (five males and five females) between 23 and 38 years
of age. The study was conducted over a 17-week period, beginning with a two-week
baseline period (no crackers administered). The subjects then consumed 100 g per
day of the different crackers in sequence, each for three weeks, interspersed by 2-week
washout periods. The study finished with a 2-week washout. Fecal samples were
collected weekly, resulting in a total of 161 fecal samples for the entire study. For
reasons unrelated to the study, we were unable to collect a total of 9 fecal samples
distributed among five subjects. All missing samples corresponded to washout periods, and their omission did therefore not affect the statistical analysis.
Subjects completed a symptoms diary to assess the potential side effects of RS administration. The symptoms included were bowel movement, stool consistency, dis-
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comfort, flatulence, abdominal pain, and bloating, and subjects were asked to score
them on a scale from 1 (none, normal, good well-being) to 5 (severe symptoms and
discomfort).

2.3.3

Collection of fecal samples and analysis by selective
culture

Fresh fecal samples were processed within an hour of defecation. A ten-fold dilution
of each sample in sterile phosphate buffered saline (PBS) (pH 7.0) was immediately
frozen at -80◦ C for later DNA extraction (see below). Samples were further introduced into an anaerobic chamber (Bactron IV Anaerobic Chamber, Shel Lab, USA),
and a 10-fold dilution series was made with pre-reduced sterile saline (0.9% NaCl).
Aliquots were plated on Brain Heart Infusion agar (BD, USA) for the enumeration
of total anaerobes (2 days), Rogosa SL (BD) for bifidobacteria (4 days), and Bacteroides Bile Esculin Agar (BD) for Bacteroides/Parabacteroides spp. (2 days), and
the plates were incubated anaerobically at 37◦ C. Dilution series were plated aerobically on MacConkey agar (BD,) for enterobacteria (1 day); and Bile Esculin Azide
Agar (Acumedia, USA) for enterococci (2 days); plates were incubated aerobically at
37◦ C. Fecal samples (2 gram) were homogenized with distilled water to obtain a slurry
for pH measurements, which were performed using an Ag/AgCl pH meter (Accumet
Basic AB15 pH meter, Fisher Scientific).

2.3.4

DNA extraction from fecal samples

Fecal homogenates were thawed and transferred to sterile bead beating tubes (Biospec
products, Bartlesville, OK, USA) containing 300 mg of zirconium beads. Cells were
recovered by centrifugation (8,000 xg for 5 min at room temperature) and suspended
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in ice-cold PBS to wash the cells. This step was repeated twice before cell pellets
were suspended in 100 l of lysis buffer (200 mM NaCl, 100 mM Tris, 20 mM EDTA,
20 mg/ml Lysozyme, pH 8.0) containing 20 mg/ml of Lysozyme (Sigma-Aldrich) and
incubated at 37C for half an hour. Buffer ASL (1.6 ml) from QIAamp DNA Stool Mini
Kit (Qiagen, Hilden, Germany) was added to each sample, after which the samples
were homogenized in a MiniBeadbeater-8 (BioSpec Products, OK, USA) for 2 min at
maximum speed. 1.2 ml of supernatant was used to purify DNA with the QIAamp
DNA Stool Mini Kit following the manufacturer’s instructions.

2.3.5

Pyrosequencing of 16S rRNA tags

The V1-V3 region of the 16S rRNA gene was amplified by PCR from fecal DNA.
The 16S primers were modified to work with the Roche-454 Titanium adapter sequences and contain the A or B Titanium sequencing adapter (shown in italics),
followed immediately by a unique 8-base barcode sequence (BBBBBBBB) and finally the 5 end of primer. A mixture (4:1) of the primers B-8FM (5- CCTATCCCCTGTGTGCCTTGGCAGTCTCAGAGAGTTTGATCMTGGCTCAG3) and B8FMBifido (5-CCTATCCCCTGTGTGCCTTGGCAGTCTCAGAGGGTTCGATTCTGGCTCAG3) were used as the forward primer during PCR. As the reverse primer,
the primer A-518R (5- CCATCTCATCCCTGCGTGTCTCCGACTCAGBBBBBBBBATTACCGCGGCTGCTGG 3) was used. Individual samples were amplified with
primers containing unique barcodes, which allowed the mixing of PCR products from
multiple samples in a single run, followed by bioinformatic assignation of the sequences to their respective samples via the barcode. Primer 8FMBifido was used in
combination with primer 8FM to detect bifidobacteria, as species within this genus do
not match the latter primer (Martı́nez et al., 2009). The PCR mixture contained 1 µl
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of forward primer mix, 1 µl of reverse primer, 0.25 µl of Ex-Taq polymerase (TaKaRa
Bio, USA), 1.5 µl of the sample, 6.25 µl of Ex-Taq buffer, 5 µl of deoxynucleotides
and 37 µl of sterile dH2O were used for the reaction. The PCR program consisted of
an initial denaturing step for 5 min at 95◦ C, followed by 30 cycles of denaturation at
95◦ C for 45 sec, annealing at 57◦ C for 45 sec and extension at 72◦ C for 2 min, with
a final step at 72◦ C for 10 min. The PCR products were quantified based on their
staining intensity using the image acquisition software Genesnap (Syngene USA).
PCR products were combined in equal amounts and gel purified using the QIAquick
Gel Extraction Kit (Qiagen, USA).
Pyrosequencing was performed by the Core for Applied Genomics and Ecology (CAGE,
University of Nebraska) from the A end with the 454/Roche A sequencing primer kit
using a Roche Genome Sequencer GS-FLX following manufacturer’s protocol for the
Roche 454 GS FLX Titanium. Sequences were binned according to barcode using
the Initial Process tool of the Ribosomal Database Project (RDP) Pyrosequencing
Pipeline (Cole et al., 2009) with default parameters (which included the removal of
sequences containing at least one ambiguous nucleotide), except for the minimum
sequence length, which was set to 300 bp. The quality approved sequences were
trimmed to 495 bp before their submission to the sequence analyses (see below).

2.3.6

Sequence analyses to characterize microbial
populations

Two independent approaches were used to analyze the sequences obtained with pyrosequencing. First, the Classifier tool (with a minimum bootstrap value of 80%) of
the RDP was applied to obtain a taxonomic assignment of all sequences. This approach allowed a fast determination of the proportions of bacterial groups at different
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taxonomic levels (phylum, family, genus). Second, sequences were assigned to Operational Taxonomic Units (OTUs) that were quantified in individual subjects. As the
entire data from the ten subjects contained too many sequences for a quality alignment, sequences were aligned by subject using the Aligner web tool of the RDP, and
then clustered using the Complete Linkage Clustering tool (with a maximum distance
cutoff of 97%). OTUs that contained less than three sequences were excluded from
the analyses. ANOVA was used to identify OTUs that were significantly affected by
the dietary treatments in each of the ten subjects. These OTUs were subjected to a
taxonomic classification and grouped according to phylum (Firmicutes, Bacteroidetes,
and Actinobacteria). Within these phyla, five random sequences of each OTU identified above were aligned with the most closely related type strains and entry in the
NCBI database using Muscle 3.6 (Edgar, 2004). Phylogenetic trees were built with
MEGA 4.0 Software (Tamura et al., 2007) by neighbor-joining with 1,000 bootstrap
replicates. These trees allowed us to visually assign OTUs as sequence clusters which,
in most cases, encompassed sequences from several subjects, and consensus sequences
were generated for each OTU. A local nucleotide database was established for each
subject in BioEdit(Hall, 1999) containing all sequences detected by pyrosequencing,
and the BLASTn algorithm was used with a 97% cutoff (minmum length 300 bp) to
quantify each OTU in the fecal bacterial populations in each sample. We verified that
this approach did not result individual sequences being assigned to different OTUs.
In two occasions, two OTUs that were initially identified as distinct had very high
sequence similarities, and were thus combined.
Diversity of the fecal microbiota was determined using 16S rRNA sequence data with
two different methods, Shannon’s index and the generation of rarefraction curves.
The DNA sequences of each sample were individually aligned and clustered using
Aligner and Complete Linkage Cluster tools of the RDP. Individual cluster files cor-
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responding to each fecal sample were used to determine the Shannon’s Index and
construct Rarefraction curves.

2.3.7

Analysis of fecal microbiota by PCR-DGGE

PCR-DGGE and quantitative analysis of molecular fingerprints was performed as
described previously (Martı́nez et al., 2009). Briefly, PCR was performed using
primers PRBA338fGC (5’-CGCCCGCCGCGCGCGGCGGGCGGGGCGGGGGCACGGGGGGACTCCTACGGGAGGCAGCAG-3’) and PRUN518r (5’-ATTACCGCGGCTGCTGG-3’) (Ovreas et al., 1997). DGGE was done as described by Walter and coworkers (2001) using a DCode universal mutation detection system (Bio-Rad, Hercules, USA), and DGGE profiles were analyzed using BioNumerics software Version
5.0 (Applied Maths). Band staining intensities were calculated as percent peak area
in relation to the total peak area of the entire fingerprint. DNA fragments whose
staining intensity changed according to dietary treatment were excised, purified as
described by Walter and coworkers (Walter et al., 2001), and cloned using the TOPO
TA Cloning Kit for Sequencing (pCR 4 TOPO Vector) (Invitrogen). Plasmids were
isolated from transformants using the QIAprep Spin Minprep kit (Qiagen, Hilden,
Germany), and inserts were sequenced by a commercial provider. Closest relatives
of the partial 16S rRNA sequences were determined using the SeqMatch web tool
provided through the Ribosomal Database Project.

2.3.8

Bifidobacterium specific qRT-PCR

Quantitative real time PCR (qRT-PCR) was performed as described by Martı́nez
et al. (2009), using a Mastercycler Realplex2 (Eppendorf AG, Hamburg, Germany)
and the Bifidobacterium-specific primers (F: 5TCGCGTC(C/T)GGTGTGAAAG3)
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and R: 5CCACATCCAGC(A/G)TCCAC3) (Rinttila et al., 2004). Standard curves
for absolute quantification of bifidobacteria in the fecal samples were prepared using
overnight cultures (14 h) of Bifidobacterium animalis ATCC 25527T and Bifidobacterium infantis ATCC 15697T .

2.3.9

Statistical analysis

One-way ANOVA tests with repeats were performed to identify differences in fecal
microbiota composition induced through the dietary treatments (RS2, RS4 and control) in all ten subjects. One-way ANOVA tests were performed to identify significant
alterations of taxa in individual subjects. Samples obtained during the baseline and
washout periods were not included into the statistical analysis. Post hoc pair-wise
comparisons were done using Tukey’s method. P-values <0.05 were considered significant unless otherwise stated.

2.4
2.4.1

Results
Multiplex sequencing of 16S rRNA tags revealed
alterations of the fecal microbiota through RS
consumption and functional differences between RS
types 2 and 4

Pyrosequencing of 16S rRNA amplicons from 161 fecal samples resulted in an average
of 3,423 sequences per sample after quality control (551,183 sequences in total) with
a mean sequence length of approximately 490 bp. The average number of operational
taxonomic units (OTUs) identified per subject was 1,081. Rarefaction curves for all
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ten subjects and the three treatments and baselines/washouts were generated and
are shown (Supplementary Figure 2.5). This analysis and diversity examination by
Shannon’s index revealed that the consumption of RS did not alter the bacterial diversity in fecal samples (Supplementary Figure 2.5).
The bacterial composition in the ten subjects during the baseline period was, as
shown by other studies (Turnbaugh et al., 2009, Ley et al., 2006b), dominated by
the phyla Firmicutes (78%) and Bacteroidetes (13%). Other phyla detected were
Actinobacteria (3%), Verrucomicrobia (1%), and Proteobacteria (1%), and 4% of the
sequences remained unclassified (Supplementary Figure 2.6A). At the family level,
the predominant groups were the Lachnospiraceae (42%), Ruminococcaceae (19%),
Bacteroidaceae (8%) (Supplementary Figure 2.6B). Among the well characterized
culturable genera were Bacteroides (7.5%), Bifidobacterium (1.3%), Fecalibacterium
(8.4%), Ruminococcus (2.5%), Roseburia (2.1%), and Dorea (3.2%) (Supplementary
Figure 2.6C).
Sequence proportions determined by pyroseqeuncing were used to establish the effects of RS on the gut microbiota composition, and the groups of colonic bacteria
that were significantly affected are shown in Table 2.1. The control crackers included
in the study (providing a daily dose of more than 55 g of native starch) did not have
a significant impact on the fecal microbiota, as the microbial populations during administration of these crackers showed little difference to those during baseline and
washout periods. In contrast, RS significantly affected several groups of colonic bacteria, with the two types of RS exerting functional differences in terms of their ability
to modulate the gut microbiota. Taxonomy-based analysis using RDP Classifier revealed major differences in the proportions of phyla associated with consumption
of RS4, including significant decreases in Firmicutes (p<0.001) by more than 10%
on average, and increases in Bacteroidetes (p<0.01) and Actinobacteria (p<0.05) by
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The bacteria populations are averages of all three time points of feeding periods.
The bacteria populations are averages of the two time points of the baseline period.
3 The bacteria populations are averages of all the six time points of the three washout periods.
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1

Phylum
Firmicutes
Bacteroidetes
Actinobacteria
Family
Bifidobacteriaceae
Porphyromonadaceae
Ruminococcaceae
Erysipelotrichaceae
Genus
Faecalibacterium
Parabacteroides
Bifidobacterium
Dorea
Species (OTU)
B. adolescentis
P. distasonis
R. bromii
F. prausnitzii
E. rectale
D. formicigenerans
C. clostridioforme
Clostridiales spp.

RS21

Table 2.1: Abundance of bacterial taxa that were impacted by RS consumption in fecal samples of ten human subjects as determined by pyrosequencing of 16S rRNA tags. Proportion
of bacterial taxa expressed in percentage (Mean ± SD)
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around 5% each 2.6. These changes were associated with a decrease in the family Ruminococcaceae (p<0.01) and increases in the genera Parabacteroides (p<0.001) and
Bifidobacterium (p<0.05). The proportion of the genus Faecalibacterium decreased
in the RS4 treatment (p<0.05), although this reduction was small (less than 1% when
compared to the baseline) (Table 2.1). The genus Dorea was determined to be significantly reduced by both types of RS (p<0.01).
To gain a more in depth understanding of the effects of RS on the relative abundances
of microbial taxa, we used a phylogeny-based strategy to analyze the sequence data
on the basis of OTUs (>97% sequence identity).

85

Figure 2.2: Characterization of the fecal microbiota in ten human subjects that consumed a random succession of crackers containing RS2, RS4, and native wheat starch
(control) by multiplex pyrosequencing of 16S rRNA tags. Phylogenetic trees that encom-
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pass the phyla (A) Firmicutes (with Clostridiales groups XIVa and IV labeled), (B) Actinobacteria
and (C) Bacteroidetes are shown. The trees contain representative sequences of all OTUs detected to
be impacted by RS in individual subjects together with sequences of related entries in the database
(which included both type strains of known species and sequences from molecular studies of human
fecal samples). Sequences were aligned in Muscle 3.6 and the trees were built using the neighborjoining algorithm with 1,000 bootstrap replicates in MEGA 4.0. Open-black and closed-gray symbols
were used to label sequences from individual subjects. OTUs that were not significantly affected
in all ten subjects were labeled as not significant (NS). The graphs next to the trees show the
abundance of OTUs and bacterial groups that were significantly altered in the treatment groups
(RS2, RS4, control). These graphs show mean proportions of the three individual samples taken
during the treatment periods for each subject. Background refers to samples taken in periods were
no crackers were consumed. Repeated measures ANOVA in combination with a Tukey’s post-hoc
test were performed to indentify differences between treatment groups, and the background was not
included in the statistic analysis. *p<0.05; **p<0.01; ***p<0.001.

First we identified OTUs that were affected through the dietary treatments in individual subjects. We then constructed phylogenetic trees with representative sequences of
these OTUs according to phylum, which are shown in Figure 2.2A (for Firmicutes),
Figure 2.2B (for Actionobacteria), and Figure 2.2C (for Bacteroidetes). The abundance of the OTUs in all ten subjects was then quantified by local BLASTn. This
analysis revealed that eight OTUs showed statistically significant differences among
treatment groups, seven of which could be linked to known bacterial species (Table 2.1,
Figure 2.2). The findings of the OTU-based approach were in general agreement with
those obtained with the Classifier tool, and the species responsible for the significant
RS induced changes in the genera Bifidobacterium, Parabacteroides, Faecalibacterium,
and Dorea did correspond to Bifidobacterium adolescentis (p<0.05), Parabacteroides
distasonis (p<0.001), Faecalibacterium prausnitzii (p<0.05) and Dorea formicigenerans (p<0.05), respectively (Table 2.1). In addition, the OTU-based analysis iden-
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tified four additional taxa that differed between the treatment groups, belonging to
the Clostridium clusters XIVa and IV. The proportion of Clostridium clostridioforme
was increased by both RS, and the increase reached statistical significance for RS4
(p<0.05). Furthermore, the abundance of the species Eubacterium rectale (p<0.05)
and Rumminococcus bromii (p<0.05) were significantly increased when RS2 was consumed when compared to RS4.

2.4.2

The population shifts induced by RS were substantial
but varied between subjects

RS, and especially RS4, led to major changes in the composition of the gut microbiota in a subset of subjects. Numerically, the most substantial alterations were
the change in the genus Bifidobacterium (e.g. Bifidobacterium adolescentis), which
increased approximately 10 fold (from 2-3% to 18-30%) in three subjects through
RS4. Other significant changes were Parabacteroides distasonis, which significantly
increased through RS4 by 7 fold on average, and Eubacterium rectale, which was significantly enriched when RS2 was consumed, reaching around 20% of the total population in two of the subjects. The most consistent alteration detected was the reduction
in Firmicutes by RS4, which occurred in nine of the subjects (Figure 2.3). Other common alterations were the increase in Bacteroidetes (seven subjects), Parabacteroides
distasonis (seven subjects), and Bifidobacterium adolescentis (six subjects) through
RS4, and the increase of Eubacterium rectale through RS2 (eight subjects). Despite
these substantial population shifts, our findings clearly showed that effects of RS and
their magnitude varied among individuals. Figure 2.3 shows compositional changes
induced by RS2 and RS4 when compared to administration of native starch for individual subjects. The data revealed that none of the community shifts induced through
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Figure 2.3: Bubble plots showing differences in the proportions of bacterial
taxa (as per cent of the total microbiota composition) detected between
the RS4 (A) and RS2 (B) periods when compared to the control period.
The sizes of the bubbles are proportional to the magnitude of the difference. Black
circles represent increases in proportions induced through RS treatment, and white
circles show a decrease.

the two RS types were observed in all ten subjects.

2.4.3

Temporal dynamics of microbial populations in
response to RS

The generation of community profiles from 17 individual samples per subject throughout the trial allowed insight into how RS influenced the population dynamics within
the fecal microbiota. This analysis showed that all the changes induced by RS were
reversible within one week, and no differences in the proportions of the bacterial
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Figure 2.4: Temporal dynamics of the human fecal microbiota in response
to the consumption of crackers containing RS2, RS4, and native wheat
starch (control) in five human subjects. Graphs on the left show proportions of
the three main phyla and four representative species (Bifidobacterium adolescentis,
Parabacteroides distasonis, Ruminococcus bromii and Clostridium clostridioforme)
as determined by pyrosequencing of 16S rRNA tags. Gel images on the right show
molecular fingerprints generated by DGGE. Bands that represent Bifidobacterium
adolescentis and Parabacteroides distasonis are labeled.
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groups were detected between the first washout sample and the baseline (Student’s
t-test, p>0.05). Figure 2.4 shows the temporal patterns of the three main phyla (Actinobacteria, Bacteroidetes, and Firmicutes) and four selected species (Ruminococcus
bromii, Clostridium clostridioforme, Parabacteroides distasonis and Bifidobacterium
adolescentis) for five representative subjects. The data revealed that bacterial groups
showed marked differences in the stability of their populations and in their temporal
response to RS. For example, levels of Bifidobacterium adolescentis and Parabacteroides distasonis were remarkably stable in fecal samples in baseline and washout
samples, and their populations returned to baseline level within one week after RS
administration was stopped. In contrast, proportions of some taxa, e.g. the species
Ruminococcus bromii and Clostridium clostridioforme showed higher fluctuations in
background samples (Figure 2.4). Although all these taxa were also significantly
impacted by dietary RS, population dynamics were more idiosyncratic, and these
bacterial groups might be more influenced by other dietary components or environmental factors.
The analysis of population dynamics revealed that RS2 and RS4 induced changes
within the fecal microbial community that differed in their temporal patterns. RS4
led to an abrupt increase in the abundance of Bifidobacterium adolescentis in some
subjects with a slight mitigation throughout the three-week feeding period (subject 1,
4, and 6). Out of the six subjects that showed an increase in Bifidobacterium adolescentis with RS4, five did also manifest an increase with RS2. However, RS2 induced
a slower gradual increase with higher proportions in week three of consumption when
compared to week one.
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2.4.4

Selective culture, PCR-DGGE and Bifidobacterium
specific quantitative RT-PCR (qRT-PCR)

Quantification of bacterial taxa in human fecal samples by pyrosequencing of 16S
rRNA tags has been validated and it showed a high correlation with other molecular methods such as qRT-PCR and phylogenetic microarray (Claesson et al., 2009,
Martı́nez et al., 2009). To investigate the impact of RS on human fecal microbiota
with independent and well established methods, we analyzed all 161 fecal samples
obtained during this study with selective culture for representative bacterial groups,
PCR-DGGE, and Bifidobacterium specific qRT-PCR.
Throughout the study, numbers of total anaerobic bacteria, enterobacteria, enterococci, bifidobacteria, and Bacteroides/Parabacteroides spp. were determined by selective culture. These bacterial taxa were selected as they were included in previous
studies that concerned the effect pre- and probiotics on the human fecal microbiota,
and enterococci and enterobacteria cannot be detected by pyrosequencing as they
constitute a minor fraction of the total microbial community in the human gut (Tannock et al., 2004, Tannock GW, 2000). Selective culture revealed significant higher
numbers of bifidobacteria and Bacteroides/Parabacteroides spp. during RS4 consumption (p<0.05) (Table 2.2), confirming the findings obtained by pyrosequencing
(Table 2.1). No significant changes were detected for enterococci and lactose fermenting enterobacteria (Table 2.2).
DGGE revealed that RS4, and to a lesser degree RS2, induced significant alterations
to the fecal microbiota of most subjects. The most consistent change detected was
a significant increase in the staining intensity of a DNA fragment that represented
Bifidobacterium adolescentis, which occurred in four subjects during RS4 consumption and in 3 subjects when RS2 was consumed. The intensity of this DGGE band
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in all the subjects showed a remarkably high correlation (r = 0.9178, p<0.0001) with
the abundance of Bifidobacterium adolescentis assessed by pyrosequencing (Supplementary Figure 2.7A). DGGE analysis confirmed the distinct dynamics of the Bifidobacterium adolescentis population in response to RS2 and RS4 that were detected
by pyrosequencing, meaning that RS4 induced a swift and reversible increase in band
intensity while RS2 caused a gradual raise (Figure 2.4). DGGE also detected an increase of Parabacteroides distasonis in one of the subjects when RS4 was consumed.
Therefore, DGGE confirmed the increase in bifidobacteria and Parabacteroides distasonis in some of the subjects, but as expected, overall resolution of this technique
was lower than pyrosequencing.
Quantitative enumeration of bifidobacteria by qRT-PCR confirmed the significant
increase in Bifidobacterium numbers during consumption of RS4 (10.3 ± 1.5 log10
cells/gram of feces; p<0.01), and also indicated a significant increase when RS2 (10.1
± 1.3 log10 cells/gram of feces; p<0.05) was consumed compared to control (9.7 ±
1.2 log10 cells/gram of feces). The total cell numbers of bifidobacteria increased by
more than three-fold on average through RS4, while RS2 doubled the numbers. In
the three subjects with the highest response to RS4, qRT-PCR showed an increase
of bifidobacteria to more than 1011 cells per gram. The cell counts obtained with
qRT-PCR in all fecal samples included in this study (n = 161) showed a high correlation (r=0.8310, p<0.0001) with the abundance of bifidobacteria determined by
pyrosequencing (Figure 2.7B).

2.4.5

RS was well tolerated by human subjects

In addition to microbiota analyses, we also collected data on bowel-related characteristics during the feeding and washout periods using a weekly symptoms diary that

93
rated bowel movement, stool consistency, discomfort, flatulence, abdominal pain, and
bloating on a scale from 1 (best) to 5 (worse). One-way ANOVA analysis revealed a
significant difference for flatulence (p<0.05), which was moderately increased during
the consumption of both types of RS when compared to periods with control crackers
(Table 2.3). No significant changes occurred in fecal pH for any of the treatments
and no significant detrimental effects were observed on bowel movement, stool consistency, or discomfort, indicating that RS at doses of 33 g per day are well tolerated
in human subjects.

2.5

Discussion

To gain a deeper understanding of the impact of two chemically different forms of RS
on the composition and temporal dynamics of the fecal microbiota, we employed a
study in 10 human subjects who were weekly monitored throughout a period of 17
weeks. The data revealed that RS types induced substrate specific shifts in the fecal
microbial community that were tightly associated with consumption and which varied
between subjects. Our in vivo findings on RS2 were in accordance to previous studies
on starch fermentation in in vitro models of the large intestine, which showed an
enrichment of Bifidobacterium adolescentis, Eubacterium rectale, and Ruminococcus
bromii (Kovatcheva-Datchary et al., 2009, Leitch et al., 2007). The same bacterial
groups, with the exception of bifidobacteria, were also enriched in fecal samples of
obese human subjects during consumption of RS3 (Walker et al., 2011). In contrast,
our findings clearly showed that the response of the fecal microbiota to RS4 differed to
that of RS2 and RS3. For example, Parabacteroides distasonis was enriched through
RS4, while Eubacterium rectale and Ruminococcus bromii showed a significant decrease. Strikingly, RS4 also led to phylum level alterations, decreasing the proportion
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of Firmicutes while increasing Bacteroidetes and Actinobacteria. Such phylum level
changes have not been observed in fecal samples of human subjects consuming RS2
in our study and RS3 as shown by Walker and coworkers (Walker et al., 2011).
There was very little overlap in the bacterial groups that responded to both RS2
and RS4. This was surprising as the RS types used in this study were both starch
polysaccharides that consist of glucose monomers with the same covalent bonds, although the RS4 was cross-linked by phosphorylation. One of the bacterial groups
that responded to both RS types was the genus Bifidobacterium, which increased
in six subjects with RS4 and in five of the same subjects with RS2. However, the
temporal dynamics of these modulations differed. RS2 led to a much slower raise in
bifidobacteria, reaching comparable numbers to RS4 only in week three. This clearly
showed that time is an important variable when studying dietary modulations of the
human gut microbiota. It appears that the ability to increase levels of bifidobacteria
is comparable between RS2 and RS4 in the long run, but extended feeding studies
will be necessary to determine the exact taxon-time patterns of responses to different
forms of RS.
Questions remain about the mechanisms by which different RS types selectively promote groups of colonic bacteria in humans in vivo. Starch fermentation per se should
not be selective as many bacterial genera (Clostridium, Bacteroides, Bifidobacterium,
Butyrivibrio, Prevotella, Roseburia, Eubacterium, Ruminococcus, etc.) present in the
human GIT can utilize this substrate in vitro, and various bacterial systems involved
in the degradation of starch have been identified by genomic approaches (Louis et al.,
2007, Kovatcheva-Datchary et al., 2009, Bird and Topping, 2008, Cho et al., 2001,
D’Elia and Salyers, 1996, Duncan et al., 2007, Flint et al., 2008, Ryan, 2004, Schell
et al., 2002, Xu et al., 2003). However, our in vivo findings showed that substrate
preferences and competitive abilities exist in the gut environment. In this respect, it is
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important to point out that the RS types used in this study varied markedly in terms
of their chemical structure. RS2 is a granular form of high amylose corn starch, while
RS4 is a chemically modified starch that is cross-linked through phosphate moieties.
Therefore, it is possible that different groups of colonic bacteria produce enzymes with
distinct activities towards the two RS types, promoting different dynamics in the gut
ecosystem. However, it is also of note that the ability of bacterial groups to make use
of RS in vivo might relate not only to the utilization but also to the binding of the
substrate. It is striking that Ruminococcus bromii, Bifidobacterium adolescentis, and
Eubacterium rectale, which showed the most substantial increases in the human gut
in response to RS2, have also been shown to form highly selective associations with
this substrate (Leitch et al., 2007). Therefore, the adherence of bacteria to starch
granules might constitute an important first step in the utilization of this substrate,
and groups of colonic bacteria might differ in their ability to adhere to granules of
RS2 and RS4. The mechanisms by which different types of RS become fermented in
the human colon remain an important area of future research.
A significant finding of this study was the individualized responses of the gut microbiota to RS2 and RS4, which has also been shown previously for RS3 (Walker et al.,
2011). Out of the nineteen OTUs that were detected to respond during this study
in individual subjects, eleven did not reach significance when all subjects were included in the analysis (e.g. Bifidobacterium longum, Ruminococcus obeum, Roseburia
intestinalis, Roseburia inulinivorans, and several Bacteroides spp.). In addition, none
of the taxa that were significantly affected by RS showed a response in all ten subjects.
There are three possible explanations for the individuality of the responses. First, few
OTU are completely conserved among humans (Turnbaugh et al., 2009, Tap et al.,
2009), thus species that were affected in some subjects might simply not be present in
other individuals. Second, strain-level differences in the ability to utilize substrates
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could contribute to the inter-individual variations. For example, it has been shown
for Bifidobacterium adolescentis that individual strains can have major differences
in their amylolytic activity (Crittenden et al., 2001, Ramsay et al., 2006). Lastly,
host factors might play an important role. For example, subject specific environmental constrains (e.g. through limitations in growth factors other than carbohydrates)
might restrict the ability of a bacterial group to increase in numbers even if a suitable growth substrate is provided. In addition, differences in host genotype might
influence transit times or the amount of digestive enzymes secreted, thus affecting
the fraction of RS that survives digestion.
There is currently no scientific consensus of what defines a healthy human microbiota in terms of its composition. Therefore, predictions on the consequences of the
compositional alterations induced through RS2 and RS4 in terms of health remain
speculative. Nevertheless, the distinct effects of RS2 and RS4 on the microbial community in the gut suggest that these substrates could have a different impact on the
host. RS2 promoted Eubacterium rectale, a species associated with high butyrate
production (Flint et al., 2007), a trait that could be especially beneficial in the prevention of inflammation and colon cancer (McIntyre et al., 1993, Scheppach et al.,
1992). In contrast, RS4 reduced the amount of Firmicutes in favor of Bacteroidetes
and bifidobacteria. Such a shift in the gut microbiota could be especially beneficial
in the prevention or treatment of obesity and related metabolic disorders. A microbiome enriched in Firmicutes has been associated with an increased capacity for
energy harvest and obesity (Ley et al., 2006a, Turnbaugh et al., 2006), and a reduction of this phylum could therefore reduce the amount of calories extracted from the
diet. Furthermore, bifidobacteria have been linked to metabolic and immunological
improvements related to type 2 diabetes (Cani and Delzenne, 2009). As we gain a
better understanding about the contributions of members of the gut microbiota to
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disease, knowledge as obtained during this study can aid in a more systematic selection of carbohydrates for intervention studies.
In this study, we demonstrated that RS2 and RS4 promote distinct compositional
alterations within the human gut microbiota. These functional differences imply that
specific bacterial populations can be selectively targeted by starches with different
chemical structures. If future research will reveal causative associations between dysbiosis and disease, then selective dietary strategies that redress these imbalances have
potential to improve health. However, the individualized responses observed during
this study certainly pose a hurdle to developing universal dietary recommendations,
and they imply that more personalized strategies that target the gut microbiome
might enhance the success rate of such applications.
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2.6

Supplementary material

RS2

b

a

0.2747
0.0193
0.0117
0.2791

3.92 ± 1.22
4.64 ± 0.95 3.96 ± 0.41
9.79 ± 0.51 9.49 ± 0.42 9.57 ± 0.19
9.73 ± 0.43 9.38 ± 0.25 9.30 ± 0.33
10.31 ± 0.33 10.45 ± 0.12 10.41 ± 0.14

Backgroundb P-value
0.0849

6.77 ± 0.76

Control
6.25 ± 0.51

5.87 ± 1.07

RS4

Numbers in bold represent the significantly higher values than the ones in italic.
Background refers to bacterial numbers obtained from the combined baseline and washout periods.

Lactose fermenting 6.55 ± 0.83
bacteria
Enterococci
4.05 ± 1.30
Bifidobacteria
9.61 ± 0.50
Bacteroidetes
9.35 ± 0.41
Total anaerobes
10.51 ± 0.27

Bacterial group

Table 2.2: Enumeration of bacterial groups through culturing. Log10 cfu/g feces
(Mean ± SD)a .

99

100

Table 2.3: Symptoms. Mean ± standard deviations of weekly symptoms
reported by the subjects in a scale from 1 (best) to 5 (worse).

Bowel
movement
Stool
consistency
Discomfort
Flatulenceb
Abdominal pain
Bloating

RS2

RS4

Control

Backgrounda

1.73 ± 0.83

1.90 ± 0.93

1.73 ± 0.77

1.74 ± 0.59

2.07 ± 1.29

2.23 ± 0.92

2.03 ± 0.91

2.00 ± 0.83

1.65
2.42
1.63
1.67

±
±
±
±

0.65 1.87 ± 0.79 1.50 ± 0.55 1.53 ± 0.40
1.28 2.27 ± 1.00 1.37 ± 0.58 1.54 ± 0.43
0.79 1.47 ± 0.67 1.40 ± 0.60 1.36 ± 0.62
0.98 1.40 ± 0.52 1.07 ± 0.14 1.29 ± 0.45

a

Background refers to bacterial numbers obtained from the combined
baseline and wash-out periods.
b
Significant differences were detected by ANOVA (p<0.05). Tukeys posthoc test did not detect significance in pair wise comparisons.

Table 2.4: Formulation of crackers per 100 g.
Ingredient

Control

RS2

RS4

Pastry flour
Midsol 50 (native starch)
Hi-Maize 260
Fibersym R RW
Soybean and cottonseed shortening
Wheat gluten
White granulated sugar
Malt extract
Sweet whey-dried
Table salt
Baking soda
Water
Ammonium bicarbonate

1.97
55.72
7.87
7.87
5.24
0.33
0.98
0.66
0.33
18.36
0.66

1.97
55.72
7.87
7.87
5.24
0.33
0.98
0.66
0.33
18.36
0.66

1.97
16.39
39.33
7.87
7.87
5.24
0.33
0.98
0.66
0.33
18.36
0.66
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Table 2.5: Baking conditions (◦ F) of crackers containing control starch, RS2,
RS4.
Control Doughs Oven Profile:
Zone 1

Zone 2

Top
460
470
Bottom
430
400
Bake time 7 minutes

Zone 3
420
380

RS4 Doughs Oven Profile:
Zone 1

Zone 2

Top
470
450
Bottom
470
470
Bake time 7 minutes

Zone 3
440
440

RS2 Doughs Oven Profile:
Zone 1

Zone 2

Top
470
450
Bottom
470
470
Bake time 8 minutes

Zone 3
440
440
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Figure 2.5: Diversity and species richness of the fecal microbiota in ten
human subjects that consumed crackers containing native starch, RS2,
RS4, or no crackers. (A) Rarefaction curves showing the amount of OTUs in all
individual fecal samples taken from the ten subjects. (B) Shannon’s Diversity Index
for all subjects during treatments and baseline/washout. Native starch (red), RS2
(green), RS4 (purple), no crackers (yellow).
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Figure 2.6: Collective fecal microbial composition including the major taxonomic groups. At the (A) phylum, (B) family, and (C) genus levels averaged for
10 human subjects corresponding to the baseline, washouts, and periods in which
crackers containing native starch (control), RS2 and RS4 were consumed.
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Figure 2.7: Confirmation of findings obtained with pyrosequencing by analyzing the fecal microbiota with PCR-DGGE and Bifidobacterium specific
qRT-PCR. (A) Pearson correlation between the abundance of Bifidobacterium adolescentis as determined by band intensity in PCR-DGGE and pyrosequencing of 16S
rRNA tags. (B) Pearson correlation between cell numbers and percent abundance of
bifidobacteria as determined by qRT-PCR and pyrosequencing, respectively.

105

Bibliography
G.C. Abell, C.M. Cooke, C.N. Bennett, M.A. Conlon, and A.L. McOrist. Phylotypes
related to ruminococcus bromii are abundant in the large bowel of humans and
increase in response to a diet high in resistant starch. FEMS Microbiol. Ecol., 66:
505–515, 2008.
N.G. Asp. Resistant starch. proceedings from the second plenary meeting of euresta:
European flair-concerted action no 11 on the physiological implications of the consumption of resistant starch in man. Eur J Clin Nutr, 46:Suppl2S1, 1992.
M. Bauer-Marinovic, S. Florian, K. Muller-Schmehl, H. Glatt, and G. Jacobasch.
Dietary resistant starch type 3 prevents tumor induction by 1,2-dimethylhydrazine
and alters proliferation, apoptosis and dedifferentiation in rat colon. Carcinogenesis, 27:1849–1859, 2006.
K.M. Behall, D.J. Scholfield, J.G. Hallfrisch, and H.G. Liljeberg-Elmstahl. Consumption of both resistant starch and beta-glucan improves postprandial plasma glucose
and insulin in women. Diabetes Care, 29:976–981, 2006.
A.R. Bird and D.L. Topping. Resistant starch as a prebiotic. ASM Press, Washington
D.C., 2008.

106
P.D. Cani and N.M. Delzenne. Cani pd, delzenne nm. Curr. Opin. Pharmacol., 9:
737–743, 2009.
P.D. Cani, A.M. Neyrinck, F. Fava, C. Knauf, R.G. Burcelin, K.M. Tuohy, G.R.
Gibson, and Delzenne N.M. Selective increases of bifidobacteria in gut microflora
improve high-fat-diet-induced diabetes in mice through a mechanism associated
with endotoxaemia. Diabetologia, 50:2374–2383, 2007.
K.H. Cho, D. Cho, G.R. Wang, and A. Salyers. New regulatory gene that contributes
to control of bacteroides thetaiotaomicron starch utilization genes. J Bacteriol,
183:7198–7205, 2001.
M.J. Claesson, O. O’Sullivan, Q. Wang, J. Nikkil, J.R. Marchesi, H. Smidt, W.M.
de Vos, R.P. Ross, and P.W. O’Toole. Comparative analysis of pyrosequencing
and a phylogenetic microarray for exploring microbial community structures in the
human distal intestine. PLoS One, 4:e6669, 2009.
J.R. Cole, Q. Wang, E. Cardenas, J. Fish, B. Chai, R.J. Farris, A.S. Kulam-SyedMohideen, D.M. McGarrell, T. Marsh, G.M. Garrity, and J.M. Tiedje. The ribosomal database project: improved alignments and new tools for rrna analysis.
Nucleic Acids Res., 37:D141–145, 2009.
M.A. Conlon and A.R. Bird.

Interactive and individual effects of dietary non-

digestible carbohydrates and oils on dna damage, scfa and bacteria in the large
bowel of rats. Br. J. Nutr., 101:1171–1177, 2009.
R. Crittenden and M.R. Playne. Modifying the human intestinal microbiota with
prebiotics. Taylor and Francis, New York, 2006.

107
R. Crittenden, A. Laitila, P. Forssell, J. Mtt, M. Saarela, T. Mattila-Sandholm, and
P. Myllrinen. Adhesion of bifidobacteria to granular starch and its implications in
probiotic technologies. Appl Environ Microbiol, 67:3469–3475, 2001.
J.N. D’Elia and A.A. Salyers. Contribution of a neopullulanase, a pullulanase, and
an alpha-glucosidase to growth of bacteroides thetaiotaomicron on starch. J. Bacteriol., 178:7173–7179, 1996.
L. Dethlefsen, S. Huse, M.L. Sogin, and D.A. Relman. The pervasive effects of an
antibiotic on the human gut microbiota, as revealed by deep 16s rrna sequencing.
PLoS Biol., 6:e280, 2008.
M.G. Dominguez-Bello, E.K. Costello, M. Contreras, M. Magris, G. Hidalgo,
N. Fierer, and R. Knight. Delivery mode shapes the acquisition and structure
of the initial microbiota across multiple body habitats in newborns. Proc. Natl.
Acad. Sci. USA, 107:11971–11975, 2010.
B. Drzikova, G. Dongowski, and E. Gebhardt. Dietary fibre-rich oat-based products
affect serum lipids, microbiota, formation of short-chain fatty acids and steroids in
rats. Br. J. Nutr., 94:1012–1025, 2005.
S.H. Duncan, A. Belenguer, G. Holtrop, A.M. Johnstone, H.J. Flint, and G.E. Lobley.
Reduced dietary intake of carbohydrates by obese subjects results in decreased
concentrations of butyrate and butyrate-producing bacteria in feces. Appl. Environ.
Microbiol., 73:1073–1078, 2007.
R.C. Edgar. Muscle: multiple sequence alignment with high accuracy and high
throughput. Nucleic Acids Res., 32:1792–1797, 2004.

108
H.J. Flint, S.H. Duncan, K.P. Scott, and P. Louis. Interactions and competition
within the microbial community of the human colon: links between diet and health.
Environ. Microbiol., 9:1101–1111, 2007.
H.J. Flint, E.A. Bayer, M.T. Rincon, R. Lamed, and B.A. White. Polysaccharide
utilization by gut bacteria: potential for new insights from genomic analysis. Nat
Rev Microbiol, 6:121–131, 2008.
H.A. Gordon and L. Pesti. The gnotobiotic animal as a tool in the study of host
microbial relationships. Bacteriol. Rev., 35:390–429, 1971.
T.A. Hall. BioEdit: a user-friendly biological sequence alignment editor analysis
program for Windows 95/98/NT. Nucleic Acids Symposium Series, 41:95–98, 1999.
M. Hamady and R. Knight. Microbial community profiling for human microbiome
projects: Tools, techniques, and challenges. Genome Res., 19:1141–1152, 2009.
B. Kleessen, G. Stoof, J. Proll, D. Schmiedl, J. Noack, and M. Blaut. Feeding resistant
starch affects fecal and cecal microflora and short-chain fatty acids in rats. J. Anim.
Sci., 75:2453–2462, 1997.
P. Kovatcheva-Datchary, M. Egert, A. Maathuis, M. Rajili-Stojanovi, A.A. de Graaf,
H. Smidt, W.M. de Vos, and K. Venema. Linking phylogenetic identities of bacteria
to starch fermentation in an in vitro model of the large intestine by rna-based stable
isotope probing. Environ. Micorbiol., 11:914–926, 2009.
R.K. Le Leu, I.L. Brown, Y. Hu, A. Esterman, and G.P. Young. Suppression of
azoxymethane-induced colon cancer development in rats by dietary resistant starch.
Cancer Biol. Ther., 6:1621–1626, 2007.

109
E.C. Leitch, A.W. Walker, S.H. Duncan, G. Holtrop, and H.J. Flint. Selective colonization of insoluble substrates by human faecal bacteria. Environ. Microbiol., 9:
667–679, 2007.
U. Lesmes, E.J. Beards, G.R. Gibson, K.M. Tuohy, and E. Shimoni. Effects of resistant starch type iii polymorphs on human colon microbiota and short chain fatty
acids in human gut models. J. Agric. Food Chem., 56:5415–5421, 2008.
R.E. Ley, D.A. Peterson, and J.I. Gordon. Ecological and evolutionary forces shaping
microbial diversity in the human intestine. Cell, 124:837–848, 2006a.
R.E. Ley, P.J. Turnbaugh, S. Klein, and J.I. Gordon. Microbial ecology: human gut
microbes associated with obesity. Nature, 444:1022–1023, 2006b.
P. Louis, K.P. Scott, S.H. Duncan, and H.J. Flint. Understanding the effects of diet
on bacterial metabolism in the large intestine. J. Appl. Microbiol., 102:1197–1208,
2007.
I. Martı́nez, G. Wallace, C. Zhang, R. Legge, A.K. Benson, T.P. Carr, E.N. Moriyama,
and J. Walter. Diet-induced metabolic improvements in a hamster model of hypercholesterolemia are strongly linked to alterations of the gut microbiota. Appl.
Environ. Microbiol., 75:4175–4184, 2009.
A. McIntyre, P.R. Gibson, and G.P. Young. Butyrate production from dietary fibre
and protection against large bowel cancer in a rat model. Gut, 34:386–391, 1993.
N.M. Moreau, L.J. Martin, C.S. Toquet, C.L. Laboisse, P.G. Nguyen, B.S. Siliart,
H.J. Dumon, and M.M. Champ. Restoration of the integrity of rat caeco-colonic
mucosa by resistant starch, but not by fructo-oligosaccharides, in dextran sulfate
sodium-induced experimental colitis. Br. J. Nutr., 90:75–85, 2003.

110
J.K. Nicholson, E. Holmes, and I.D. Wilson.

Gut microorganisms, mammalian

metabolism and personalized health care. Nat. Rev. Microbiol., 3:431–438, 2005.
A.C. Nilsson, E.M. Ostman, J.J. Holst, and I.M. Bjorck. Including indigestible carbohydrates in the evening meal of healthy subjects improves glucose tolerance, lowers
inflammatory markers, and increases satiety after a subsequent standardized breakfast. J. Nutr., 138:732–739, 2008.
A.P. Nugent. Health properties of resistant starch. Nutr. Bull., 30:27–54, 2005.
A.G. Ramsay, K.P. Scott, J.C. Martin, M.T. Rincon, and H.J. Flint. Cell-associated
alpha-amylases of butyrate-producing firmicute bacteria from the human colon.
Microbiology, 152:3281–3290, 2006.
T. Rinttila, A. Kassinen, E. Malinen, L. Krogius, and A. Palva. Development of
an extensive set of 16s rdna-targeted primers for quantification of pathogenic and
indigenous bacteria in faecal samples by real-time pcr. J. Appl. Microbiol., 97:
1166–1177, 2004.
C.J. Robinson, B.J. Bohannan, and V.B. Young. From structure to function: the
ecology of host-associated microbial communities. Microbiol. Mol. Biol. Rev., 74:
453–476, 2010.
K.J. Ryan. Normal Microbial Flora. McGraw-Hill, New York, 2004.
M.A. Schell, M. Karmirantzou, B. Snel, D. Vilanova, B. Berger, G. Pessi, M.C.
Zwahlen, F. Desiere, P. Bork, M. Delley, and F. Pridmore, R.D. Arigoni. The
genome sequence of bifidobacterium longum reflects its adaptation to the human
gastrointestinal tract. Proc Natl Acad Sci USA, 99:14422–14427, 2002.

111
W. Scheppach, H. Sommer, T. Kirchner, G.M. Paganelli, P. Bartram, S. Christl,
F. Richter, G. Dusel, and H. Kasper. Effect of butyrate enemas on the colonic
mucosa in distal ulcerative colitis. Gastroenterology, 103:51–56, 1992.
S. Silvi, C.J. Rumney, A. Cresci, and Rowland I.R. Resistant starch modifies gut
microflora and microbial metabolism in human flora-associated rats inoculated with
faeces from italian and uk donors. J. Appl. Microbiol., 86:521–530, 1999.
K. Tamura, J. Dudley, M. Nei, and S. Kumar. MEGA4: Molecular Evolutionary
Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol, 24:1596–1599,
2007.
G.W. Tannock. The search for disease-associated compositional shifts in bowel bacterial communities of humans. Trends Microbiol., 16:488–495, 2008.
G.W. Tannock, K. Munro, R. Bibiloni, M.A. Simon, P. Hargreaves, P. Gopal,
H. Harmsen, and G. Welling. Impact of consumption of oligosaccharide-containing
biscuits on the fecal microbiota of humans. Appl. Environ. Microbiol., 70:2129–
2136, 2004.
Harmsen HJ Welling GW Smart J Gopal PK. Tannock GW, Munro K. Analysis of
the fecal microflora of human subjects consuming a probiotic product containing
lactobacillus rhamnosus dr20. Appl. Environ. Microbiol., 66:2578–2588, 2000.
J. Tap, S. Mondot, F. Levenez, E. Pelletier, C. Caron, J.P. Furet, E. Ugarte, R. Muñoz
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3.1

Abstract

The involvement of the gut microbiota in metabolic disorders, and the ability of whole
grains to affect both host metabolism and gut microbial ecology, suggest that some
benefits of whole grains are mediated through their effects on the gut microbiome.
Nutritional studies that assess the effect of whole grains on both the gut microbiome
and human physiology are needed. We conducted a randomized cross-over trial in
which 28 healthy humans consumed a daily dose of 60 grams of whole grain barley
(WGB), brown rice (BR), or an equal mixture of the two (BR+WGB), and characterized their impact on fecal microbial ecology and blood markers of inflammation,
glucose and lipid metabolism. All treatments increased microbial diversity, the Firmicutes/Bacteroidetes ratio, and the abundance of the genus Blautia in fecal samples.
The inclusion of WGB enriched the genera Roseburia, Bifidobacterium, and Dialister, and the species Eubacterium rectale, Roseburia faecis and Roseburia intestinalis.
Whole grains, and especially the BR+WGB treatment, reduced plasma interleukin-6
(IL-6) and peak postprandial glucose. Shifts in the abundance of Eubacterium rectale
were associated with changes in the glucose and insulin postprandial response. Interestingly, subjects with greater improvements in IL-6 levels harbored significantly
higher proportions of Dialister and lower abundance of Coriobacteriaceae. In conclusion, this study revealed that a short-term intake of whole grains induced compositional alterations of the gut microbiota that coincided with improvements in host
physiological measures (e.g. inflammation) related to metabolic dysfunctions in humans.
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3.2

Introduction

Obesity is associated with an increased risk in cardiovascular disease, type-2 diabetes, non-alcoholic fatty-liver disease, and some cancers, and constitutes a major
health concern worldwide (Hu, 2011, Cornier et al., 2008). A diet high in whole
grains and dietary fibers has been shown to improve metabolic parameters related
to these metabolic disorders (Fung et al., 2002, Jensen et al., 2004, Liu et al., 2009,
2003, Murtaugh et al., 2003, Nettleton et al., 2008). The mechanisms responsible for
the benefits of whole grains are not completely understood. It has been proposed
that the dietary fiber present in whole grains increases the viscosity of the digesta
and binds to bile acids in the small intestine, thus contributing to decreased sugar
and lipid (cholesterol) absorption (Behall et al., 2004, Alminger and Eklund-Jonsson,
2008). In addition, phytochemicals and other bioactive compounds in whole grains
might provide metabolic benefits (Adom and Liu, 2002, Harris and Kris-Etherton,
2010, Nilsson et al., 2006). Furthermore, the metabolic inflammation associated with
obesity and related diseases is now considered to trigger metabolic dysfunctions (Gregor and Hotamisligil, 2011), and the benefits of whole grains might be due to an
anti-inflammatory action (Nilsson et al., 2008b, Rosén et al., 2011). In this respect,
bacterial fermentation of undigestible constituents of whole grains in the gastrointestinal tract has been suggested to be partly responsible for the benefits of whole
grains (Harris and Kris-Etherton, 2010, Nilsson et al., 2008a, North et al., 2009).
A consideration of the gut microbiome in the context of the health effects of whole
grains has become especially relevant in the light of recent research that indicated an
etiological role of gut bacteria in metabolic disorders. Obesity and type 2 diabetes
have been linked to alterations in the intestinal microbiota in both humans and animal models (Cani et al., 2007, Larsen et al., 2010, Ley et al., 2006, Turnbaugh et al.,
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2006, Vijay-Kumar et al., 2010). If these aberrations contribute to human disease is
still unclear, but pathophysiological indicators are reduced in animal models when
animals are kept germ-free or when treated with antibiotics, and manifestations of
disease can be transmitted through the gut microbiota (Cani et al., 2008, Henao-Mejia
et al., 2012, Ley et al., 2005, Vijay-Kumar et al., 2010). Proposed mechanisms by
which the microbiota contributes to metabolic aberrations are the induction of lipolysis leading to increased fat storage (Bäckhed et al., 2007), hepatic de-novo synthesis
of triglycerides (Bäckhed et al., 2004), and the alteration of bile acid metabolites
with consequences to lipid metabolism in the host (Claus et al., 2011). Furthermore,
the gut microbiome might exacerbate the systemic inflammation associated with obesity and related metabolic disorders (Ding et al., 2010, Hotamisligil, 2006), possibly
through the induction of endotoxemia driven by lipopolysaccharide (LPS) translocation through the intestinal epithelium (Amar et al., 2008, Cani et al., 2007, 2008, Li
and Hotamisligil, 2010).
The interplay between the gut microbiota and host metabolism and the ability of
whole grains to affect both of these aspects suggest that one mechanism by which
whole grains confer their benefits might be through a modulation of the gut microbiome. Recent research has revealed that the composition and metabolism of the gut
microbiota can be modulated through prebiotics and fiber (Flint et al., 2007, Louis
et al., 2007), and these carbohydrates have been shown to improve metabolic markers in experimental models (Cani et al., 2007, Neyrinck et al., 2011). Despite these
encouraging findings, human studies that investigate the effects of whole grains and
cereal fibers on host metabolism have neglected, until now, to characterize the gut
microbiome and explore its potential contribution in mediating health improvements
(Tilg and Kaser, 2011). In addition, although the effect of fiber on the gut microbiota
has been recently studied in experimental animals (Neyrinck et al., 2011, Van den
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Abbeele et al., 2011), information on how whole grains impact human gut microbiome
composition is lacking.
The aims of this study were to characterize the impact of the incorporation of whole
grains to an otherwise unrestricted diet on gut microbial ecology in healthy human
subjects, and to investigate whether a connection with metabolic and immunological
improvements exists. For this purpose, we performed a human crossover study with
three four-week whole grain treatments, and collected fecal and blood samples at baseline and at the end of each treatment. The effect of whole grains on fecal microbiota
composition was characterized by pyrosequencing of 16S rRNA gene tags, and inflammatory and metabolic markers related to metabolic dysfunctions in humans were
measured in blood samples. The molecular characterization of fecal microbiota in
parallel to host phenotyping allowed an investigation of associations between dietary
induced metabolic changes and shifts in the gut microbiome.

3.3
3.3.1

Materials and methods
Subjects

The human trial was approved by the Institutional Review Board of the Kansas State
University (KSU) (IRB Approval Number: 5298), and written informed consent was
obtained from all subjects. Healthy participants (see Supplementary materials for
inclusion/exclusion criteria) were recruited through leaflets distributed on-campus by
the College of Human Nutrition at the Kansas State University, Manhattan, KS.
Twenty-eight participants, seventeen females and eleven males (age 25.9 ± 5.5 years)
took part in the study.
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3.3.2

Test meals

Whole grain Prowashonupana Barley (Sustagrain R Barley Quick Flakes, ConAgra
Mills) and whole grain brown rice (Insta Grains R Brown Rice Flakes, Briess) flakes
were used in this study. Three test meals with different amounts of total dietary fiber
(TDF) were included: a barley treatment (WGB), consisting of 60 g of barley (18.7 g
TDF); a brown rice and barley treatment (BR+WGB), consisting of 30 g each barley
and brown rice (11.5 g TDF); and a brown rice treatment (BR), consisting of 60 g
of brown rice (4.4 g TDF). Subjects were provided with individual bags containing a
daily dose of the corresponding treatment (60 g of flakes). Nutritional information of
the whole grain flakes used in the study is available in the Supplementary materials
and Supplementary Table 3.3.

3.3.3

Study design

Figure 3.1: Experimental design. Time line of the randomized crossover trial.
Three four-week dietary treatments were assessed in succession. The treatments were
interspaced by two-week wash-out (WO) periods. Blood and stool samples (indicated
by arrows) were collected during the baseline (BL) and at the end of each four-week
treatment period.

The study was conducted as a randomized crossover trial over 17 weeks (Figure3.1).
The first week served as a baseline period, after which each subject underwent three
four-week dietary treatments (BR, BR+WGB, WGB) in random order, and inter-
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spaced by two-week washout periods. The study was conducted under free-living
conditions, and no dietary restrictions were imposed except that subjects were expected to be non-vegetarian. Subjects were instructed to consume the 60 g of flakes
daily either plain, with yogurt or with milk, without time restrictions. Weekly symptom diaries were completed by the subjects in which they self-reported bowel movement, discomfort, flatulence, bloating, stool consistency and general well-being on a
scale from 1 to 5 (1 being optimal/normal and 5 worst/abnormal).

3.3.4

Subject parameters and determination of metabolic
and immunological markers

Subject parameters were measured at the Human Metabolism Laboratory at KSU.
Total body composition was assessed at baseline with dual-energy X-ray absorptiometry (Prodigy, GE-Lunar, USA). Blood samples were drawn at baseline and at the
end of each dietary treatment after a 12 h overnight fast. An initial blood sample was
drawn (time 0). A standard drink containing 75 g of glucose (Fisher) was consumed
within 10 min, and blood samples were collected at 15, 30, 45, 60, 90 and 120 min
postprandially. Blood was immediately placed in tubes containing K2-EDTA (Vacutainer, BD, USA) and centrifuged at 1,000-1,500 x g for 13 min at 5-10◦ C. Aliquots
of plasma were transferred into tubes for storage at -80◦ C until further testing.
Glucose and insulin were measured in plasma samples in duplicate using an automated analyzer (YSI 2300, USA) and the Human Gut Hormone Immunoassay kit
(Milliplex, USA) with a dual laser flow cytometer (Luminex 100), respectively. A
lipid profile, consisting of total cholesterol (TC), high-density lipoprotein (HDL), and
non-HDL cholesterol was performed on the preprandial samples (time 0) using the
Cholestech LDX System (Cholestech, USA). Three markers of inflammation were

121
measured in plasma samples by enzyme-linked immunosorbent assays (ELISAs) (in
duplicate): lipopolysaccharide binding protein (LBP) (USCN Life Science and Technology, USA), high-sensitive C-reactive protein (hs-CRP) (Symansis, New Zealand),
and interleukin 6 (IL-6) (R&D Systems, USA).
Short chain fatty acids (SCFA) were quantified in fecal samples by gas chromatography as described in the Supplementary materials.

3.3.5

Compositional analysis of the fecal microbiota by
pyrosequencing

Subjects provided fecal samples within 24 h of blood sampling and 2 h of defecation.
Fecal material and 1:10 fecal homogenates in phosphate buffered saline (pH=7) were
immediately frozen (-80◦ C) and stored until further processing. Bacterial DNA was
extracted from fecal homogenates as described by Martı́nez and co-workers (2010),
using the QIAamp DNA Stool Mini Kit (Qiagen, Germany) in combination with enzymatic and mechanical cell lysis. Pyrosequencing of amplicons obtained by PCR with
universal primers targeting the V1-V3 region of the 16S rRNA gene was performed as
previously described (Martı́nez et al., 2010), using the 454 Genome Sequencer FLX
with GS FLX Titanium series reagents at the Core for Applied Genomics and Ecology
(CAGE, University of Nebraska).
Sequence processing was performed combining features of QIIME (Caporaso et al.,
2010) and the Ribosomal Database Project (RDP) pipeline (Cole et al., 2009). Threethousand quality-controlled sequences per sample were randomly selected and used
for taxonomic classification. Sequences were assigned to a bacterial phylum, family,
and genus using the Classifier tool of the RDP (Wang et al., 2007). In addition,
sequences were assigned to Operational Taxonomic Units (OTU) with 97% sequence
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homology as described in the Supplementary materials. Chao1 species richness estimator, and Shannons and Simpsons (defined as 1-Dominance) diversity indices were
computed with QIIME.

3.3.6

Query for genes encoding β-glucanases in genomes of
human gut microbes

The web-based Integrated Microbial Genomes platform (IMG) of the Joint Genome
Institute (JGI) (http://img.jgi.doe.gov/) was used to identify large-bowel associated
bacteria with β-glucanase encoding activity. The strains included are listed in the
Supplementary materials. For the species identified to contain β-glucanase genes,
their abundance in the fecal microbiota of our subjects was quantified by BLASTn.

3.3.7

Statistics

Results are presented as means ± SD. Differences in bacterial taxa and host phenotypes among treatments were determined by one-way ANOVA with repeated measures
in combination with Tukeys post-hoc tests, and P<0.05 was considered statistically
significant. If the data were not normally distributed, values were subjected to transformations such as square root or logarithm with base 10 to achieve normality. If
normality could not be achieved through transformations, non-parametric tests were
performed (i.e.: Kruskall-Wallis). When only two groups of data were compared,
Students t-tests were performed. Correlations between host parameters and bacterial populations were assessed by Pearsons correlation tests using GraphPad Prism
version 5.00 (GraphPad Software, USA). Associations between inflammatory markers
and gut microbiome composition were also analyzed through linear models using SAS.
Additional information on the statistical methods can be found in the Supplementary
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materials.

3.4
3.4.1

Results
Physiologic, metabolic, and microbiome
characteristics of the study population

Twenty-eight volunteers, eleven males and seventeen females, participated in the nutritional trial, and subjects parameters are presented in Table 3.1. Based on percent
body fat, thirteen subjects were considered overweight, using as cutoff values >31%
body fat for women and >25% for men for classification as overweight. Metabolic
and immunological markers included in the study were plasma fasting glucose and
insulin levels, glycemic and insulin postprandial response, a lipid panel (TC, HDL,
non-HDL), and inflammatory markers (hs-CRP, IL-6 and LBP). The rationale for
the inclusion of these markers is their suitability in determining the progression of
metabolic aberrancies and the risk of cardiovascular disease (Cardellini et al., 2005,
Ridker, 2009, Schumann et al., 1990, Spranger et al., 2003), and their association with
obesity (Sun et al., 2010). Accordingly, positive correlations between body fat and
all three inflammatory markers were observed (Figure 3.2 A-C). LBP and hs-CRP
were highly correlated (r=0.90, P<0.0001) (Figure 3.2 D). The linear model identified
body fat as a significant factor affecting IL-6 (P<0.01), hs-CRP (P<0.0001), and LBP
(P<0.0001). Furthermore, significant positive correlations existed between markers
of inflammation and glucose metabolism (Figure 3.2 A). Together, these associations
substantiate the link between adiposity and a low-grade systemic inflammation (Hotamisligil, 2006).
Pyrosequencing revealed that the baseline fecal microbiota of the participants was
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P-valueb

a

Women with over 31% body fat, and men with over 25% body fat were considered as overweight individuals. All others
were considered lean.
b
NS = Not significant.

a

Age
Weight (kg)
BMI (kg/m2 )
Body fat mass (kg)
Body fat (%)
Cholesterol (mmol/l)
Total cholesterol
Non high-density lipoprotein
High-density lipoprotein
Fasting plasma glucose (mmol/l)
Fasting plasma insulin (µIU/ml)
Inflammatory markers
IL-6 (pg/ml)
(min-max)
Hs-CRP (mg/L)
(min-max)
LBP (µg/ml)
(min-max)

Gender

Overall

Table 3.1: Baseline characteristics of the 28 subjects, and differentiated by gender and percent body fat.
Values are presented as mean ± SD.
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Figure 3.2: Associations among host physiological characteristics and their
correlation with bacterial populations in fecal samples at baseline. Heatmap
displaying correlation coefficients between metabolic and physiological parameters of
the study population at baseline (A). Correlations between hs-CRP with body fat (B),
LBP with body fat (C), hs-CRP and LBP (D), hs-CRP and Ruminococcaceae (E),
LBP with Ruminococcaceae (F), and Oscillibacter with postprandial AUC glucose
(F). Pearsons r correlation and the corresponding P values are presented.
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dominated by the phyla Firmicutes and Bacteroidetes, with lower proportions of
Verrucomicrobia and Actinobacteria, in agreement with previous molecular characterizations of the human fecal microbiota (Ley et al., 2006, Martı́nez et al., 2010). We
investigated whether associations between host phenotypes and microbial populations
existed (Supplementary Figure 3.5). No significant correlation was determined between any bacterial group and percent body fat or BMI, although overweight subjects
harbored significantly lower abundances of Ruminococcaceae (10.8 ± 5.4% versus 17.9
± 9.9%, P<0.05) and Faecalibacterium (1.8 ± 1.8% versus 3.7 ± 2.5%, P<0.05). The
analysis revealed negative correlations between the family Ruminococcaceae and all
three inflammatory markers at baseline (Figures 3.2 E-F, and Supplementary Figure
3.5). Within this family, the genera Faecalibacterium and Ruminococcus displayed
negative correlations with hs-CRP (r=-0.48, P<0.05, and r=-0.60, P<0.01, respectively). The analysis also revealed a negative association between Oscillibacter and
postprandial glucose AUC (Figure 3.2F). Regarding the markers of lipid metabolism,
proportions of Bacteroidetes, Bacteroidaceae, and Bacteroides were positively correlated to plasma HDL values (r=0.54, P<0.05; r=0.56, P<0.05; r=0.56, P<0.05;
respectively) (Supplementary Figure 3.6).

3.4.2

Supplementation of whole grains altered composition
of the fecal microbiota

Sequence data determined by pyrosequencing were used to establish the effects of
whole grains on the gut microbiota composition, and this analysis revealed that all
three test meals impacted the gut microbiota. All three treatments significantly
increased the bacterial diversity measured by Shannons and Simpsons indices but not
by Chao1 (Supplementary Figure 3.7). These results indicate that although species
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richness did not increase (determined by Chao1), community evenness did (Shannons
and Simpsons).

Table 3.2: Abundance of dominant bacterial taxa in fecal
samples as determined by 454 pyrosequencing. Values are
presented as mean ± SD.

Confirmation
Baseline

BR

BR+WGB

WGB

by

P-value
non linear model

Phylum
Firmicutes

57.30 ± 14.13

65.06 ± 11.40†

65.53 ± 10.64†

65.42 ± 12.05†

0.003

Yes

Bacteroidetes

37.99 ± 14.35

30.74 ± 11.62†

29.85 ± 11.93†

30.32 ± 12.22†

0.01

Yes

Verrucomicrobia

1.82 ± 1.98

1.34 ± 1.53

0.68 ± 0.80

0.59 ± 0.80

NS

Yes

Actinobacteria

1.24 ± 0.97

1.42 ± 1.78

2.23 ± 3.32

2.05 ± 2.73

NS

Yes

Bacteroidaceae

28.55 ± 15.73

22.89 ± 10.37

21.19 ± 11.87†

23.48 ± 12.62

0.013

Yes

Lachnospiraceae

22.21 ± 7.90

22.62 ± 7.91

23.11 ± 6.56

22.65 ± 7.63

NS

Yes

Ruminococcaceae

14.64 ± 8.76

17.32 ± 8.90

16.53 ± 8.06

15.82 ± 8.32

NS

Yes

Incertae Sedis XIV

5.79 ± 3.15

7.63 ± 4.47

8.16 ± 3.97††

8.62 ± 4.32††

0.001

Yes

Porphyromonadaceae

3.40 ± 3.07

2.69 ± 3.42

2.76 ± 3.10

1.95 ± 1.55†

0.022

No

Prevotellaceae

2.97 ± 9.24

2.34 ± 6.56

3.59 ± 10.10

2.39 ± 6.50

NS

Yes

Verrucromicrobiaceae

1.85 ± 4.58

0.77 ± 1.53

0.68 ± 1.28

0.59 ± 0.80

NS

Yes

Family

Continued on next page
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Table 3.2 – continued from previous page
Confirmation
Baseline

BR

BR+WGB

WGB

by

P-value
non linear model

Rikenellaceae

1.77 ± 2.09

1.68 ± 1.85

1.12 ± 1.06

1.35 ± 1.68

NS

Yes

Veillonellaceae

1.59 ± 1.13

1.52 ± 1.19

1.86 ± 1.19

1.97 ± 1.60

NS

Yes

Bacteroides

28.55 ± 15.73

22.89 ± 10.37

21.19 ± 11.87†

23.48 ± 12.62

0.022

Yes

Blautia

5.68 ± 3.15

7.61 ± 4.47

8.14 ± 3.97††

8.61 ± 4.32††

0.001

Yes

Ruminococcus

4.20 ± 4.91

5.35 ± 5.05

4.171 ± 5.75

3.46 ± 4.32

NS

Yes

Faecealibacterium

2.82 ± 2.38

3.06 ± 2.29

3.86 ± 3.22

3.86 ± 3.19

NS

Yes

Prevotella

2.79 ± 8.89

1.99 ± 6.24

3.34 ± 9.84

2.02 ± 6.30

NS

Yes

Dorea

2.59 ± 2.01

3.12 ± 2.22

3.08 ± 1.80

2.75 ± 1.86

NS

Yes

Parabacteroides

2.58 ± 3.05

2.06 ± 3.23

2.10 ± 3.14

1.59 ± 1.44

NS

Yes

Roseburia

1.98 ± 1.35

1.70 ± 1.25

2.42 ± 1.58

3.06 ± 2.91‡‡

0.01

Yes

Akkermansia

1.85 ± 4.58

0.77 ±1.53

0.68 ± 1.28

0.59 ± 0.80

NS

Yes

Coprococcus

1.82 ± 2.09

1.91 ± 2.08

1.47 ± 2.22

1.35 ± 1.78

NS

Yes

Alistipes

1.76 ± 2.08

1.67 ± 1.85

1.11 ± 1.05

1.34 ± 1.67

NS

Yes

Oscillibacter

1.27 ± 1.04

1.24 ± 1.00

1.08 ± 0.83

0.96 ± 0.61

NS

Yes

Bifidobacterium

0.99 ± 1.88

1.02 ± 1.64

1.95 ± 3.16

1.84 ± 2.54

0.011

No

Genus
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Continued on next page

Table 3.2 – continued from previous page
Confirmation
Baseline

BR

BR+WGB

WGB

by

P-value
non linear model

Subdoligranulum

0.94 ± 1.03

1.17 ± 1.43

1.42 ± 1.73

1.09 ± 1.02

NS

Yes

Dialister

0.75 ± 1.17

0.60 ± 0.89

0.94 ± 1.21

1.14 ± 1.69

0.027

No

Odoribacter

0.26 ± 0.24

0.28 ± 0.35

0.28 ± 0.41

0.15 ± 0.18††

0.002

No

0.15 ± 0.14

0.13 ± 0.18

0.15 ± 0.24

0.07 ± 0.10††

0.001

No

679 (Eubacterium rectale 94%)

0.25 ± 0.32

0.31 ± 0.42

0.43 ± 0.57

0.57 ± 0.63††‡‡

<0.0001

Yes

956 (Roseburia faecis 99%)

0.12 ± 0.17

0.06 ± 0.07

0.26 ± 0.31

0.53 ± 0.92††‡‡‡

<0.0001

Yes

0.09 ± 0.12

0.04 ± 0.05

0.17 ± 0.18

0.30 ± 0.42†‡‡‡

<0.0001

Yes

3 (Blautia wexlerae 100%)

1.07 ± 0.78

1.58 ± 1.11

1.49 ± 0.98

1.82 ± 1.14†††*

<0.0001

Yes

179-188 (Blautia spp.)

1.81 ± 1.13

2.38 ± 1.69

2.75 ± 1.75

2.80 ± 2.04††

0.006

Yes

2.48 ± 2.67

2.75 ± 3.27

3.65 ± 3.45

4.83 ± 3.98†‡‡*

0.001

Yes

OTUs
1737 (Odoribacter splanicus
99%)

770

(Roseburia

intestinalis

100%)

44-19-199-93

(Eubacterium

rectale 98%)
Significantly different † P<0.05 †† P<0.01 ††† P<0.001 compared to Baseline.
Significantly different ‡ P<0.05 ‡‡ P<0.01 ‡‡‡ P<0.001 compared to BR.
Significantly different * P<0.05 ** P<0.01 *** P<0.001 compared to BR+WGB.
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NS = Not significant.
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The analysis revealed that whole grains had a measurable effect on the composition
of the gut microbiota. In accordance to previous studies that assessed the effect of
diet on the gut microbiome (Davis et al., 2011, Martı́nez et al., 2010), substantial
inter-individual variation was observed (Supplementary Table 3.4). Despite this variability, several diet induced shifts reached statistical significance in the entire study
population. The proportion of the phylum Firmicutes increased, while Bacteroidetes
were reduced (Table 3.2). The decrease in Bacteroidetes was largely caused by a
reduction of the genus Bacteroides (Table 3.2).
The increase in Firmicutes was more comprehensive and shifts in the abundance of
several taxa were detected. All three dietary treatments increased the abundance of
the genus Blautia and two OTUs within this genus (Table 3.2), although significance
was only achieved when WGB was included in the treatment. Several compositional
shifts were strictly associated with the consumption of WGB, namely the genera Roseburia, Bifidobacterium, and Dialister and the species Eubacterium rectale, Roseburia
faecis, and Roseburia intestinalis (Table 3.2), and many of these taxa increased gradually with WGB intake. The linear regression model confirmed all of these significant
changes except for the species Bifidobacterium, and Dialister. Other taxa clearly responded to WGB, but due to inter-individual variation, these shifts did not reach
statistical significance. For example, Bacteroides coprocola showed over a ten-fold
increase with WGB consumption, but the species was only detected in three subjects
(Supplementary Table Table 3.4). Although both whole grains led to an increase in
the Firmicutes/Bacteroidetes ratio, no family or genus showed a significant increase
for BR, suggesting that this test meal induced diverse alterations in the gut microbiome that are not consistent among subjects.
No significant differences were detected in the amounts of SCFA for any of the treatments. It is possible that an increase in SCFA production could not be detected in
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fecal samples as most SCFA are absorbed in the gastrointestinal tract (Millet et al.,
2010).

3.4.3

Distribution of β-glucanase genes in human gut
microbes

WGB contains a high amount of β-glucans (14.1%), while none were detected in BR
(Supplementary Table 3.3). In order to test if the ability to hydrolyze β-glucans could
explain the specific shifts in the fecal microbiota induced through WGB, we investigated distribution of β-glucanase genes in 112 strains originating from the human gut.
This analysis revealed that β-glucanase genes are present in a variety of gut bacterial
species from a broad taxonomic range, including 10 Bacteroides, 4 Bifidobacterium,
3 Collinsella, 2 Clostridium, 2 Coproccus, 2 Eubacterium, 1 Ruminococcus, 2 Roseburia, and 1 Akkermansia species (Supplementary Table S2). Of these species, only
Eubacterium rectale, Roseburia faecis and Roseburia intestinalis were significantly
increased through WGB, indicating that the mere presence of β-glucanase encoding
genes does not predict the changes in community composition in response to the diet.

3.4.4

Whole grain consumption improved metabolic and
immunological markers

The daily consumption of 60 g of whole grains for four weeks improved immunological and metabolic markers in the human subjects. The findings for the entire study
population are shown in Supplementary Table 3.5, and differentiated by gender and
body fat in Supplementary Tables 3.6, 3.7, 3.8, and 3.9. A significant decrease in
plasma IL-6 levels for the BR+WGB treatment versus baseline values was detected
(Figure 3.3 A). Quantitatively, this reduction was highest in overweight subjects (Fig-
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Figure 3.3: Immunological and metabolic improvements induced through
whole grain consumption. Plasma IL-6 levels in the entire subject population (A),
in overweight participants (B), and in females (C). Maximum postprandial glucose
levels in the entire subject population (D) and overweight subjects (E) during the
H
three treatments (BR, BR+WGB, WGB) and at baseline. ∗ P<0.05, ∗∗ P<0.01,
P<0.1.

ure 3.3 B). In women, all three treatments significantly reduced IL-6 (Figure 3.3 C).
The linear model analysis confirmed the anti-inflammatory effect of whole grains and
revealed a significant reduction of IL-6 for BR+WGB and WGB treatments (P<0.01,
P<0.05). Despite not achieving statistical significance due to high inter-individual
variation, hs-CRP plasma levels were halved during the BR+WGB period compared
to the baseline (Supplementary Tables 3.5-3.9). Whole grain consumption significantly improved glucose and lipid metabolism.
Postprandial peak glucose levels were significantly lowered in overweight subjects dur-
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ing the BR+WGB period (P<0.05), and the reduction approached significance in the
entire study population (P<0.1) (Figure 3.3 D-E). Fasting glucose levels were significantly decreased in women and overweight subjects, and in females, total cholesterol
was significantly reduced (Supplementary Tables 3.6-3.9).

3.4.5

Improved metabolism following whole grain intake are
linked to the fecal microbiota

To determine whether effects of whole grains were connected with the gut microbiome, a correlation analysis was performed between bacterial shifts and changes
in metabolic markers that occurred during the BR+WGB period. We focused the
analysis on the BR+WGB treatment as it induced the most significant metabolic
improvements (Figure 3.3). This analysis revealed that shifts in the abundance of
Eubacterium rectale were negatively correlated with changes in glucose AUC and insulin AUC (Supplementary Figure 3.8 A-B). The association between Eubacterium
rectale and maximum postprandial glucose levels approached significance (Supplementary Figure 3.8 C).
In addition, we categorized subjects into three groups (terciles) according to the magnitude of the improvements in IL-6, hs-CRP, fasting glucose and glucose peak through
BR+WGB. The baseline proportions of the bacterial groups between the three groups
were compared. This analysis revealed that the gut microbiota of subjects with the
highest improvement in IL-6 (3rd tercile) contained significantly higher percentages of
Veillonellaceae (Figure 3.4 A), and within this family, the genus Dialister (Figure 3.4
B). Conversely, Coriobacteriaceae were significantly decreased in subjects with the
highest improvement in IL-6 (Figure 3.4 C). No significant differences in microbiome
composition were detected between the terciles generated for hs-CRP, fasting glucose,
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Figure 3.4: Abundance of specific taxa in subjects that showed differences
in their IL-6 response to whole grains. Subjects were classified into terciles
according to the magnitude of the change in plasma IL-6 levels induced by whole
grain consumption (BR+B treatment versus baseline). The proportions of bacterial
taxa in fecal samples during the baseline were compared in the three terciles and
significant differences existed in the proportions of Veillonellaceae (A), Dialister (B)
and Coriobacteriaceae (C) in fecal samples during baseline. ∗ P<0.05, ∗∗ P<0.01.

and postprandial glucose peak.

3.4.6

Gastrointestinal symptoms

Self-reported symptoms diaries revealed that 60 g of WGB significantly increased all
the gastrointestinal symptoms surveyed, especially flatulence, while 30 g caused only
a slight increase in flatulence (Supplementary Table 3.10). The addition of BR to the
diet did not result in any reported changes in symptoms.

3.5

Discussion

The metabolic and immunological benefits of whole grains have been shown in various studies (Behall et al., 2004, Fung et al., 2002, Jensen et al., 2004, Nilsson et al.,
2006, 2008b), and a contribution of the gut microbiome to these effects has been
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suggested (North et al., 2009). However, the assessment of bacterial participation in
these processes has been limited to hydrogen breath measurements, and the effects
of whole grains on the gut microbiome structure have not been investigated. In this
study, we showed that whole grains have a significant effect on the composition of the
fecal microbiota that coincided with metabolic and immunological improvements in
healthy human individuals.
All whole grain test meals caused an increase in community diversity within the subjects, driven by an increase in evenness of bacterial species. Therefore, whole grains
seem to differ in their effects on the gut microbiota when compared to prebiotics and
dietary fibers, which have not been shown to increase community diversity (Davis
et al., 2011, Martı́nez et al., 2010, Van den Abbeele et al., 2011). These differences
might be due to compositional complexity of whole grains, which contain an array of
carbohydrates, potentially affecting a wider scope of bacterial taxa. Interestingly, a
higher microbial diversity in fecal samples was also observed in children from Burkina Faso, who consumed a diet high in whole grains, legumes, and vegetables, when
compared to Europeans (De Filippo et al., 2010). In addition, weaning in human
infants leads to a drastic increase in diversity likely caused by the incorporation of
more diverse arrays of dietary carbohydrates (reviewed in Koropatkin et al. (2012)).
Therefore, it appears that bacterial diversity in the gut can be increased by providing
a broader range of undigestible substrates, and our findings showed that this can be
achieved by intake of whole grains.
In this study, effects on the gut microbiota composition that occurred with both BR
and WGB as well as shifts specific to WGB were observed. Both whole grains increased the Firmicutes/Bacteroidetes ratio and the abundance of the genus Blautia.
The overall shift in microbiota structure in favor of an expansion of Firmicutes could
be the result of an increased carbohydrate intake (Duncan et al., 2008). However,
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in a previous study, we did not observe an increase in the Firmicutes/Bacteroidetes
ratio with the consumption of crackers containing resistant starches (Martı́nez et al.,
2010), although the dose of carbohydrates and fiber in these crackers exceeded that
of the whole grain test meals. Interestingly, a decrease of Bacteroides was also shown
to be associated with a long-term consumption of diets rich in whole grains, dietary
fibers, and vegetables in African children and US individuals (De Filippo et al., 2010,
Wu et al., 2011). These and our findings suggest that other components included
in whole grains and other plant derived food products might influence community
structure at the phylum level, specifically decreasing Bacteroidetes. The reason for
the increase in the genus Blautia through whole grains might be due to a syntrophic
effect. Blautia species are acetogenic and might benefit from the production of hydrogen, which is a product of glycan fermentation, and therefore likely induced by
whole grain consumption (Koropatkin et al., 2012, Nakamura et al., 2010).
We detected several bacterial taxa that displayed a specific increase with WGB, several with a clear dose response. This is likely due to its high content of β-glucans.
Accordingly, the bacteria that specifically responded to WGB harbor genes encoding
for β-glucanases and utilize the substrate in vitro (Hughes et al., 2008, Tasse et al.,
2010). However, the in vivo findings cannot solely be explained based on functional
and genomic attributes of community members, as Bacteroides species decreased during WGB consumption, but possess β-glucanase genes and can utilize β-glucans in
vitro (Crittenden et al., 2002, Tasse et al., 2010, Zhao and Cheung, 2011). A possible
explanation for our in vivo findings could entail preferences towards distinct β-glucan
structures and molecular weights. The β(1-4) to β(1-3) linkage ratio in barley is 2.3-3,
while Bacteroides species have been shown to especially posses β(1-3)-glucanase activity (Salyers et al., 1977). Moreover, barley derived -glucan fractions of high molecular
weight have also shown little fermentation aptitude by Bacteroides (Hughes et al.,
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2008). However, previous human trials with prebiotics and resistant starches have
also revealed that the ability to utilize substrates in vitro does not predict success
of species in vivo (Davis et al., 2011, Martı́nez et al., 2010, Koropatkin et al., 2012).
Therefore, although the findings obtained suggest that β-glucans are the main cause
for the shifts in composition induced by WGB, the exact mechanisms by which these
changes are restricted to some taxa are likely to be due to competitive interactions.
A main objective of this study was to determine if the effects of whole grains on the
gut microbiome are associated with physiological benefits. The whole grains in our
study led to immunological and metabolic improvements, especially when BR+WGB
was consumed. Plasma IL-6 was reduced, and a tendency for a decrease in plasma hsCRP was detected. In addition to this anti-inflammatory effect, an improvement in
the glycemic response during BR+WGB treatment was detected. Our findings are in
agreement with previous research that established the immunological and metabolic
benefits of whole grains (Casiraghi et al., 2006, Kallio et al., 2008, Nilsson et al.,
2008b, Rosén et al., 2011). Most importantly, inflammation has been identified as
a main cause of metabolic disorders (Hotamisligil, 2006), and the anti-inflammatory
effect could provide a mechanism by which whole grains improve glucose metabolism.
The anti-inflammatory effect of whole grains might be mediated through its effect
on the gut microbiota. A remarkable positive correlation between LBP and hs-CRP
was identified in our study population, supporting a link between bacterial LPS and
systemic inflammation. The associations of these markers with body-fat support the
hypothesis that endotoxemia could contribute to metabolic aberrancies (Cani et al.,
2007, Delzenne and Cani, 2011). Whole grain barley caused the expansion of bacterial taxa such as bifidobacteria and Roseburia, which have been suggested to affect
immune/inflammatory and metabolic functions in animal models (Cani et al., 2008,
Neyrinck et al., 2011). Although one could envision that these shifts might under-
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lie the anti-inflammatory effect of whole grains, no significant correlations between
these taxa and inflammatory markers were observed. However, shifts in the abundance of Eubacterium rectale induced through the BR+WGB diet correlated with
decreased postprandial glucose and insulin responses. This organism produces the
anti-inflammatory SCFA butyrate, which might contribute to the immunological effects of whole grain consumption.
Interestingly, compositional differences at baseline were detected in the gut microbiome of subjects that differed in the magnitude of their anti-inflammatory response
to whole grains. Subjects with the greatest reduction in plasma IL-6 concentration
had significantly higher proportions of Dialister and a lower abundance of Coriobacteriaceae. These bacterial groups have been linked to chronic inflammation in previous
studies. Dialister invisus and Coriobacteriaceae have been shown to be reduced and
increased in patients with Crohns disease and colitic mice, respectively (Clavel et al.,
2009, Joossens et al., 2011, Willing et al., 2010, Würdemann et al., 2009). The strong
association of Dialister and Coriobacteriaceae with IL-6 response suggests that these
taxa may condition the capability of an individual to be immunologically responsive
to whole grains.
Associations between bacterial groups, inflammatory state, and host metabolism independent of whole grain intake were observed in this study during baseline (Figure
3.3). Ruminococcaceae negatively correlated with markers of inflammation and were
more dominant in normoweight individuals. In addition, Bacteroidetes positively
correlated with HDL cholesterol. These observations could result from an impact of
these taxa on host physiology, and these associations provide a rationale to develop
dietary strategies that target Ruminococcaceae and Bacteroidetes to improve human
metabolic and immunological functions. However, host physiology (inflammatory
state, cholesterol/bile acid metabolism) might also shape the microbiome composi-
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tion. If systemic inflammation impacts levels of Ruminococcaceae and cholesterol
metabolism of Bacteroidetes, then these interactions could explain the existing discrepancies related to an altered microbiome in obese versus normoweight individuals
(Ley et al., 2006, Duncan et al., 2008, Schwiertz et al., 2010). Not obesity per se,
but the associated inflammatory and metabolic aberrations could shape microbiome
composition and might cause variable and more complex patterns of dysbiosis.
Our study has provided novel information about the relationship between whole
grains, the gut microbiota, and host metabolism. Whole grains induced alterations
in the characteristics and composition of the fecal microbiota that coincided with
immunological and metabolic benefits. The ability of whole grains to increase microbial diversity in the gut might be beneficial in diseases associated with a reduced
diversity (obesity, Crohns disease), and the clear associations between the reduction of IL-6 and the presence of certain bacterial taxa (Dialister, Coriobacteriaceae)
indicate an important functional role of gut bacteria in the physiologic effects of
whole grains. Although much more work is necessary to unravel the complexity of
the microbiome-host interplay, the connections between the gut microbiome and diet
induced physiological benefits revealed during this study represent important basic
information that advocate for an increased consideration of the gut microbiota and
especially its individuality in the development of personalized nutritional strategies.
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3.7

Supplementary information

3.7.1

Materials and Methods

3.7.1.1

Subjects

Interviews were conducted with the volunteers to explain the protocol, determine
whether they met the inclusion criteria, and record demographic data (age and gender). Exclusion criteria were treatment with antibiotics within 3 months prior to the
beginning of the study or throughout its duration, being vegetarian, exercise of more
than 2 h weekly, a history of a chronic gastrointestinal disorder, and the use of antihypertensive or lipid-lowering medications. Twenty-nine healthy adults were recruited
to participate in this study. One female subject was excluded during the study as she
required antibiotic treatment. Prior to the beginning of the study, training sessions
were held to explain the protocol to the subjects.
Participants were instructed to incorporate the whole grains to their regular diet.
Other instructions included withholding from strenuous physical activity and alcohol consumption on the day prior to blood drawing. Compliance with the dietary
treatments was encouraged by meeting with the subjects on a weekly basis, on which
occasions symptom diaries were collected and a bag with 7 daily portions of the
treatment flakes were distributed.

3.7.1.2

Test meals

Prowashonupana (Sustagrain R Barley Quick Flakes, ConAgra Mills) is a waxy, hulless
barley variety differing from standard barley in terms of its composition. Prowashonupana contains exceptionally high levels of total dietary fiber (30%), almost half
being accounted for by -glucan, and low levels of starch (<30%). Brown rice has
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high amounts of soluble starch (around 75%) and small amounts of total dietary
fiber (around 7%). The processing of the barley flakes was as follows, cleaned grain
kernels were roller cut and steam treated at 100.5◦ C for 40 min to ensure microbiological safety and passed through flaking rolls to reduce the pieces to a thickness
of 0.020 ± 0.002 inches. The flakes were then cooled down to room temperature,
seized, screened and packaged. The brown rice (Insta Grains R Brown Rice Flakes,
Briess) was used as provided by the manufacturer. It is currently unknown how the
processing conditions of both whole grains affect their functionality when compared
to the unprocessed grains.
Digestible and resistant starches in the two flakes were measured in the products (KRSTAR, Megazyme, Ireland), as well as β-glucans (K-BGLU, Megazyme, Ireland),
and total dietary fiber (Andersson et al., 1999, AACC, 2011). The nutritional data
of the flakes is presented in Supplementary Table 3.3.

3.7.1.3

Compositional analysis of the fecal microbiota by
pyrosequencing

Sequences were binned by primer barcodes using QIIME (Caporaso et al., 2010). Sequences that were shorter than 300 bp or longer than 550 bp, contained one or more
ambiguous nucleotides, had one or more mismatches to the primer or barcode, had
an average quality scores below 25, or contained homopolymer runs over 6 bp, were
removed. Chimeras were removed using the Blast Fragments Algorithm included in
QIIME.
OTU picking was performed by aligning sequences using the RDP Infernal Alignment tool and clustered with the Complete Linkage Clustering algorithm (RDP). As
current OTU picking algorithms tend to generate too many clusters (Ghodsi et al.,
2007), abundance of OTUs identified to be associated with host phenotypes or di-

143
etary treatments were confirmed using BLASTn. For this purpose, 5 representative
sequences per OTU were taxonomically assigned and aligned by ClustalW within
their respective phylum. A distance matrix was generated and phylogenetic trees
(one per phylum) were constructed using the Neighbor-joining algorithm (MEGA
4.0) (Tamura et al., 2007). OTUs were assigned visually as clusters within the phylogenetic trees, and membership was confirmed by sequence comparisons and restricted
to sequences with >97% similarity. Consensus sequences were generated for each
OTU. To quantify each OTU, a local database was created in BioEdit (Hall, 1999)
with all the sequences. BLASTn with >97% similarity and >95% length overlap was
used to determine the number of sequences belonging to individual OTUs. OTUs
that shared a majority of their sequences were merged.

3.7.1.4

Genome queries for β-glucanase activity

The web-based Integrated Microbial Genomes (IMG) database of the Joint Genome
Institute (JGI) was used to identify gut organisms with beta-glucanase function.
The following bacteria were included:Bacteroides caccae ATCC 43185, Bacteroides
coprocola M16, Bacteroides dorei 5 1 36/D4, Bacteroides dorei DSM 17855, Bacteroides eggerthii 1 2 48FAA, Bacteroides eggerthii DSM 20697, Bacteroides finegoldii DSM 17565, Bacteroides fragilis 3 1 12, Bacteroides fragilis 638R, Bacteroides
fragilis NCTC 9343, Bacteroides fragilis YCH46, Bacteroides intestinalis 341, Bacteroides ovatus 3 8 47FAA, Bacteroides ovatus ATCC 8483, Bacteroides ovatus SD
CC 2a, Bacteroides ovatus SD CMC 3f, Bacteroides stercoris ATCC 43183, Bacteroides thetaiotaomicron VPI-5482, Bacteroides uniformis ATCC 8492, Bacteroides
vulgatus ATCC 8482; Bacteroides vulgatus PC510, Bacteroides xylanisolvens SD
CC 1b, Bacteroides xylanisolvens XB1A, Bifidobacterium adolescentis ATCC 15703,
Bifidobacterium adolescentis L2-32, Bifidobacterium catenulatum DSM 16992, Bifi-
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dobacterium longum DJO10A, Bifidobacterium longum NCC2705, Bifidobacterium
longum subps. infantis 157F-NC, Bifidobacterium longum subps. infantis ATCC
16697, Bifidobacterium longum subps. infantis JCM 1217, Bifidobacterium longum
subsp. longum ATCC 55813, Bifidobacterium longum subsp. longum BBMN68, Bifidobacterium longum subsp. longum CCUG 52486, Bifidobacterium longum subsp.
longum F8, Bifidobacterium longum subsp. longum JDM301, Bifidobacterium longum
subsp. longum KACC 91563, Bifidobacterium pseudocatenulatum DSM 20438, Blautia hansenii VPI C7-24, Blautia hydrogenotrophica DSM 10507, Bryantella formatexigens I-52, Butyrivibrio crossotus DSM 2876, Clostridiales sp. SM4/1, Clostridiales
sp. 1 7 47FAA, Clostridiales sp. SS3/4, Clostridiales sp. SSC/2, Clostridium bolteae
ATCC BAA-613, Clostridium butyricum 5521, Clostridium butyricum E4, Clostridium leptum DSM 753, Clostridium ramosum VPI 0427, Clostridium sp. M62/1,
Clostridium spiroforme DSM 15579, Collinsella aerofaciens ATCC 25986, Collinsella
intestinalis DSM 13280, Collinsella stercoris DSM 13279, Coprococcus comes ATCC
27758, Coprococcus eutactus ATCC 27759, Dialister invisus DSM 15470, Dorea formicigenerans ATCC 27755, Dorea longicatena DSM 13814, Eggerthella lenta VPI 0255,
Enterococcus fecalis ATCC 29200, Enterococcus fecalis ATCC 4200, Eubacterium biforme DSM3989, Eubacterium cylindroides T2-87, Eubacterium eligens ATCC 27750,
Eubacterium hallii DSM 3353, Eubacterium limosum KIST612, Eubacterium rectale
ATCC 33656, Eubacterium rectale DSM 17629, Eubacterium rectale M104/1, Eubacterium ventriosum ATCC 27560, Faecalibacterium prausnitzii KLE1255, Faecalibacterium prausnitzii A2-165, Faecalibacterium prausnitzii L2-6, Faecalibacterium prausnitzii M21/2, Faecalibacterium prausnitzii SL3/3, Lachnospiraceae 1 1 57FAA, Lachnospiraceae 1 4 56FAA, Lachnospiraceae 2 1 46FAA, Lachnospiraceae 2 1 58FAA,
Lachnospiraceae 3 1 46FAA, Lachnospiraceae 3 1 57FAA, Lachnospiraceae 4 1 37FAA,
Lachnospiraceae 5 1 37FAA, Lachnospiraceae 6 1 63FAA, Lachnospiraceae 9 1 43BFAA,
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Lachnospiraceae sp 5 1 63FAA, Lachnospiraceae 8 1 57FAA, Olsenella uli DSM 7084,
Odoribacter splanchnicus DSM 20712, Parabacteroides distasonis ATCC 8503, Parabacteroides merdae ATCC 43184, Parabacteroides sp. D13, Phascolarctobacterium sp
YIT 12067, Prevotella bryantii B14, Roseburia intestinalis L1-82, Roseburia intestinalis M50/1, Roseburia intestinalis XB6B4, Roseburia inulinivorans DSM 16841,
Ruminococcaceae bacterium D16, Ruminococcus bromii L2-63, Ruminococcus gnavus
ATCC 29149, Ruminococcus lactaris ATCC 29176, Ruminococcus obeum A2-162, Ruminococcus obeum ATCC 29174, Ruminococcus torques ATCC 27756, Ruminococcus
torques L2-14, Slackia exigua ATCC 700122, Slackia heliotrinireducens DSM 20476,
Turicibacter sanguinis PC909.

3.7.1.5

Short chain fatty acid determination

SCFAs were determined based on approaches described by Campbell et al. (1997),
with slight modifications. Undiluted fecal samples were removed from storage at
-80◦ C and thawed on ice, and 0.4 g were diluted in 2.8 ml water containing 5-10
mM 4-methylvaleric acid and vortexed. 0.4 ml of 25% (w/v) metaphosphoric acid
was added and the sample was vortexed again, followed by centrifugation for 20
min at 15,000 x g. The supernatant was stored overnight at -20◦ C. Samples were
thawed and centrifuged in the same conditions as before. SCFA were quantified by
gas chromatography (Perkin Elmer Clarus with Perkin Elmer Elite-FFAP column)
in a 4 µl injection volume, and the data was analyzed with appropriate software
(TotalChrom, Perkin Elmer, USA). Moisture quantification in the fecal samples was
done as follows. Approximately 0.2 g of feces was introduced into a plastic tube with
a small perforation in its cap and frozen overnight at -20◦ C. Samples were freeze dried
for at least 36 hours until stable weight of the sample was achieved, and dry weight
was calculated. SCFA were expressed on a dry basis.
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3.7.1.6

Statistics

Correlations between host parameters and bacterial populations were assessed by
Pearsons correlation test (GraphPad Prism v5.0). Graphs were generated for parameters that showed significant correlations and were visually inspected. If the removal
of one single data-point caused the association to become non-significant, the data
point was considered an outlier and removed. Associations between inflammatory
markers and members of the gut microbiome were further analyzed with the following linear models:
Iijt = β 0 + β 1 Fat + β 2 Gender + β 3 Age + β 4 T2 + β 5 T3 + β 6 T4 (1)
Mhjt = β 0 + β 1 Fat + β 2 Gender + β 3 Age + β 4 T2 + β 5 T3 + β 6 T4 (2)
hjt is the inflammatory marker h for subject j in treatment t, h=1,,80; j=128;
t=1,2,3,4;
Fat indicates the percent body fat; Gender is a binary variable that takes values of
0 if the subject is female and 1 otherwise; Age is the age of subject in years; T2 is
a binary variable that assigns 1 if the treatment is 30 g of WGB and BR each and
0 otherwise; T3 is a binary variable that assigns 1 if the treatment is 60 g of WGB
and 0 otherwise; T4 is a binary variable that assigns 1 if the treatment is 60 g of BR
and 0 otherwise; and T1 represents no treatment and is left out of the models as the
base. Fixed effects and random effects methods were used to estimate models (1) and
(2). Chi-square estimates that measure the heterogeneity of the responses clustered
by subject, were used as the criterion for choice between fixed and random effects
estimation methods. For the models with Chi-square values associated with P<0.1,
random effects method was chosen.
Because hs-CRP concentrations >10 mg/l in plasma are indicative of acute inflammation unrelated to cardiovascular disease risk (Pearson et al., 2003). Therefore, 4
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samples from 4 different subjects were excluded from the analysis. If the same samples also displayed abnormally high values of LBP or IL-6 levels, these data points
were also considered outliers and removed. 2 and 3 samples were excluded from LBP
and IL-6 analysis, respectively. One subject was excluded from the analysis of glucose
parameters as incomplete data was obtained for this subject.
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Table 3.3: Nutritional information of the barley and brown rice flakes
used in the study.a

Calories (kcal per 100g)
Fat (%)
Saturated fat (%)
Cholesterol (%)
Total carbohydrates (%)
Digestible starch (%)b
Resistant starch (%)b
Total dietary fiber (%)c
Insoluble fiber (%)c
Soluble fiber (%)c
β-glucan (%)d
Protein (%)
a

Barley

Brown rice

392
6.7
1.7
0.0
64.6
32.3
0.2
31.1
22.8
8.3
14.1
18.2

366
3.0
1.0
0.0
80.0
83.3
0.5
7.3
6.8
0.5
0.0
8.0

Nutrient composition as provided by the manufacturers except when
specifically noted.
b
Measured with K-RSTAR Megazyme kit. (Expressed as dry basis).
c
Measured according to AACCI Approved Method 32-25.01 with modifications from Andersson et al. (1999). (Expressed as dry basis).
d
Measured with K-BGLU Megazyme kit. (Expressed as dry basis).

Table 3.4: Human colonic bacteria with beta-glucanse enconding
genes determined in the Integrated Microbial Genomes system
(IMG). The number and type of -glucanases are indicated for the individual species. The number of subjects in which the species was detected and the
direction of the shifts in response to WGB intake are presented. Proportions
of the species according to dietary treatment are presented as mean ± SD.

Bacterial

Number and type of

Number of sub-

Response in

species

enzymes encoded

jects in which

individual

detected

subjects

2β-glucanase precursor

10

Bacteroides

7β-glucanase/β-

Akkermansia

Baseline

BR

BR+WGB

WGB

P-value

10 NP

0.84 ± 1.82

0.57 ± 1.3

0.34 ± 0.86

0.41 ± 0.66

NS

10

17 NP

0.2 ± 0.75

0.09 ± 0.21

0.13 ± 0.31

0.13 ± 0.43

NS

24

2↑, 22 NP

0.37 ± 1.52

0.14 ± 0.5

1.06 ± 3.73

1.24 ± 4.68

NS

24

24 NP

1.88 ± 3.81

1.60 ± 2.90

1.37 ± 2.75

1.34 ± 2.84

NS

4

4 NP

0.04 ± 0.2

0.06 ± 0.19

0.06 ± 0.33

0.02 ± 0.08

NS

18

1↓, 17 NP

2.68 ± 8.12

1.81 ± 6.04

1.60 ± 5.05

1.21 ± 4.56

NS

municiphila

caccae

glucanase synthase

Bacteroides co-

4 endoglucanase, 2β-

procola

glucanase/β-glucanase
synthase

Bacteroides

1β-glucanase,

2β-

dorei

glucanase/β-glucanase
synthase

Bacteroides

2β-glucanase/β-

finegoldii

glucanase synthase

Bacteroides

2β-glucanase

fragilis

cursor,

3

preputative

β-glucanase precursor
Continued on next page
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Table 3.4 – continued from previous page
Bacterial

Number and type of

Number of sub-

Response in

species

enzymes encoded

jects in which

individual

detected

subjects

25

Bacteroides in-

2β-glucanase/β-

testinalis

glucanase synthase, 6

Baseline

BR

BR+WGB

WGB

P-value

3↑

0.32 ± 0.55

0.93 ± 2.66

0.38 ± 0.69

0.47 ± 0.76

NS

25

25 NP

0.57 ± 0.79

0.72 ± 1.38

0.52 ± 0.98

0.40 ± 0.52

NS

26

3↓,

4.55 ± 4.55

3.34 ± 3.3

2.77 ± 3.38

3.57 ± 4.59

NS

0.35 ± 1.39

0.36 ± 1.03

0.32 ± 1.15

0.33 ± 0.97

NS

1.07 ± 0.78

1.58 ± 1.11

1.49 ± 0.98

1.82 ± 1.14

<0.0001

endoglucanase
Bacteroides

2β-glucanase/β-

ND

ovatus

glucanase synthase, 6
endoglucanase

Bacteroides

3β-

thetaiotaomi-

glucanase/precursor,

cron

2

endoglucanase

E

precursor
Bacteroides

1β-glucanase/β-

uniformis

glucanase synthase, 8

1↑,

22

NP

endoglucanase
Bacteroides eg-

2 endoglucanase

7

1↓, 6 NP

No matches found

28

6↑,

gerthii
Blautia
wexlerae
Blautia

1↓,

11

NP
hy-

No matches found

4

4 NP

0.00 ± 0.01

0.00 ± 0.01

0.00 ± 0.02

0.00 ± 0.01

NS

No matches found

7

7 NP

0.01 ± 0.02

0.00 ± 0.01

0.00 ± 0.01

0.01 ± 0.02

NS

drogenotrophica
Blautia

coc-

coides
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Table 3.4 – continued from previous page
Bacterial

Number and type of

Number of sub-

Response in

species

enzymes encoded

jects in which

individual

detected

subjects

No matches found

4

No matches found

1,3-β-glucosidase

Blautia

pro-

Baseline

BR

BR+WGB

WGB

P-value

4 NP

0.01 ± 0.03

0.00 ± 0.01

0.00 ± 0.01

0.00 ± 0.01

NS

5

5 NP

0.10 ± 0.26

0.05 ± 0.16

0.18 ± 0.91

0.08 ± 0.34

NS

14

4↑, 10 NP

1.81 ± 1.13

2.38 ± 1.69

2.75 ± 1.75

2.80 ± 2.04

0.006

14

2↑, 12 NP

0.22 ± 0.42

0.36 ± 0.83

0.64 ± 1.3

0.48 ± 1.08

NS

17

1↑, 16 NP

0.16 ± 0.42

0.17 ± 0.50

0.18 ± 0.33

0.23 ± 0.50

NS

4 endoglucanse

7

7 NP

0.07 ± 0.22

0.14 ± 0.65

0.08 ± 0.24

0.07 ± 0.20

NS

7 endoglucanase

4

4 NP

0.01 ± 0.03

0.00 ± 0.01

0.00 ± 0.01

0.00 ± 0.01

NS

ducta
Blautia
hansenii
Blautia

spp.

(Ruminococccus obeum)
Bifidobacterium

2

adolescentis

endoglucanase,

putative

β-1,32

endoglucanase
Bifidobacterium

2 endoglucanase

ND

angulatum
Bifidobacterium

1

putative

longum

exoglucanase,

β-1,32

en-

doglucanase
Bifidobacterium
pseudocatenulatum
Clostridium
butyricum
Continued on next page
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Table 3.4 – continued from previous page
Bacterial

Number and type of

Number of sub-

Response in

species

enzymes encoded

jects in which

individual

detected

subjects

Clostridium

2β-glucanase/β-

ramosum

glucanase synthase, 2

Baseline

BR

BR+WGB

WGB

P-value

17 NP

0.08 ± 0.22

0.14 ± 0.28

0.1 ± 0.19

0.08 ± 0.18

NS

ND

endoglucanase
Collinsella

2 endoglucanase

17

2 endoglucanase

ND

2 endoglucanase

ND

2 endoglucanase

25

1↑, 24 NP

0.29 ± 0.38

0.35 ± 0.42

0.33 ± 0.48

0.29 ± 0.45

NS

Coprococcus

1β-glucanase/β-

13

1↑, 12 NP

0.68 ± 1.23

0.64 ± 1.23

0.62 ± 1.29

0.75 ± 1.35

NS

eutactus

glucanase synthase, 8

0.52 ± 0.97

0.41 ± 0.72

0.56 ± 0.86

0.81 ± 1.41

NS

aerofaciens
Collinsella intestinalis
Collinsella
stercoris
Coprococcus
comes

endoglucanase
Dialister invi-

No matches found

sus
endoglu-

14

2↑, 12 NP

0.22 ± 0.42

0.36 ± 0.83

0.64 ± 1.3

0.48 ± 1.08

NS

eligens

canase

Eubacterium

1 endo-1,4-β-glucanase

28

14↑, 14 NP

2.48 ± 2.67

2.75 ± 3.27

3.65 ± 3.45

4.83 ± 3.98

0.001

1 endo-1,4-β-glucanase

28

1↑, 27 NP

0.25 ± 0.3

0.21 ± 0.32

0.14 ± 0.24

0.16 ± 0.18

NS

Eubacterium

1

putative

rectale
Roseburia
inulinivorans
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Table 3.4 – continued from previous page
Bacterial

Number and type of

Number of sub-

Response in

species

enzymes encoded

jects in which

individual

detected

subjects

Not in database

27

5 endo-1,4-β-glucanase

28

Roseburia fae-

Baseline

BR

BR+WGB

WGB

P-value

10↑, 17 NP

0.12 ± 0.17

0.06 ± 0.07

0.26 ± 0.31

0.53 ± 0.92

<0.0001

9↑, 19 NP

0.09 ± 0.12

0.04 ± 0.05

0.17 ± 0.18

0.30 ± 0.42

<0.0001

cis
Roseburia
intestinalis

NP = No pattern. NS = Not significant. ND = Not detected.
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BR

a

P<0.05 compared to Baseline.

Cholesterol
Total cholesterol (mmol/l) 4.86 ± 1.15
4.76 ± 0.79
Non-HDL (mmol/l)
3.09 ± 1.04
3.15 ± 0.84
HDL (mmol/l)
1.63 ± 0.43
1.60 ± 0.37
Plasma glucose
Fasting (mmol/l)
5.15 ± 0.73
4.87 ± 0.49
AUC ([mmol/l]2 )
784 ± 184
763 ± 164
Max. peak (mmol/l)
9.08 ± 2.78
8.58 ± 2.02
Plasma insulin
Fasting (µUI/ml)
6.77 ± 1.96
6.60 ± 2.13
2
AUC ([µUI/ml] )
3463 ± 1523
3606 ± 1520
Max. peak (µUI/ml)
44.08 ± 19.19 44.70 ± 19.56
Inflammatory markers
IL-6 (pg/ml)
1.68 ± 1.36
1.21 ± 0.99
Hs-CRP (mg/L)
1.60 ± 2.23
1.33 ± 1.65
LBP (µg/ml)
14.41 ± 19.65 14.39 ± 2.09

Baseline
4.89 ± 0.94
3.32 ± 0.94
1.57 ± 0.36
4.81 ± 0.50
770 ± 179
8.19 ± 2.35
7.03 ± 2.07
3540 ± 1481
45.13 ± 21.61
1.12 0.63
1.36 ± 1.88
13.78 ± 18.30

4.81 ± 0.39
746 ± 132
7.92 ± 1.46
6.51 ± 2.02
3333 ± 1035
42.86 ± 14.49
0.90 ± 0.45a
0.95 ± 1.23
13.23 ± 19.04

WGB

4.56 ± 0.89
3.00 ± 0.85
1.55 ± 0.45

BR+WGB

Overall

0.0295
NS
NS

NS
NS
NS

NS
NS
<0.1

NS
NS
NS

P-value

Table 3.5: Treatment effect on metabolic and immunological markers for all subjects. Metabolic
data of the 28 participants, at baseline and at the end of the 4-week dietary treatments (BR, BR+WGB,
WGB). Values are presented as mean ± SD.
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a

P<0.05 compared to Baseline.

Cholesterol
Total cholesterol (mmol/l) 4.42 ± 1.11
Non-HDL (mmol/l)
2.78 ± 0.74
HDL (mmol/l)
1.30 ± 0.28
Plasma glucose
Fasting (mmol/l)
5.14 0.72
AUC ([mmol/l]2 )
860 ± 232
Max. peak (mmol/l)
10.13 ± 3.25
Plasma insulin
Fasting (µUI/ml)
6.63 ± 1.75
2
AUC ([µUI/ml] )
3436 ± 1787
Max. peak (µUI/ml)
42.76 ± 20.55
Inflammatory markers
IL-6 (pg/ml)
1.18 ± 0.81
Hs-CRP (mg/L)
0.35 ± 0.22
LBP (µg/ml)
4.76 ± 2.96

Baseline
4.31 ± 0.91
2.90 ± 0.93
1.33 ± 0.31
4.91 ± 0.39
762 ± 166
8.21 ± 1.80
6.38 ± 1.80
3399 ± 1086
41.46 ± 12.37
1.99 ± 3.63
0.31 ± 0.24
4.42 ± 2.22

5.10 ± 0.64
851 ± 143
10.08 ± 1.67
5.93 ± 1.90
3816 ± 1704
48.63 ± 19.14
1.42 ± 1.35
0.92 ± 1.26
6.50 ± 5.48

BR+WGB

4.59 ± 0.85
3.01 ± 0.96a
1.41 ± 0.30

BR

Males

1.09 ± 0.58
0.76 ± 1.07
6.19 ± 4.09

6.05 ± 2.12
3600 ± 1586
48.54 ± 22.37

4.86 ± 0.34
857 ± 180
8.99 ± 2.37

4.46 ± 0.89
3.08 ± 0.82
1.23 ± 0.24

WGB

NS
NS
NS

NS
NS
NS

NS
NS
<0.1

NS
0.0327
NS

P-value

Table 3.6: Treatment effect on metabolic and immunological markers for male subjects.
Metabolic data of male participants, at baseline and at the end of the 4-week dietary treatments (BR,
BR+WGB, WGB). Values are presented as mean ± SD.
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b

a

P<0.05 compared to Baseline.
P<0.01 compared to Baseline.

Cholesterol
Total cholesterol (mmol/l) 5.02 ± 1.14
Non-HDL (mmol/l)
3.29 ± 1.16
HDL (mmol/l)
1.84 ± 0.37
Plasma glucose
Fasting (mmol/l)
5.15 ± 0.76
AUC ([mmol/l]2 )
739 ± 138
Max. peak (mmol/l)
8.40 ± 2.27
Plasma insulin
Fasting (µUI/ml)
6.85 ± 2.12
2
AUC ([µUI/ml] )
3480 ± 1405
Max. peak (µUI/ml)
44.93 ± 18.86
Inflammatory markers
IL-6 (pg/ml)
2.01 ± 1.58
Hs-CRP (mg/L)
2.35 ± 2.56
LBP (µg/ml)
20.44 ± 23.19

Baseline
4.73 ± 0.87
3.06 ± 0.83
1.69 ± 0.48
4.75 ± 0.40
735 ± 110
7.74 ± 1.23
6.60 ± 2.20
3294 ± 1037
43.76 ± 16.01
1.10 ± 0.86b
1.33 ± 1.43
18.73 ± 22.74

4.72 ± 0.29
706 ± 155
7.61 ± 1.61
7.04 ± 2.22
3483 ± 1442
42.15 ± 19.98
1.16 ± 0.83a
1.57 ± 1.85
19.32 ± 25.62

BR+WGB

4.87 ± 0.76
3.24 ± 0.78
1.73 ± 0.36

BR

Females

1.67 ± 2.39a
1.72 ± 2.19
18.52 ± 22.04

7.66 ± 1.83
3505 ± 1465
42.92 ± 21.50

4.77 ± 0.59
718 ± 162
7.66 ± 2.26

5.15 ± 0.89
3.47 ± 1.00
1.76 ± 0.25

WGB

0.0028
NS
NS

NS
NS
NS

0.0344
NS
NS

0.0342
NS
NS

P-value

Table 3.7: Treatment effect on metabolic and immunological markers for female subjects.
Metabolic data of female participants, at baseline and at the end of the 4-week dietary treatments (BR,
BR+WGB, WGB). Values are presented as mean ± SD.
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a

P<0.05 compared to Baseline.

Cholesterol
Total cholesterol (mmol/l) 4.84 ± 1.26
Non-HDL (mmol/l)
3.24 ± 1.21
HDL (mmol/l)
1.61 ± 0.45
Plasma glucose
Fasting (mmol/l)
5.37 ± 0.93
AUC ([mmol/l]2 )
867 ± 184
Max. peak (mmol/l)
9.66 ± 2.14
Plasma insulin
Fasting (µUI/ml)
6.93 ± 1.70
2
AUC ([µUI/ml] )
3730 ± 1677
Max. peak (µUI/ml)
48.39 ± 19.92
Inflammatory markers
IL-6 (pg/ml)
2.03 ± 1.32
Hs-CRP (mg/L)
2.26 ± 2.47
LBP (µg/ml)
22.45 ± 24.90

Baseline

7.60 ± 1.58
3804 ± 1482
49.94 ± 21.17
1.40 ± 0.77
1.86 ± 1.87
22.16 ± 22.66

6.82 ± 1.78
3249 ± 1128
43.19 ± 16.16
0.97 ± 0.52a
1.37 ± 1.52
21.63 ± 23.90

7.10 ± 2.53
3952 ± 1665
50.23 ± 22.63
1.64 ± 1.27
2.12 ± 1.96
23.56 ± 26.42

4.88 ± 0.42
811 ± 160
8.43 ± 1.79

4.88 ± 0.37
774 ± 128
7.99 ± 1.32a

4.87 ± 0.45a
800 ± 187
8.53 ± 2.11

5.03 ± 1.05
3.52 ± 1.05
1.51 ± 0.35

WGB

4.51 ± 0.89
3.12 ± 0.90
1.37 ± 0.40

BR+WGB

4.84 ± 0.86
3.35 ± 0.97
1.47 ± 0.32

BR

Overweight

0.0438
NS
NS

NS
NS
NS

0.0231
NS
0.0428

NS
NS
NS

P-value

Table 3.8: Treatment effect on metabolic and immunological markers for overweight subjects.
Metabolic data of overweight participants, at baseline and at the end of the 4-week dietary treatments
(BR, BR+WGB, WGB). Values are presented as mean ± SD.
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b

a

P<0.05 compared to Baseline.
P<0.01 compared to Baseline.

Cholesterol
Total cholesterol (mmol/l) 4.75 ± 1.07
Non-HDL (mmol/l)
2.94 ± 0.85
HDL (mmol/l)
1.65 ± 0.42
Plasma glucose
Fasting (mmol/l)
4.94 ± 0.40
AUC ([mmol/l]2 )
707 ± 153
Max. peak (mmol/l)
8.58 ± 3.09
Plasma insulin
Fasting (µUI/ml)
6.62 ± 2.22
2
AUC ([µUI/ml] )
3216 ± 1382
Max. peak (µUI/ml)
40.34 ± 18.38
Inflammatory markers
IL-6 (pg/ml)
1.35 ± 1.36
Hs-CRP (mg/L)
1.04 ± 1.93
LBP (µg/ml)
6.36 ± 6.67

Baseline
4.61 ± 0.92
2.89 ± 0.83
1.71 ± 0.45
4.75 ± 0.42
720 ± 135
7.98 ± 2.80
6.24 ± 2.24
3411 ± 978
42.57 ± 13.45
0.83 ± 0.38
0.59 ± 0.83
5.40 ± 5.63

4.87 ± 0.54
730 ± 140
7.86 ± 1.62
6.17 ± 1.69
3284 ± 1354
39.90 ± 15.67
0.81 ± 0.32
0.66 ± 0.99
4.83 ± 5.58

BR+WGB

4.69 ± 0.75
2.98 ± 0.71
1.72 ± 0.38

BR

Normoweight

0.86 ± 0.32
0.94 ± 1.86
5.21 ± 6.83

6.54 ± 2.36
3295 ± 1493
40.96 ± 26.83

4.74 ± 0.57
731 ± 192
8.63 ± 2.01

4.77 ± 0.84
3.14 ± 0.83
1.62 ± 0.37

WGB

NS
NS
NS

NS
NS
NS

NS
NS
NS

NS
NS
NS

P-value

Table 3.9: Treatment effect on metabolic and immunological markers for normoweight subjects.
Metabolic data normoweight participants, at baseline and at the end of the 4-week dietary treatments (BR,
BR+WGB, WGB). Values are presented as mean ± SD.
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Table 3.10: Gastrointestinal symptoms. Weekly gastrointestinal symptoms
of the 28 participating subjects, scored in a scale from 1 (best/normal) to 5
(worst/abnormal) during the baseline and at the end of each 4-week dietary
treatment (BR, BR+WGB, WGB). Values are presented as mean ± SD.
Baseline
Bowel movement
Stool consistency
General well-being
Flatulence
Abdominal pain
Bloating
a

1.5
1.5
1.2
1.3
1.1
1.2

±
±
±
±
±
±

0.5
0.6
0.3
0.5
0.2
0.4

BR
1.3
1.4
1.2
1.4
1.1
1.2

P<0.05 compared to Baseline.
P<0.001 compared to Baseline.
c
P<0.05 compared to BR.
d
P<0.01 compared to BR.
e
P<0.001 compared to BR.
f
P<0.05 compared to BR+B.
g
P<0.01 compared to BR+B.
h
P<0.001 compared to BR+B.
b

±
±
±
±
±
±

BR+WGB
0.5
0.5
0.4
0.5
0.3
0.4

1.7
1.8
1.5
2.2
1.4
1.6

±
±
±
±
±
±

0.6
0.6
0.6
0.9b,e
0.6
0.7a,c

WGB
2.0
2.0
2.2
3.1
1.8
2.2

±
±
±
±
±
±

P-value

0.8a,d <0.01
0.8a,d <0.01
0.6b,e,g <0.001
1.0b,g,h <0.001
0.8c,e,f <0.001
0.8b,e,g <0.001
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Figure 3.5: Association between inflammatory and metabolic markers and
bacterial taxa in fecal samples. A heat map shows correlation coefficients (Pearson) between BMI, percent body fat, IL-6, hs-CRP, LBP and glucose AUC with
proportions of bacterial taxa in fecal samples.
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Figure 3.6: Associations between Bacteroidetes related taxa and HDL
plasma levels at baseline. Correlations between proportions of Bacteroidetes (A),
Bacteroidaceae (B) and Bacteroides (C) in fecal samples with HDL measured in
plasma at baseline. Pearsons r correlation and the P values are presented.

Figure 3.7: Impact of whole grains on the fecal microbiota. Diversity of the
bacterial population in fecal samples assessed by Shannons (A) and Simpsons (B)
-diversity indices. ∗ P<0.05, ∗∗ P<0.01.
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Figure 3.8: Association between diet induced shifts in glycemic response
and the proportion of Eubacterium rectale. Correlation of the shift of the
Eubacterium rectale abundance with the shifts observed in postprandial AUC (A),
Insulin AUC (B), and maximum glucose levels (C). Shift refers to differences between
values obtained during the BR+B period and the baseline. Pearsons r correlation
and the P values are presented.
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H. Nahrstedt, M. Wos-Oxley, S. Ott, S. Schreiber, K.N. Timmis, and A.P. Oxley. Gordonibacter pamelaeae gen. nov., sp. nov., a new member of the Coriobacteriaceae isolated from a patient with Crohn’s disease, and reclassification of
Eggerthella hongkongensis Lau et al. 2006 as Paraeggerthella hongkongensis gen.
nov., comb. nov. J. Syst. Evol. Microbiol., 59:1405–1415, 2009.
J. Zhao and P.C. Cheung. Fermentation of β-glucans derived from different sources
by bifidobacteria: evaluation of their bifidogenic effect. J. Agric. Food Chem., 59:
5986–5992, 2011.

174

Chapter 4
Diet-induced metabolic
improvements in a hamster model
of hypercholesterolemia are
strongly linked to alterations of the
gut microbiota

Inés Martı́nez∗ , Grant Wallace∗ , Chaomei Zhang, Ryan Legge, Andrew K. Benson,
Timothy P. Carr, Etsuko N. Moriyama and Jens Walter. Appl. Environ. Microbiol.,
75:4175–4184, 2009.

∗

These authors contributed equally to this work.

175

4.1

Abstract

The mammalian gastrointestinal microbiota exerts a strong influence on host lipid
and cholesterol metabolism. In this study, we have characterized the interplay among
diet, gut microbial ecology, and cholesterol metabolism in a hamster model of hypercholesterolemia. Previous work in this model had shown that grain sorghum lipid
extract (GSL) included in the diet significantly improved the high-density lipoprotein
(HDL)/non-HDL cholesterol equilibrium (T. P. Carr, C. L. Weller, V. L. Schlegel, S.
L. Cuppett, D. M. Guderian, Jr., and K. R. Johnson, J. Nutr. 135:2236-2240, 2005).
Molecular analysis of the hamsters’ fecal bacterial populations by pyrosequencing of
16S rRNA tags, PCR-denaturing gradient gel electrophoresis, and Bifidobacteriumspecific quantitative real-time PCR revealed that the improvements in cholesterol
homeostasis induced through feeding the hamsters GSL were strongly associated
with alterations of the gut microbiota. Bifidobacteria, which significantly increased
in abundance in hamsters fed GSL, showed a strong positive association with HDL
plasma cholesterol levels (r=0.75; p=0.001). The proportion of members of the family
Coriobacteriaceae decreased when the hamsters were fed GSL and showed a high positive association with non-HDL plasma cholesterol levels (r=0.84; p=0.0002). These
correlations were more significant than those between daily GSL intake and animal
metabolic markers, implying that the dietary effects on host cholesterol metabolism
are conferred, at least in part, through an effect on the gut microbiota. This study
provides evidence that modulation of the gut microbiota-host metabolic interrelationship by dietary intervention has the potential to improve mammalian cholesterol
homeostasis, which has relevance for cardiovascular health.
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4.2

Introduction

The mammalian gut microbiota interacts intimately with its host, affecting both host
metabolic and immunological phenotypes with important consequences for health
(Gordon and Pesti, 1971, Hooper and Gordon, 2001, Nicholson et al., 2005). Recent studies have revealed complex linkages between the gut microbiome and host
metabolism, with the microbes exerting effects on the energy balance by influencing
glucose and lipid metabolism (Bäckhed et al., 2004a, Cani et al., 2007, Martin et al.,
2007). This intimate metabolic relationship is most likely the consequence of a long
coevolutionary process that resulted in a mutualistic relationship between the host
and its microbial partners (Ley et al., 2006). However, life in industrialized societies
has introduced profound changes into the human environment (e.g., diet, antibiotics,
hospital deliveries, hygiene, etc.) that are markedly different from the conditions to
which humans have evolved and that are likely to have occurred too abruptly for
the human microbiome to adjust. Consequently, aberrations of the gut microbiota
induced through lifestyle factors could be relevant to the etiology of several complex
human diseases whose occurrence has markedly increased in developed countries. Interestingly, imbalances in the gut microbiota have been reported for obesity, type
1 and 2 diabetes, some allergies, and inflammatory bowel diseases in humans and
animal models (Cani et al., 2007, Ley et al., 2005, Tannock, 2008, Turnbaugh et al.,
2006, Wen et al., 2008). The connection between gut bacteria and disease suggests an
intriguing paradigm on how to view and potentially treat complex diseases. Specific
bacterial populations in the intestine could be pharmaceutical targets to maintain or
restore metabolic functions (Cani and Delzenne, 2007, Flint et al., 2007).
Coronary heart disease (CHD) continues to be a major cause of death in developed
countries and is another example of a western disease that is less common in un-
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derdeveloped countries but increases in frequency with adoption of western customs
(Bickler and DeMaio, 2008). Most risk factors for CHD (obesity, high blood pressure, type 2 diabetes, heredity, high cholesterol , and diet) have been linked to the
gut microbiota (Cani et al., 2007, Flint et al., 2007, Holmes et al., 2008, Midtvedt,
1999, Turnbaugh et al., 2008), and gut bacteria have been suggested to play a role in
the etiology of cardiovascular disease (Fava et al., 2006, Ordovas and Mooser, 2006).
Cholesterol metabolism is a key factor in susceptibility to CHD, and as early as 1959,
it has been shown that germfree rats have higher serum cholesterol concentrations
than their conventional counterparts do (Danielsson and Gustafsson, 1959). Several
mechanisms have been proposed by which gut bacteria could influence host cholesterol
metabolism (Delzenne et al., 2006). Bacterial conversions of bile acids (such as the
formation of secondary bile acids) are likely to play a role, as they affect enterohepatic
circulation, de novo synthesis of bile acids, emulsification, and cholesterol absorption
(Cowles et al., 2002, Martin et al., 2007, Midtvedt, 1999). A further mechanism by
which gut bacteria might influence cholesterol metabolism is through Fiaf (fastinginduced adipocyte factor), which is selectively suppressed in the intestinal epithelium
by the gut microbiota (Bäckhed et al., 2004a,b). Fiaf is an important regulator of lipid
metabolism (e.g., through its inhibition of lipoprotein lipase) and has been shown to
increase total cholesterol and high-density lipoprotein (HDL) cholesterol levels when
overexpressed in transgenic mice (Mandard et al., 2006).
There are several reasons why hamsters are an excellent model for studying the
metabolic relationships among diet, cholesterol metabolism, and gut microbiota in
relation to health. First, hamsters are omnivorous, and their blood lipid profiles respond to diets in a predictive manner similar to humans (Bravo et al., 1994). Second,
unlike mice and rats which lack cholesterol ester transfer protein, hamsters exhibit all
of the enzymatic pathways in lipoprotein and bile metabolism that are also present
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in humans. They exhibit limited hepatic synthesis of cholesterol and bile acids, resulting in more relevant data when extrapolating to humans (Horton et al., 1995).
Third, hamsters develop atherosclerosis in a predictive manner in response to dietary
manipulation (Mitchell and McLeod, 2008).
Using the Golden Syrian hamster model, Carr and coworkers have shown that the
hexane-extractable lipid fraction of grain sorghum whole kernels (GSL), when included in the hamsters’ diet, leads to a significant reduction of plasma non-HDL and
liver cholesterol levels while increasing HDL cholesterol levels (Carr et al., 2005). We
extended this researc h and performed a comprehensive molecular characterization of
the fecal microbiota of the hamsters by pyrosequencing of 16S rRNA tags, denaturing gradient gel electrophoresis (DGGE), and Bifidobacterium specific quantitative
real-time PCR (qRT-PCR) in order to test whether metabolic effects of GSL were
associated with specific modifications of the gut microbiota.

4.3
4.3.1

Materials and methods
Animal experiments

The fecal samples analyzed here were obtained during a previous study that determined the effect of GSL included in the diet on the cholesterol metabolism of hamsters,
and the handling of animals, feed composition, GSL composition, sample collection,
and preparation have been described previously (Carr et al., 2005). Briefly, groups
of seven or eight male F1B Syrian hamsters (Bio Breeders, Watertown, MA) were
housed in cages (each hamster in an individual cage) and kept at 25C with a 12-h
light-12-h dark cycle. Hamsters were fed a modified AIN-93 M diet (Reeves et al.,
1993) supplemented with 0%, 1% and 5% grain sorghum lipid extract at the expense

179
of cornstarch. Daily feed intake was determined to assess individual GSL ingestions.
GSL was prepared from whole kernels obtained from a mixture of commercial red
grain sorghum hybrids grown in Nebraska. Hamsters had free access to food and
water throughout the study. After the hamsters were on their respective diets for 3
weeks, the complete fecal output for each hamster was collected over 7 days. The fecal
samples were ground, weighed, and stored frozen at -80◦ C until the DNA extractions
were performed.

4.3.2

DNA extraction

The fecal samples were diluted in ice-cold phosphate-buffered saline (pH 7) in a 1:10
ratio and centrifuged at 8,000 xg for 5 min. This washing step was repeated two times.
Bacterial cell pellets were resuspended in 750 µl lysis buffer (200 mM NaCl, 100 mM
Tris [pH 8.0], 20 mM EDTA, 20 mg/ml lysozyme) and transferred to a microcentrifuge
tube containing 300 mg of 0.1-mm zirconium beads (BioSpec Products). Samples were
then incubated at 37◦ C for 20 min followed by the addition of 85 µl of 10% sodium
dodecyl sulfate solution and 40 µl proteinase K (15 mg/ml). After incubation for 15
min at 60◦ C, 500 µl of phenol-chloroform-isoamyl alcohol (25:24:1) was added, and the
samples were homogenized in a MiniBeadbeater-8 (BioSpec Products) at maximum
speed for 2 min. Samples were cooled on ice before the layers were separated by
centrifugation at 10,000 xg for 5 min. The top layer was extracted twice with phenolchloroform-isoamyl alcohol (25:24:1) and twice with chloroform-isoamyl alcohol; DNA
was recovered by standard ethanol precipitation. The DNA pellets were dried for 30
min at room temperature and later resuspended in 100 µl of Tris-HCl buffer (10 mM,
pH 8.0).
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4.3.3

Analysis of the gut microbiota of hamsters by
pyrosequencing of 16S rRNA tags

The V1-V3 region of the 16S rRNA gene was amplified by PCR using bar-coded universal primers 8F and 518R containing the A and B sequencing adaptors (454 Life Sciences). The forward primer (A-8FM) was 5-gcctccctcgcgccatcagAGAGTTTGATCMTGGCTCAG-3 where the sequence of the A adaptor is shown in lowercase letters.
The reverse primer (B-518) was 5-gccttgccagcccgctcagNNNNNNNNATTACCGCGGCTGCTGG-3 where the sequence of the B adaptor is shown in lowercase letters and
N represents an eight-base bar code that is unique for each sample. Prior to sequencing, amplicons from the individual PCR samples were quantified using the Quant-iT
PicoGreen double-stranded DNA assay (Invitrogen) and quality controlled on an Agilent 2100 bioanalyzer. The amplicons from each reaction mixture were mixed in
equal amounts based on concentration and subjected to emulsion PCR, and amplicon libraries were generated as recommended by 454 Life Sciences. Sequencing was
performed from the B end using the 454/Roche B sequencing primer kit using a Roche
Genome Sequencer GS-FLX using the standard protocol. Samples were combined in
a single region of the picotiter plate such that approximately 1,000 to 2,000 sequences
were obtained from each animal. The data analysis pipeline removed low-quality sequences (i) that do not perfectly match the PCR primer at the beginning of a read,
(ii) that are shorter than 200 bp in length, (iii) that contain more than two undetermined nucleotides (N), or (iv) that do not match a bar code. Sequences (1,000 to
2,000 per animal) were quality controlled and binned according to bar codes.
Taxonomy-based analyses were performed by assigning taxonomic status to each sequence using the CLASSIFIER program of the Ribosomal Database Project (Wang
et al., 2007). To estimate species richness and diversity, taxonomy-independent meth-
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ods wer used. Sequences were aligned using Infernal Aligner; sequences from individual animals and then pooled sequences from all animals of a single treatment group
were aligned. Cluster analysis was performed using the complete linkage clustering
algorithm available through the Pyrosequencing pipeline of the Ribosomal Database
Project (Cole et al., 2009). Clustering was done with a 97% cutoff for inclusion into
an operational taxonomic unit (OTU) and was performed on alignments of sequences
from individual animals. The number of species and species richness were estimated
by further sampling-based (rarefaction) analyses of OTU data and of calculated Shannon diversity indices.

4.3.4

PCR-DGGE analysis

PCR was performed using universal primers PRBA338fGC (5-CGCCCGCCGCGCGCGGCGGGCGGGGCGGGGGCACGGGGGGACTCCTACGGGAGGCAGCAG-3) and PRUN518r (5-ATTACCGCGGCTGCTGG-3 (Ovreas et al., 1997), which amplify
the V3 region of the 16S rRNA gene. DGGE was performed by the method of Walter and coworkers (Walter et al., 2000) using a DCode universal mutation detection
system (Bio-Rad, Hercules, CA). DNA bands in the DGGE gel were visualized by
standard ethidium bromide staining and photographed using the InGenius gel documentation system (Syngene, Frederick, MD). DGGE images were analyzed using
BioNumerics software version 5.0 (Applied Maths, Kortrijk, Belgium). Bands were
manually assigned, and the normalized banding patterns were used to generate distance matrices by calculating the Pearson product moment correlation coefficients for
all pair-wise combinations of patterns. This approach compares profiles in a pair-wise
manner based on the entire densitometric curve, therefore accounting for both band
position and intensity. DGGE fingerprints were transformed to peak profiles using
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the BioNumerics software, and the intensities of individual bands were determined as
a percentage of the peak surface area relative to the surface area of the entire molecular fingerprint of the sample. To determine the effects of feeding hamsters GSL,
normalized fragment intensities of all bands in DGGE fingerprints were determined
and compared for the feeding groups.
In order to identify species represented by bands detected by DGGE, bands of fecal
fingerprints from two or three animals were excised from the gel, purified, and reamplified by the method of ben Omar and Ampe (ben Omar and Ampe, 2000), and cloned
using the TOPO TA Cloning kit for sequencing (Invitrogen). Plasmids were isolated
from three transformants per band using the QIAprep spin minprep kit (Qiagen), and
inserts were sequenced by a commercial provider following the manual of the cloning
kit. Closest relatives of the partial 16S rRNA sequences were determined using the
nucleotide blast web tool at the NCBI website (website) and the Seqmatch web tool
provided through the Ribosomal Database Project (website). A phylogenetic tree was
generated from the consensus sequence of the F bands in three individual animals using the unweighted-pair group method using average linkages and neighbor-joining
algorithms in the MEGA4 software package (Tamura et al., 2007). There were a total
of 178 positions in the final data set, and the evolutionary distances were computed
by using the Kimura two-parameter method and are reported as the number of base
substitutions per site.

4.3.5

Specific quantification of bifidobacteria by qRT-PCR

Quantification of total bifidobacteria was performed by quantitative real-time PCR
using primers BifFor (5-TCGCGTCYGGTGTGAAAG-3) and BifRev (5-CCACATCCAGCRTCCAC-3) (Rinttila et al., 2004). PCRs were performed using a Master-
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cycler Realplex2 (Eppendorf AG, Hamburg, Germany). Each PCR was done in a 25
µl volume. The reaction mixture comprised 11.25 µl of the 20 SYBR solution and 2.5
RealMasterMix (Eppendorf AG, Hamburg, Germany), 0.5 µM of each primer, and 1
µl of DNA template. The amplification program consisted of an initial denaturation
step of 5 min at 95◦ C, followed by 35 cycles, where 1 cycle consisted of 15 s at 95◦ C
(denaturation), 20 s at 58◦ C (annealing), and 30 s at 68◦ C (extension), and fluorescence at each step was measured. To control the specificity of the amplifications, a
melting curve was done consisting of a denaturation step of 15 s at 95◦ C, an increase
from 58◦ C to 95◦ C over a 20 min period, and a final step of 15 s at 95◦ C. Cultures
of B. animalis ATCC 25527T and B. infantis ATCC 15697T were used to generate standard curves for absolute quantification of bifidobacteria in the fecal samples.
Bacterial counts of overnight cultures (12 h) were determined by plate counting, and
a 10-fold dilution series was performed in phosphate-buffered saline buffer for each
strain. DNA was isolated from individual samples of the dilution series using the
method for fecal samples. Standard curves were made by plotting the threshold cycle
values obtained from DNA of the dilution series as a linear function of the base 10
logarithm of the number of bifidobacteria. Two individual qRT-PCR runs of all fecal
DNA templates in duplicate were performed, and means of all four values were used
for the analysis. Despite the use of two different strains of bifidobacteria to generate
one standard curve, its correlation coefficient r2 was >0.96.
To quantify the Bifidobacterium animalis-like phylotype detected by DGGE, we used
a specific primer (Bh1) based on a highly variable region of the sequence of fragment
F in the DGGE gel (5-GGCAGGGGGTTTTCCTC-3). This primer was used in
combination with primer BifRev (Rinttila et al., 2004) used for the Bifidobacterium
genus-specific qRT-PCR. PCR was performed as described above. The specificity
of the PCR was tested using DNA isolated from fecal samples from 10 human sub-
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jects and DNA from B. animalis ATCC 25527T and Bifidobacterium infantis ATCC
15697T . The PCRs all gave negative results with the primer combination Bh1 and
BifRev and positive results with primers BifFor and BifRev (data not shown). As
we had no cultural representative of the phylotype represented by band F, we used a
standard curve generated as described above with B. animalis ATCC 25527T and B.
infantis ATCC 15697T and primers BifFor and BifRev. Although the standard curve
was generated with a different forward primer, it can be assumed that no significant
bias is introduced, as the efficiencies of the two PCR systems were virtually identical
(0.51 for primers BifFor and BifRev and 0.56 for primers Bh1 and BifRev).

4.3.6

Correlation analysis of gut microbiota-host metabolic
functional relationships

Correlation analysis between metabolic host parameters and bacterial populations at
different taxonomic levels was performed by the method of Cani and coworkers (Cani
et al., 2007). Metabolic parameters included in the correlation analysis were the levels of cholesterol absorption, fecal cholesterol, plasma total cholesterol, plasma HDL
cholesterol, plasma non-HDL cholesterol, liver total cholesterol, liver-free cholesterol,
liver triglycerides, liver phospholipids, and liver-esterified cholesterol. The determination of these metabolic phenotypes and the methods applied were reported previously
(Carr et al., 2005).

4.3.7

Genome comparisons

The web-based Integrated Genomics Platform of the Joint Genome Institute (JGI)
was used to identify functions enriched in bifidobacteria (Markowitz et al., 2007).
The Abundance Profile Search was used to identify clusters of orthologous groups
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of proteins (COGs) that were more abundant in individual bifidobacterial genomes
(Bifidobacterium adolescentis ATCC 15703, Bifidobacterium adolescentis L2-32, Bifidobacterium animalis subsp. lactis HN019, Bifidobacterium dentium ATCC 27678,
Bifidobacterium longum DJO10A, and Bifidobacterium longum NCC2705) compared
to the genomes of a selection of bacteria commonly present in the mammalian gastrointestinal tract (Bacteroides caccae ATCC 43185, Bacteroides capillosus ATCC
29799, Bacteroides fragilis NCTC 9343, Bacteroides fragilis YCH46, Bacteroides
ovatus ATCC 8483, Bacteroides stercoris ATCC 43183, Bacteroides thetaiotaomicron VPI-5482, Bacteroides uniformis ATCC 8492, Bacteroides vulgatus ATCC 8482,
Clostridium acetobutylicum ATCC 824, Clostridium bartlettii DSM 16795, Clostridium bolteae ATCC BAA-613, Clostridium leptum DSM 753, Clostridium ramosum
DSM 1402, Clostridium sp. strain L2-50, Clostridium sp. strain SS2/1, Clostridium thermocellum ATCC 27405, Collinsella aerofaciens ATCC 25986, Coprococcus
eutactus ATCC 27759, Dorea formicigenerans ATCC 27755, Dorea longicatena DSM
13814, Enterobacter sp. strain 638, Enterococcus faecalis V583, Enterococcus faecium DO, Escherichia coli K-12, Eubacterium dolichum DSM 3991, Eubacterium
siraeum DSM 15702, Eubacterium ventriosum ATCC 27560, Faecalibacterium prausnitzii M21/2, Lactobacillus reuteri 100-23, Lactobacillus reuteri F275, Lactobacillus salivarius subsp. salivarius UCC118, Methanobrevibacter smithii ATCC 35061,
Parabacteroides distasonis ATCC 8503, Parabacteroides merdae ATCC 43184, Peptostreptococcus micros ATCC 33270, Providencia stuartii ATCC 25827, Ruminococcus gnavus ATCC 29149, Ruminococcus obeum ATCC 29174, Ruminococcus torques
ATCC 27756, and Salmonella enterica serovar Typhimurium LT2). Functions associated with lipid metabolism were specifically selected from the enriched COGs and
added to the function list. A function profile of these COGs was then generated for
all of the gut species. Please refer to the IMG web page for details (website).
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4.3.8

Statistical analysis

Results are presented as means standard deviations (SDs). Statistical tests for treatment effects of the GSL on the abundance of individual taxonomic ranks or DGGE
band intensities were performed by one-way analysis of variance (ANOVA) analysis
followed by Tukey’s posthoc multiple comparison tests. The Mann-Whitney test was
used to compare Shannon diversity indices of gut populations. Correlations between
metabolic parameters and bacterial populations were assessed by Pearson’s correlation test using GraphPad Prism version 5.00 (GraphPad Software, San Diego, CA).

4.4
4.4.1

Results
Characterization of the hamster gut microbiota by
pyrosequencing of 16S rRNA tags

To determine whether proportional changes of the gut microbiota were associated
with the effects of GSL on cholesterol metabolism in hamsters, we analyzed the fecal microbiota of hamsters fed 0% (n = 7), 1% (n = 7), and 5% (n = 7) GSL by
pyrosequencing of the V3 region of the 16S rRNA gene. A total of 34,424 sequences
were studied; the average sequence length was around 250 bp, and an average of 1,639
sequences per animal were studied. Taxonomy-based analysis showed that the composition of the hamster gut microbiota at the phylum level is similar to that of humans
and mice, being dominated by Firmicutes and Bacteroidetes. An unusual feature of
the hamster gut microbiota, however, was that Firmicutes comprised the vast majority of the taxa (94%) with Bacteroidetes making up only 4% of the population. The
remaining bacteria belonged to the phyla Verrucomicrobia and Actinobacteria (each
representing around 1% of the total sequence tags) and Proteobacteria and candidate
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Figure 4.1: Characterization of the gut microbiota composition of hamsters
fed different amounts of GSL as determined by pyrosequencing of 16S
rRNA tags (V3 region). Composition of the gut microbiota of hamsters fed 0%,
1%, and 5% GSL (n = 7 per group) at the family level (A) and the genus level
(B). (C) Rarefaction curves of OTUs from sequences of fecal samples from individual
hamsters fed 0% GSL (red), 1% GSL (green), and 5% GSL (blue). (D) Shannon
diversity indices of the gut microbiota of individual hamsters fed 0% GSL (red),
1% GSL (green), and 5% GSL (blue). OTUs were identified using 97% cutoffs for
rarefaction and Shannon diversity indices.
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division TM7 (0.07% and 0.024% of sequences, respectively).
At the family level, the predominant groups in hamsters of the control group were
the Erysipelotrichaceae, Eubacteriaceae , Ruminococcaceae, and Lactobacillaceae,
represented by an average of 59%, 19%, 13% and 5% of the total fecal microbiota,
respectively (Figure 4.1A). Of the bacterial groups on the genus level, the most dominant were unclassified Erysipelotrichaceae, Allobaculum, unclassified Eubacteriaceae,
Ruminococcus, and Lactobacillus, comprising 31%, 28%, 19%, 11%, and 5% of the
total sequence pool on average in control animals, respectively (Figure 4.1B). With
the exception of Allobaculum, these genera are also shared with the gut microbiota
reported for mice, humans, and primates (Eckburg et al., 2005, Ley et al., 2005,
McKenna et al., 2008, Turnbaugh et al., 2008). As shown in Supplementary Figure 4.5 in the supplemental material, pyrosequencing revealed high animal-to-animal
variability on both the family and genus levels.

4.4.2

Effects of GSL on specific taxa of the hamster gut
microbiota

Sequence proportions determined by pyrosequencing were used to establish the effects of the GSL on the gut microbiota composition. To identify specific taxa that
were affected by the feeding treatments, the proportions of taxa in each rank of each
animal were tested for treatment effects. As shown in Table 4.1, ANOVA identified
one family, the Coriobacteriaceae (p=0.042), and two bacterial groups at the genus
level, unclassified members of the family Erysipelotrichaceae (p=0.0016) and genus
Pseudoramibacter (p=0.017), as being significantly affected by the inclusion of GSL
to the hamsters’ diet. Moreover, values for the genus Allobaculum (p=0.096) and unclassified members of the family Coriobacteriaceae (p=0.064) approached statistical
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Table 4.1: Abundance of bacterial groups in the fecal microbiota of hamsters
that changed by including GSL in the diet as determined by pyrosequencing of
16S rRNA tagsa
Bacterial taxa

Family level
Coriobacteriaceae
Genus level
Allobaculum
Pseudoramibacter
Unclassified members of the
following families
Coriobacteriaceae
Erysipelotrichaceae

Abundance of bacterial groupb(% of total sequences
obtained with sample [mean ± SD]) in hamsters fed:
0% GSL

1% GSL

5% GSL

1.22 ± 0.79

0.79 ± 0.63

0.31 ± 0.33c

27.82 ± 15.9
0.11 ± 0.09

30.63 ± 15.8
0.48 ± 0.30c

43.55 ± 7.0e
0.35 ± 0.21c

1.0 ± 0.7
31.0 ± 7.4

0.69 ± 0.62
32.7 ± 14.0

0.23 ± 0.31e
12.39 ± 6.0d

a

There were seven hamsters in each group.
Values that were significantly different or approaching statistical significance are
shown in boldface type.
c Statistically significantly different from the value for hamsters fed 0% GSL (p<0.05)
by ANOVA.
d This value was statistically significantly different from the value for hamsters fed 0%
GSL (p<0.01) and from the value for hamsters fed 1% GSL (p<0.01) by ANOVA.
e Approaching statistical significance compared to the value for hamsters fed 0% GSL
(p<0.1) by ANOVA.
b

significance.
Taxonomy-independent analysis of the hamster gut microbiota from individual animals showed that with a conservative level of 97% identity as a cutoff for OTUs,
nearly 200 OTUs were observed in the average of 1,600 sequences from each animal
(Figure 4.1C). Individual animals in the 5% GSL feeding group showed a trend toward
fewer OTUs in the rarefaction curves. The Shannon diversity indices from individual animals also showed a trend of fewer OTUs in animals fed 5% GSL (blue lines)
compared to animals fed 0% GSL (Figure 4.1D). Grouping of the samples by GSL
showed significant differences between 0% and 5% GSL (p<0.0001, Mann-Whitney
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test). Thus, 5% GSL had the effect of reducing the diversity of the gut microbiota.

4.4.3

DGGE analysis of fecal microbiota of hamsters fed
GSL

To validate the findings obtained with pyrosequencing, fecal bacterial populations of
the hamsters were also analyzed by PCR-DGGE. The DGGE gel is shown in Figure
4.2A, and the results of analysis of the gel are presented in Table 4.2. Feeding the
hamsters 5% GSL significantly increased the staining intensity of band C (p=0.037)
and band F (p=0.011). Band A showed a high animal-to-animal variation, and no
consistent impact of GSL was detected. Sequence analysis of amplicons from these
bands revealed that they represent bacteria related to Ruminococcus bromii (band
A), Allobaculum stercoricanis (band C), and Bifidobacterium animalis (band F). Phylogenetic comparison of the sequence from band F with the closest hits in the RDP
database revealed this sequence to be most similar to Bifidobacterium animalis, and
it is referred to as the Bifidobacterium animalis-like phylotype in this article (a phylogenetic tree is shown in Figure 4.2B).
Although providing less depth, DGGE analysis showed good agreement with the results from pyrosequencing. Both methods detected the increase of bacteria related
to Allobaculum and the high animal-to-animal variability of bacteria related to Ruminococcus. Relative species quantification obtained with pyrosequencing showed
high correlations with staining intensities of DGGE bands representing the same bacterial groups (for Ruminococcus, r=0.94; for Allobaculum, r=0.81; both p<0.0001)
(see Supplementary Figure 4.6). This is remarkable, as both methods are only semiquantitative and entail multitemplate PCR susceptible to PCR bias. The main difference between the findings by pyrosequencing and DGGE was in the proportions
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Ratio of staining intensities of major bands as a proportion of total fingerprint intensity (shown
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b
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c
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d
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Table 4.2: Ratio of staining intensities of major bands as a proportion of total fingerprint intensity
and results of sequence analysis of selected bands
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Figure 4.2: Impact of GSL on the gut microbiota composition of hamsters
fed 0% GSL (n = 7), 1% GSL (n = 7), and 5% GSL (n = 8) as determined
by DGGE and qRT-PCR. (A) DGGE showing fingerprints of DNA isolated from
the fecal samples of hamsters. Lanes 1 to 32 contain DNA from individual hamsters.
Lane M contains markers from reference strains. Bands C and F showed significant
increases in staining intensity in fecal fingerprints of hamsters fed 5% GSL. The bands
A, C, and F marked by an arrow were excised, purified, and sequenced (Table 4.2). (B)
Phylogenetic tree of DGGE band F with sequences that revealed highest similarities
in GenBank. The tree was inferred using the unweighted-pair group method using
average linkages, and the percentage of replicate trees in which the associated taxa
clustered together in the bootstrap test (1,000 replicates) are shown next to the
branches. A neighbor-joining tree resulted in essentially the same phylogeny (data
not shown). (C) Cell numbers of total bifidobacteria in hamster fecal samples as
determined by qRT-PCR. (D) Quantification of the Bifidobacterium animalis -like
phenotype detected by DGGE in hamster fecal samples by qRT-PCR. (E) Correlation
of cell numbers of bifidobacteria with daily GSL intake.
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of bifidobacteria, where a significant proportion could be detected only by DGGE,
while only 0.03% of the total sequences obtained by pyrosequencing corresponded
to bifidobacteria. The difference can be explained by the use of primer 8F in pyrosequencing, which shows three mismatches with the 16S rRNA genes from five
Bifidobacterium species for which whole-genome sequences were available (data not
shown). Accordingly, many studies employing direct analysis of 16S rRNA genes to
study the human gut microbiota and using the primer 8F, which is one of the most
commonly used primers for such approaches, resulted in a significant underrepresentation of Bifidobacterium species (Eckburg et al., 2005, Palmer et al., 2007, Suau
et al., 1999, Zoetendal et al., 2008).

4.4.4

Quantification of bifidobacteria using qRT-PCR

Since primer 8F resulted in an underrepresentation of bifidobacteria in pyrosequencing
and to confirm and quantify the bifidogenic effect of the GSL detected by DGGE
analysis, a specific qRT-PCR procedure was used to determine the numbers of total
bifidobacteria and the Bifidobacterium animalis-like phylotype. As shown in Figures
4.2 C and D, qRT-PCR analysis showed a significant increase in cell numbers of total
bifidobacteria (p=0.012) and the Bifidobacterium animalis-like phylotype (p=0.019).
As shown in Figure 4.2E, the numbers of bifidobacteria from individual hamsters
were highly variable, but a significant correlation between cell numbers and daily
GSL intake was observed.
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4.4.5

Bifidobacteria and Coriobacteriaceae showed high
correlations with important markers of host
cholesterol metabolism

In a previous study using the animals studied here, dietary GSL reduced cholesterol
absorption, plasma non-HDL cholesterol concentrations, and liver esterified cholesterol levels, while raising plasma HDL cholesterol levels (Carr et al., 2005). To determine whether alterations of the gut microbiota in hamsters fed GSL were associated with an improvement in cholesterol metabolism, a correlation analysis was
used to determine correlations between all bacterial taxa at different taxonomic levels and host metabolic phenotypes. The analysis revealed highly positive correlations
between HDL plasma concentrations and total bifidobacteria (r=0.75, p=0.0011),
between HDL plasma concentrations and Bifidobacterium animalis-like phylotype
(r=0.77, p=0.0009), among total Coriobacteriaceae and non-HDL plasma concentrations (r=0.84, p=0.0002), and between unclassified Coriobacteriaceae and both nonHDL plasma concentration (r=0.82, p=0.0004) and cholesterol absorption (r=0.71,
p=0.0042). These high correlations were observed only in animals fed 1% and 5%
GSL, and inclusion of the values from control animals significantly reduced correlations (Table 4.3). Graphs showing the highest correlations between bacterial taxa
and metabolic phenotypes are shown in Figure 4.3, and a metabolic network diagram
linking GSL, bacterial phylotypes, and host cholesterol metabolism is shown in Figure
4.4. Interestingly, the correlations between bifidobacteria and HDL cholesterol concentration and between Coriobacteriaceae and non-HDL concentration showed higher
significance than correlations achieved between GSL intake and the respective host
metabolic phenotypes.
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Table 4.3: Correlations between abundance of bacterial taxa and markers of
cholesterol metabolisma
Bacterial taxa

Family level
Coriobacteriaceae
Genus level
Bifidobacterium
Allobaculum
Pseudoramibacter
Unclassified members of
the following families
Coriobacteriaceae
Erysipelotrichaceae
a
b

Correlationb(r value) between abundance of bacterial
taxa and the following marker of cholesterol metabolism:
GSL intake
Non-HDL
HDL level
Cholesterol
level
absorption
-0.54 (-0.50)

0.84 (0.37)

-0.56 (-0.18)

0.68 (0.50)

0.56 (0.61)
0.50 (0.48)
-0.24 (0.23)

-0.61 (-0.33)
-0.28 (-0.53)
0.07 (-0.39)

0.75 (0.34)
0.24 (0.50)
-0.12 (0.19)

-0.42 (-0.51)
-0.45 (-0.37)
0.08 (-0.40)

-0.48 (-0.52)
-0.74 (-0.70)

0.82 (0.40)
0.45 (0.34)

0.52 (-0.19)
-0.48 (-0.32)

0.71 (0.47)
0.68 (0.56)

Values for animals fed 1% and 5% GSL are presented.
Values for all animals, including control animals, are presented in parentheses.
Correlation coefficients with an r of <0.7 are shown in boldface type.

Figure 4.3: Specific bacterial populations in the guts of hamsters show high
associations with both cholesterol metabolic phenotypes and GSL intake.
(A and B) Correlations between cell numbers of total bifidobacteria (A) and the
Bifidobacterium animalis-like phenotype (B) with HDL cholesterol. (C) Correlation
between proportion of Coriobacteriaceae and non-HDL cholesterol. (D) Correlation
between unclassified members of the family Coriobacteriaceae and cholesterol absorption. Data from control animals (0% GSL) were excluded from the analysis.
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Figure 4.4: Metabolic network showing the associations between daily GSL
intake, gut microbiota composition, and host cholesterol metabolism in
hamsters fed 0%, 1%, and 5% GSL. Results of the correlations of cell numbers
of bifidobacteria and proportions of Coriobacteriaceae and phenotypic markers were
obtained with data from animals fed 1% and 5% GSL. Red connections indicate a
positive correlation, while blue connections show correlations that are inverse. Green
connections show associations with no statistical significance. Metabolic data were
obtained by Carr and coworkers in a previous study (Carr et al., 2005).
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4.4.6

Genome comparisons of bifidobacteria and other gut
organisms

By comparing the relative abundance of different functional categories in 47 genomes
of gut bacteria, we observed that proteins belonging to the COG clusters COG0400
(predicted esterase), COG0657 (esterase/lipase), and COG2272 (carboxylesterase
type B) are enriched in six Bifidobacterium genomes (see Table 4.4 in the supplemental material). Carboxylesterases represented by COG0400 and COG2272 belong
to enzymes that hydrolyze a wide variety of substrates, ranging from methylcaplyrate
to p-nitrobenzyl (Hong et al., 1991, Zock et al., 1994).

4.5

Discussion

In humans, CHD is associated with high levels of low-density lipoprotein and low
levels of high-density lipoprotein. The characterization of the gut microbiota in a
hamster model of hypercholesterolemia showed that dietary intervention with GSL
had a major impact on the composition of the gut microbiota and that these modulations were highly associated with improvements in the HDL and non-HDL cholesterol
equilibrium. With consumption of GSL, population levels of bifidobacteria increased
and showed a strong positive association with increases in HDL cholesterol levels. In
contrast, relative abundance of members of the family Coriobacteriaceae decreased
with feeding the hamsters GSL, and a high positive correlation with non-HDL cholesterol and cholesterol absorption was discovered. The findings indicate that GSL intake
influences the HDL/non-HDL equilibrium, at least in part, through an alteration of
the gut microbiota. We infer this because correlation coefficients between bifidobacterial and Coriobacteriaceae populations and plasma cholesterol concentrations were
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higher than associations among GSL intake, host phenotypes, and cholesterol absorption (Figure 4.4). In addition, if bacterial phylotype/host phenotype correlations were
merely a result of GSL affecting both bacterial taxa and cholesterol metabolism independently, one would assume that all bacterial taxa whose abundance correlated with
GSL intake would show an association with host phenotypes. However, much lower
correlation coefficients with non-HDL and HDL plasma concentrations were observed
between relative abundance of unclassified members of the family Erysipelotrichaceae
and the genus Allobaculum, although these taxa showed significant associations with
GSL intake (Table 4.3). However, it should be considered that bifidobacteria and
Coriobactericeae are just two of hundreds of groups, and other bacteria, independent
of GSL administration, are likely to interact with host cholesterol metabolism.
Changes in the composition of the hamsters’ gut microbiota induced by GSL consumption were limited to a relatively small number of bacterial groups (Tables 4.1 and 4.3).
These compositional adjustments had the net effect of reducing the overall species
richness (number of individual species per unit population). However, the overall composition of the microbiota at the phylum level was not affected by GSL. The reason
for this finding was that increases of dominant bacterial taxa were ‘balanced’ by a reduction of related bacteria, leaving the relative proportions of higher taxonomic taxa
unaffected. Allobaculum belongs to the family Erysipelotrichaceae, and uncharacterized bacteria of this family declined as Allobaculum increased with feeding the hamsters GSL. Thus, the overall proportions within the family Erysipelotrichaceae and
the phylum Firmicutes were not changed. Similar findings were obtained for the phylum Actinobacteria, where numbers of bifidobacteria increased while the abundance
of members of the family Coriobacteriaceae declined. As shown in Supplementary
Figure 4.7, significant inverse correlations were obtained between these related bacterial groups in individual animals. Similar diet-induced compositional adjustments of
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the gut microbiota that maintain the overall composition at higher taxonomic levels
have also been observed in humans. For example, the decline of bacteria belonging to
the Roseburia and Eubacterium rectale groups induced through reduced carbohydrate
intake was balanced by an increase in the number of related members of the Clostridium coccoides cluster in human fecal samples (Duncan et al., 2008). Furthermore,
the diet of human infants appears to influence the Bifidobacterium/Coriobacteriaceae
ratio, with higher numbers of bifidobacteria in breast-fed infants while there were
higher numbers of coriobacteria when the infants were fed formula (Harmsen et al.,
2000). Collectively, these findings indicate that homeostatic reactions that restore the
overall equilibrium of the gut microbiota are often a natural consequence of compositional changes induced through diet. Nevertheless, as indicated by the correlation
analysis in our study, an alteration of the gut microbiota at lower taxonomic levels is
still likely to have important functional consequences for the host.
The mechanisms by which bifidobacteria and coriobacteria affect cholesterol metabolism remain an important field of future research. Including GSL in the diet reduced
cholesterol absorption efficiency, which was directly correlated with non-HDL cholesterol concentration (Carr et al., 2005). The high correlations of unclassified members of the family Coriobacteriaceae with both non-HDL cholesterol and cholesterol
absorption suggest that these bacteria could have a negative impact on cholesterol
homeostasis through increasing cholesterol absorption. Bifidobacteria, on the other
hand, showed high positive correlation with HDL cholesterol levels and no association with cholesterol absorption. Bifidobacteria have been shown to affect cholesterol
and lipid metabolism in animal models when administered as probiotics or when
stimulated by prebiotics (Crittenden and Playne, 2006, Delzenne et al., 2006). The
mechanism by which bifidobacteria achieve these effects remain speculative, but they
might impact cholesterol metabolism indirectly by suppressing numbers of Coriobac-
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teriaceae. For both bacterial groups, the capability to transform bile acids has been
reported (Ridlon and Hylemon, 2006), and this phenotypic trait might influence host
cholesterol metabolism through an impact on enterohepatic circulation. The strong
correlations between bacterial taxa and cholesterol metabolism were observed only
in animals fed GSL and not in control animals, suggesting that GSL influences the
relative abundance of these organisms as well as metabolic characteristics.
The consumption of lipids has not yet been associated with increases in numbers of
intestinal bifidobacteria. In contrast, Cani and coworkers (Cani et al., 2007) showed
that a high-fat diet significantly lowered the number of bifidobacteria in mice. The
composition of the GSL administered to the hamsters in our study contained not only
mono-, di-, and triglycerides but also esters, alcohols, and other lipophilic compounds,
such as waxes, sterols, and polycosanols (Carr et al., 2005). Carbohydrates or fiber
are an unlikely explanation for the bifidogenic effect of GSL, as the amounts of fiber
in hexane extracts of grains are negligible (Carr et al., 2005). Interestingly, genome
comparisons revealed that bifidobacteria possess metabolic capacities that could allow them to utilize complex lipids, including lipids that may not be utilized by other
members of the gut microbiota or the host. Schell and colleages detected four genes
encoding long-chain fatty acyl-coenzyme A synthetases in the genome of Bifidobacterium longum, more than any other prokaryote genome available at that time, except
for Streptomyces coelicolor and another gastrointestinal tract inhabitant, Bacteroides
fragilis (Schell et al., 2002). These findings together with the enrichment of putative
esterases in bifidobacterial genomes detected above indicate that bifidobacteria are
likely to utilize specific components of GSL leading to the increase in numbers in the
gut.
The correlation analysis identified the Bifidobacterium/Coriobacteriaceae equilibrium
to be important for the plasma cholesterol levels in hamsters, with bifidobacteria
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being beneficial and coriobacteria being detrimental. While extrapolation of our observations to humans is still speculative, our findings suggest that bifidobacteria and
coriobacteria could be potential targets for the prevention of metabolic aberrations
that play a role in CHD. Clearly, it will be essential to first identify the exact bacterial taxa within the human gut microbiota that have strong correlations to cholesterol
metabolism, which in itself is a challenging task. Unlike the inbred population of hamsters used in our study, human subjects have significant genetic diversity, and genetic
factors that affect cholesterol metabolism play a more important role in humans than
in the animal model. Furthermore, human subjects follow individual lifestyles and
consume different diets, and they harbor variable and individual communities of the
gut bacteria. All these factors will hamper the identification of bacterial contributors
to human cholesterol metabolism. Nevertheless, it is tempting to speculate that the
positive impact of breast-feeding on the Bifidobacterium/Coriobacteriaceae ratio in
human infants (Harmsen et al., 2000) could be responsible for the higher HDL cholesterol levels observed in adults that were breast-fed in infancy (Parikh et al., 2007).
This study provides new and important perspectives on dietary modulation of the
mammalian gut microbiota and its effects on the host. The findings indicate that a
complex mixture of lipids can exert a prebiotic effect that leads to improvements in
host cholesterol metabolism. In conclusion, this study provided evidence that modulation of bacterial populations in the gut has the potential to improve mammalian
cholesterol homeostasis, which has relevance in the prevention of CHD.
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Table 4.4: COGs involved in lipid metabolism identified as enriched in the genomes of bifidobacteria.
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Figure 4.5: Composition of the fecal microbiota of individual hamsters fed
0%, 1%, and 5% GSL as part of their diet at the family taxonomic level
(A) and genus taxonomic level (B).
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Figure 4.6: Results obtained by pyrosequencing of 16S rRNA tags and
DGGE showed good coherence. Correlations between relative abundance of bacterial taxa as determined by pyrosequencing and band intensity in DGGE analysis of
A) Allobaculum and B) Ruminococcus.

Figure 4.7: Inverse correlation between the abundance of related bacterial
groups in fecal samples of hamsters fed GSL. A) Abundance of Allobaculum and
unclassified Erysipelotrichaceae, which both belong to the family Erysipelotrichaceae
and the phylum Firmicutes, as determined by pyrosequencing. B) Abundance of bifidobacteria and Coriobacteria, which both belong to the phylum Actinobacteria, as
determined by pyrosequencing (for Coriobacteriaceae) and qRT-PCR (for bifidobacteria). Data from all 21 animals were plotted regardless of the GSL treatments.
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5.1

Introduction

The mammalian gastrointestinal tract (GIT) is colonized by trillions of microorganism
(the gut microbiota), a large fraction of which are bacteria. This microbial community has an extensive impact on host metabolism with important consequences for
vertebrate biology (Allen and Torres, 2008, Reddy et al., 1972, Claus et al., 2011).
First, the contribution of gut microbes to the utilization and storage of nutrients is
a key beneficial trait that underlies host-microbiota symbiosis (Bäckhed et al., 2007,
Gordon and Pesti, 1971). Second, the interplay between diet, the gut microbiota, and
host metabolism influences the development of metabolic disorders in humans, with
various central pathophysiological indicators of disease being reduced in germ-free
or antibiotic treated diet-induced and genetic animal models of metabolic diseases
(Bäckhed et al., 2004, Ley et al., 2005, Vijay-Kumar et al., 2010, Membrez et al.,
2008, Rabot et al., 2010). Therefore, a precise mechanistic understanding of the interrelationships between gut microbes and host metabolism is necessary to gain a
more complete understanding of the host-microbial symbiosis in the vertebrate gut
and to develop informed strategies to prevent metabolic disorders through modulation of the gut microbiome.
The host lipidome, and specifically cholesterol metabolism, are key factors in the susceptibility to coronary heart disease (CHD), and have been shown to be influenced
by the gastrointestinal microbiota (Danielsson and Gustafsson, 1959, Li et al., 2008,
Holmes et al., 2011, Swann et al., 2011). With the advent of novel molecular technologies that have enhanced the characterization of microbial communities, associations
between host lipid metabolism with bacterial taxa and community structure of the
gut microbiome have been identified in both human and animals. Spencer et al.
(2011) showed that in humans, levels of Erysipelotrichaceae were directly associated
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with changes in liver fat induced through dietary choline depletion, and higher proportions of this bacteria have been identified in morbidly obese individuals (Zhang
et al., 2009). This bacterial family was also linked to lipidemic imbalances and other
pathological states in mice, and was associated with cholesterol metabolism in a
hamster model of hypercholesterolemia (Zhang et al., 2010, Martı́nez et al., 2009). A
second family, the Coriobacteriaceae, has also been repeatedly linked to the host lipidiome. Coriobacteriaceae displayed strong positive correlations with plasma non-HDL
in hamsters (Martı́nez et al., 2009). Claus et al. (2011) confirmed the connection between Coriobacteriaceae, and especially the genus Eggerthella, with lipid metabolism
in mice, showing positive correlations with hepatic triglyceride levels. The recurrent
identification of associations between Coriobacteriaceae and Erysipelotrichaceae, and
specific taxa within members of these families, with host lipid and cholesterol phenotypes observed in independent experiments in humans and animals, suggests a
genuine link between these bacterial groups and host metabolism (Claus et al., 2011).
Despite the strong evidence linking Coriobacteriaceae and Erysipelotrichaceae with
host lipid metabolism, causality has not yet been established. Understanding the
directionality of the associations between gut microbiota composition and function
with host metabolism is crucial to develop therapies that target specific bacterial
groups to ameliorate these disorders (Claus et al., 2011). The important similarities
between hamsters and humans in terms of their lipid profiles, enzymatic pathways
in lipoprotein and bile metabolism, and susceptibility to diet-induced atherosclerosis
pose advantages in using these animals to investigate the interplay between cholesterol
metabolism and the gut microbiota. However, the impossibility of rearing hamsters
germ-free precludes the study of causative relationships between specific bacterial taxa
and host cholesterol metabolism using gnotobiotic approaches. Thus, alternative experimental designs need to be developed to provide insight into the interrelationship
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between cholesterol metabolism and the gut microbiota.
In this study, we have characterized the interaction between the gut microbiota and
cholesterol metabolism in hamsters that received two types of plant sterol esters (PSE)
or a control diet (Rasmussen et al., 2006). PSE cause inhibition of cholesterol absorption in the small intestine and consequently lower systemic cholesterol concentrations.
The cholesterol-lowering mechanisms of PSE have been fairly well described, and include the displacement of cholesterol in intestinal micelles, co-crystallization between
PSE and cholesterol leading to the formation of insoluble crystals, and the impediment of cholesterol hydrolysis by lipases and cholesterol esterases (Heinemann et al.,
1991, Ntanios and Jones, 1999, Normén et al., 2000, Trautwein et al., 2003, Brown
et al., 2010a,b). Accordingly, the dietary addition of PSE led to a reduction in plasma
and liver cholesterol levels, and increased cholesterol by fecal excretion (Rasmussen
et al., 2006). In addition to the impact of PSE on the cholesterol metabolism, dietary
addition of PSE induced significant shifts in the gut microbiota of the hamsters that
showed remarkably tight associations with host cholesterol metabolism. The associations between several bacterial taxa with fecal and biliary cholesterol excretion
showed an excellent fit to a sigmoidal inhibitory nonlinear model that describes doseresponse relations between bacteria and inhibitory compounds (Mouton et al., 2005,
MacDougal, 2006), indicating that host cholesterol excretion can shape microbiome
structure through the antimicrobial action of cholesterol.
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5.2
5.2.1

Materials and methods
Animal experiments and diets

The fecal samples analyzed here were obtained during a previous study that determined the effect of PSE included in the diet on lipid metabolism of hamsters, and
the handling of animals, feed composition, sample collection, and metabolic analysis
has been described previously (Rasmussen et al., 2006). Briefly, Bio-F1B male Syrian
hamsters (Bio Breeders, MA, USA) were individually caged and randomly assigned
to four dietary treatments throughout a 4-week period: a modified AIN-93M diet
containing no PSE (C), or containing 5% (w/w) plant sterols esterified with fatty
acids from beef tallow (BT), stearic acid (SA), or soybean oil at the expense of dietary fiber. The final energy distribution of each diet was 36% fat, 35% carbohydrate
and 29% protein. The animals were housed in a facility with controlled atmosphere
(25◦ C) under 12-hour light:dark cycles, and had access to food and water ad libitum. The animals were euthanized by CO2 asphyxiation after 4 weeks of dietary
intervention. Blood was collected by cardiac puncture, and plasma was obtained by
centrifugation (2,000 x g for 30 min at 4◦ C). Total and HDL cholesterol were enzymatically quantified in the plasma samples. Livers were excised and immediately
frozen in liquid nitrogen. Total cholesterol, triglycerides, free cholesterol, esterified
cholesterol and phospholipids were measured in the livers. Cholesterol absorption was
quantified in fecal samples collected at week 3 with radiolabeled sterols, as previously
described (Schneider et al., 2000). The complete fecal output was collected during
week 4 and stored frozen (80◦ C). Fecal quantification of neutral sterols, bile acids,
cholesterol, dihydrocholesterol, coprostan-3-one and coprostan-3-ol was performed as
previously described (Rasmussen et al., 2006), and fecal samples were subjected to
DNA extraction.
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5.2.2

Characterization of the fecal microbiota

The gut microbiota was characterized in fecal samples of hamsters fed a control diet
(C) (n=7) or plant sterols esterified with stearic acid (SA) (n=9) and beef tallow (BT)
(n=6). DNA was extracted by a standard phenol-chloroform extraction method in
combination with enzymatic and mechanical cell lysis (Martı́nez et al., 2009). The
fecal microbial community was characterized by massive parallel sequencing of the
V2-V3 region of the 16S rRNA gene using the Roche Genome Sequencer GS-FLX (454
Life Sciences) (Martı́nez et al., 2009). The samples were sequenced with the forward
primer (A-338F) 5-gcctccctcgcgccatcagACTCCTACGGGAGGCAGCAG-3 and the
reverse primer (B-518R) 5-gccttgccagcccgctcagNNNNNNNNATTACCGCGGCTGCTGG-3 (with the A and B adaptors indicated in lower case, and an eight nucleotide
barcode shown as Ns).
The resulting sequences were quality controlled using the QIIME pipeline (Caporaso
et al., 2010). Sequences <150 bp or >350 bp in length were removed, as well as sequences containing one or more ambiguous nucleotides or mismatches to the primer or
barcode, sequences with a quality score below 25, and with homopolymer runs longer
than 6 bp. Chimera removal was performed using the Blast Fragments algorithm in
QIIME. An average of 1,700 sequences per sample were obtained after quality control.
Taxonomical characterization of the sequences was done with the Classifier tool from
the Ribosomal Database Project (RDP) (Wang et al., 2007), which classified the sequences from the phylum to the genus level. Additionally, an Operational Taxonomic
Unit (OTU) based approach with 97% sequence similarity cutoff at a lower taxonomic level. OTUs were generated by aligning the quality-controlled sequences with
the Infernal Alignment algorithm of RDP, followed by clustering with the Complete
Linkage Clustering tool of RDP. OTUs determined to be significantly affected by plant
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sterol consumption or associated with host physiological parameters were confirmed
using BLASTn. For this purpose, 5 representative sequences of the selected OTUs
were taxonomically assigned and aligned by ClustalW within their respective phylum. Phylogenetic trees were constructed for the sequences belonging to each phylum
with the Neighbor-joining algorithm and distance matrices were generated (MEGA
4.0) (Tamura et al., 2007). OTUs were re-assigned with sequences with >97% similarity, and consensus sequences were generated for each new OTU. The consensus
sequences were aligned in BioEdit (Hall, 1999) with the BLASTn algorithm against a
local database of the entire dataset containing the sequences generated in this study.
Sequences that showed >97% similarity and at least 95% overlap were considered to
belong to the OTU. UniFrac analysis was performed using the QIIME pipeline to
investigate the beta-diversity of the samples.

5.2.3

In vitro inhibition bacterial assays

Several bacterial strains originating from the mammalian gastrointestinal tract were
used to test the bacteriostatic effects of cholesterol, cholesteryl-linoleate, and the
PSE β-sitosteryl-stearate stigmastanyl-stearate when included incorporated into micelles and added to the medium. The bacteria used were: Bifidobacterium longum
subsp. infantis ATCC15697T (in MRS medium supplemented with 0.5 mg/L Lcysteine), Lactobacillus reuteri Lpuph-1 (in MRS medium), Eggerthella lenta ATCC
25559T (in MRS medium), Slackia heliotrinireducens ATCC 29202T, Collinsella intestinalis ATCC 13228T (in Peptone Yeast Glucose medium), two human isolates of
Collinsella aerofaciens KD-D8-5 and IM-D3-18 (in PYG medium), Clostridium histolyticum ATCC 19401T (in PYG medium). All media were pre-reduced for 24 h,
and cultures were grown at 37◦ C for 18 h under anaerobic conditions in a Bactron IV
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Anaerobic Chamber (Shel Lab).
Micelles containing cholesterol (¿98% purity, Sigma), cholesteryl-linoleate (¿99% purity Sigma), stigmastanol (>95% purity, Sigma) or PSE that were synthesized as
previously described (Brown et al., 2010b). Enough chloroform was used to solubilize
161 mg of cholesterol, cholesterol-linoleate, or PSE. Separately, chloroform was added
to 221 mg of lecithin until solubilization was reached. 48 µl of the sterol containing
solutions were mixed with 41 µl of the lecithin solution, after which the mixture was
flushed with nitrogen to remove the chloroform. The resulting mixture of lecithin
and sterols was suspended in 10 ml of a 1x10-6 mM solution of bile salt sodium taurocholate (>97% purity, Sigma) in distilled water. Then, sonication was performed
for 3-6 min with 30% amplitude using a Branson 450 Sonifier (Danbury, USA). The
resulting solutions were filter sterilized with 0.45 µm pore filters (Fisherbrand, Fisher
Scientific). Given the bactericidal/bacteriostatic capacity of bile acids, micelles containing bile acids but no sterols were used as control (Percy-Robb and Collee, 1972).
500 µl of pre-reduced micelle suspensions (control) were added to 500 µl of the prereduced double-concentrated (2X ) media. The mixtures were inoculated with 5 µl
of a 1:10 dilution of the bacterial cultures. Cultures were incubated in anaerobiosis
at 37◦ C for 12 h, and spectrophotometric optical density (OD) quantifications were
performed at 600 nm of wavelength (BioMate3, Thermo Scientific). The experiments
were preformed in triplicate.

5.2.4

Statistical analysis

The impact of the treatments on the microbiota was analyzed by one-way ANOVAs
and Tukeys post-hoc tests. Correlations between bacterial groups and physiological
measurements were assessed with Pearsons correlations and non-linear regressions.

222
The non-linear model used was the four-parameter sigmoidal inhibitory model commonly used to describe dose-response relations between bacteria and inhibitory compounds. The model is represented by equation (1) (Mouton et al., 2005, MacDougal,
2006), where X represents the metabolic parameter, Y the abundance of the bacterial
taxon, Yo and Ymax are the minimum and maximum effects, respectively EC50 is
the concentration where 50% of the maximum effect is measured, and the slope is the
sigmoidicity coefficient.

(1)

Y = Yo +

Ymax ∗ X slope
slope
EC50
+ X slope

The statistical analyses described above were performed using GraphPad Prism version 5.0 (GraphPad Software, USA). P<0.05 in the ANOVAs, and correlation coefficients r>0.60 (in absolute value) were considered significant. Results were expressed
as mean ± SD unless otherwise stated.

5.3
5.3.1

Results
Dietary supplementation with 5% plant sterols
induced substantial alterations of the fecal microbiota
of hamsters

454 pyrosequencing was used to characterize the fecal microbiota of hamsters fed a
control diet, or a diet supplemented with 5% plant sterols esterified with stearic acid
(SA) or beef tallow (BT). The inclusion of PSE in the diet, in particular SA, had
extensive effects on the fecal microbiota composition. UniFrac analysis revealed that
the fecal communities of hamsters fed the SA diet clustered separate from those of
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Figure 5.1: Alpha- and beta- diversity measurements of the fecal bacterial
communities. Principal coordinate analysis based on Unifrac distances, segregated
fecal microbial communities of hamsters fed plant sterols esterified with stearic acid
(blue) and beef tallow (red) from animals fed a control diet (green) (A). Shannon’s
diversity index (B). ∗ P<0.05.

the control group (Figure 5.1 A). Analysis of Shannon’s diversity coefficients revealed
that dietary addition of SA reduced the diversity of the fecal microbiota when compared to control (P<0.05), and that although not significant, BT had a tendency to
also decrease diversity (Figure 5.1 B).
Dietary PSE significantly modulated the gut microbiota at all taxonomic levels (Table
5.1). PSE had a dramatic effect on the abundance of the phylum Actinobacteria, and
especially on unclassified members of the family Coriobacteriaceae, which dropped to
negligible proportions when SA was fed and were strongly reduced in the BT group.
Several OTUs belonging to this family were reduced through PSE (Table 5.1, Supplementary Figure 5.6), with an OTU (OTU1) closely related to the species Eggerthella
lenta being the most numerical dominant.
SA induced a significant increase in the phylum Firmicutes, and the relative propor-
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Table 5.1: Abundance of fecal bacterial taxa of hamsters fed a control diet,
or diets enriched in plant sterol esters. The taxa presented were significantly
affected by plant sterols esterified with stearic acid (SA) or beef tallow (BT), or were
determined to be associated with host metabolic markers of the lipid metabolism

Phylum
Actinobacteria
Firmicutes
Family
Coriobacteriaceae
Eubacteriaceae
Genus
Unclassified
Coriobacteriaceae
Unclassified
Erysipelotrichaceae
Unclassified
Eubacteriaceae
OTUs
OTU1
(Eggerthella lenta 97%)
OTU2
(Gordonibacter pamelaeae 93%)
OTU4
(Slackia heliotrinireducens 97%)
OTU8
(Allobaculum stercoricanis 91%)
OTU9
(Allobaculum stercoricanis 86%)
OTU10
(Eubacterium cylindroides 87%)
OTU12
(Allobaculum stercoricanis 94%)
OTU13
(Eubacterium biforme 87%)
OTU15
(Clostridium sufflavum 90%)
OTU16
(Eubacterium limosum 93%)
a

P<0.05 compared to Control.
P<0.01 compared to Control.
c
P<0.001 compared to Control.
d
P<0.05 compared to BT.
e
P<0.01 compared to BT.
b

Control

SA

BT

ANOVA
P-value

16.55 ± 7.27
72.88 ± 5.50

3.24 ± 1.90c
85.07 ± 7.25bd

8.37 ± 5.04a
76.44 ± 4.90

0.0002
0.0025

11.63 ± 7.30
0.02 ± 0.05

0.88 ± 0.49c
10.85 ± 11.58ad

2.71 ± 2.32b
0.61 ± 1.32

0.0002
0.0156

11.57 ± 7.30

0.87 ± 0.49c

2.66 ± 2.27b

0.0002

1.08 ± 0.30a

0.66 ± 0.24

0.76 ± 0.40

0.0409

0.02 ± 0.05

10.85 ± 11.58ec

0.61 ± 1.32

<0.0001

6.98 ± 7.46

0.24 ± 0.31a

0.04 ± 0.07a

0.0078

2.05 ± 0.76

0.12 ± 0.10c

0.81 ± 1.19a

0.0002

1.22 ± 0.93

0.03 ± 0.10b

0.24 ± 0.30a

0.0011

6.56 ± 4.80

1.48 ± 2.24a

2.71 ± 2.51

0.0205

3.30 ± 3.19

0.15 ± 0.14b

0.31 ± 0.28a

0.0051

1.03 ± 1.00

0.08 ± 0.07a

0.28 ± 0.23

0.0125

3.14 ± 1.55

0.71 ± 0.86b

1.43 ± 1.08a

0.0021

0.52 ± 0.25

0.09 ± 0.09b

0.22 ± 0.40

0.0100

0.91 ± 0.67

0.20 ± 0.29a

0.29 ± 0.21a

0.0105

0.04 ± 0.06

8.55 ± 12.71

0.62 ± 1.49

0.0972
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tions of Actinobacteria and Firmicutes in the animals showed a strong negative correlation (r=-0.61, P<0.01), suggesting that the increase in Firmicutes induced through
PSE was at the expense of Actinobacteria. Members of the Eubacteriaceae family did
account for the increase in Firmicutes in the SA group (Table 5.1). However, these
shifts could not be traced to lower taxonomic levels, suggesting that several distinct
taxa increased at the genus and species level. Although total Firmicutes showed an
increase with SA, several OTUs belonging to this phylum did not follow the general trend and instead showed a significant decrease (OTUs 12, 13, and 15) (Table
5.1, Supplementary Figure 5.7). In additions, unclassified members of the Family
Erysipelotrichaceae were also reduced by both PSE.

5.3.2

Correlation analysis showed a highly interlinked
relationship between the microbiome and the host
lipidome

The feeding of PSE induced extensive changes in the lipid and cholesterol metabolism
of the hamsters (Rasmussen et al., 2006), and many of the individual metabolites were
highly interrelated with each other (Figure 5.2 A). One of the goals of the present
study was to investigate whether these effects were associated with specific bacterial groups in the gastrointestinal tract (GIT). Linear correlations and non-linear
regression models were used to explore these host-microbiota associations. This analysis revealed remarkable links between the microbiome and host metabolism at all
taxonomic levels (Figure 5.2 B). The tightest associations were observed within the
phylum Actionbacteria, and especially the family Coriobacteriaceae, which showed
remarkable associations with cholesterol absorption (r=0.75, P<0.0001), whole body
cholesterol synthesis (r=-0.75, P<0.0001), fecal biliary cholesterol excretion (r=-0.75,
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Figure 5.2: Associations among host markers of the lipid metabolism, and
with fecal bacterial populations. Heatmap displaying correlation coefficients
among markers of the host lipid metabolism (A), and between host lipid profile and
abundance of fecal bacterial populations (B). Pearson’s r correlation and the corresponding.

P<0.0001), liver free cholesterol (r=0.73, P<0.0001), plasma non-HDL cholesterol
(r=0.68, P=0.0005), and liver weight (r=0.82, P<0.0001), among others. Therefore,
this study confirmed the close associations between Coriobacteriaceae and plasma
non-HDL cholesterol and cholesterol absorption that were observed in our previous
study (Martı́nez et al., 2009), and identified additional connections between lipid
metabolism and this bacterial taxa. Several OTUs within the Coriobacteriaceae
shared the high associations observed for the whole family (Figure 5.2 B).
Total Firmicutes and unclassified Erysipelotrichaceae also displayed significant associ-
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ations with host lipidemic markers, although they were less pronounced than the ones
determined for the Coriobacteriaceae, with the exception of fecal total sterols, which
displayed a high negative associations with unclassified Erysipelotrichaceae (r=-0.88,
P<0.0001). Several OTUs classified as Firmicutes related to described species within
the genera Allobaculum, Eubacterium, and Clostridium (albeit with low 16S rRNA
homologies) showed significant associations with host lipid metabolism. Multivariate analysis also identified Allobaculum, Coriobacteriaceae and Eggerthella as the
fundamental bacterial groups linked to the cholesterol metabolism (P=0.06), and
determined cholesterol synthesis to be the main metabolic marker involved in this
association.

5.3.3

The data suggested that the improvements in the
host lipid metabolism were independent from the gut
microbiota

Coprostan-3-one, coprostan-3-ol and dihydrocholesterol are products of bacterial fermentation of cholesterol in the GIT, and are to a large degree excreted and could
therefore contribute to the reduction in host cholesterol levels (Schneider et al., 2000).
However, fecal concentrations of these cholesterol derivatives were not affected by
feeding PSE nor did they correlate with any of the host lipid metabolism markers
tested (Figure 5.2 A). In addition, the correlation analysis did not provide evidence
for an association between the coprostan-3-one, coprostan-3-ol, and dihydrocholesterol and specific bacterial members of the gut microbiota (Figure 5.2). These findings indicate that PSE induced shifts of the gut microbiome did not impact bacterial
cholesterol metabolites in the gastrointestinal lumen, nor was the bacterial action
on the cholesterol pool responsible for the improvements observed in the host lipid
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metabolism.

5.3.4

Associations between bacterial taxa and cholesterol
synthesis, fecal biliary cholesterol excretion, and fecal
total cholesterol excretion fit a mathematical model of
bacterial inhibition

Upon visual inspection of the correlation graphs between bacterial taxa with host
cholesterol synthesis and excretion, these negative interactions were clearly not linear
but rather had an exponential relationship. More importantly, these associations resembled the dose-response curves in microbial antibiotic assays. We therefore tested
how bacterial proportions and cholesterol synthesis/excretion fitted a four-parameter
sigmoid model for bacterial inhibition used to describe dose-response relations between bacteria and inhibitory compounds (Mouton et al., 2005, MacDougal, 2006).
Graphs presented in Figure5.3 display the host metabolite-microbial relationships
with the tightest associations, and reveal that the empirical data obtained in the
hamster experiments is an excellent fit to the inhibitory model. For example, the
associations between Coriobacteriaceae and host cholesterol synthesis, fecal biliary
cholesterol excretion, and fecal cholesterol excretion fitted the model with regression coefficients of R of -0.93, -0.87, and -0.91 respectively. The model was also an
excellent fit for the data obtained for OTU1, which is related to Eggerthella lenta.
Interestingly, the fecal proportions of OTU13 that was classified as a member of the
Firmicutes phylum also showed an association with an excellent fit to the model. The
fact that these bacterial taxa displayed associations to fecal cholesterol concentrations
in the feces that fit an inhibition model suggests a bactericidal/bacteriostatic role of
cholesterol excreted through the bile in hamsters.
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Figure 5.3: Inhibitory associations between fecal bacterial populations and
markers of host cholesterol metabolism. Four-parameter sigmoidal inhibitory
regressions between fecal abundance of Coriobacteriaceae with whole body cholesterol synthesis (A), fecal biliary cholesterol excretion (B), fecal cholesterol excretion
(C), between the proportions of OTU1 with whole body cholesterol synthesis (D),
fecal biliary cholesterol excretion (E), fecal cholesterol excretion (F), and between
the abundance of OTU13 with whole body cholesterol synthesis (G), fecal biliary
cholesterol excretion (H), fecal cholesterol excretion (I).
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5.3.5

Cholesteryl-linoleate but not PSE inhibit growth of
gut bacteria in vitro

To provide further insight into the associations between bacteria and cholesterol
metabolism, we determined the ability of cholesterol, cholesteryl-linoleate, stigmastanol and β-sitosterol to inhibit bacterial growth when included in micelles formed
with bile acids and lecithin which are natural components of micelles in the gut
(Mukhopadhyay and Maitra, 2004). We tested for the inhibition of seven strains of gut
bacteria belonging to the Actionbacteria and Firmicutes, as members of these phyla
were most affected in our animal experiments. Three bacteria out of the seven strains

Figure 5.4: In vitro inhibition of fecal bacterial isolates by sterols. Optical density difference between micelles containing cholesterol, cholesteryl-linoleate,
β-sitosterol, and stigmasterol compared to control micelles without sterols for the gut
bacterial isolates Lactobacillus reuteri (A), Collinsella aerofaciens (B), and Clostridium histolyticum (C).

tested were inhibited by micelles that contained cholesteryl-linoleate when compared
to control micelles with only lecithin and bile acid, Lactobacillus reuteri, Clostridium
histolyticum, and Collinsella aerofaciens (Figure 5.4). Growth of Lactobacillus reuteri
was also inhibited by micelles containing cholesterol. Most importantly, inclusion of
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PSE to the micelles had either no or only a minor inhibitory action.

5.4

Discussion

In this study, we characterized the interplay between the gut microbiota and cholesterol metabolism in hamsters that received plasma cholesterol-lowering PSE in order
to gain mechanistic information on cause and effect. The data revealed that the modifications of host cholesterol metabolism induced through PSE were tightly associated
with specific alterations of the gut microbiota over the entire taxonomic scale. The
strongest associations were identified between bacteria of the Coriobacteriaceae and
Erysipelotrichaceae and the host lipidome. Therefore, our findings are in accordance
with previous research that revealed connections between these bacterial families and
host metabolism in mice, hamsters, and humans (Claus et al., 2011, Zhang et al.,
2009, 2010). The study also confirmed our previous findings in hamsters fed grain
sorghum lipids (GSL), which also displayed strong positive and negative associations
between Coriobacteriaceae and plasma HDL-cholesterol levels and cholesterol absorption, respectively (Martı́nez et al., 2009). The strong associations between bacterial
taxa in the gut and the host lipidome are of significant interest to the field as they
suggest that bacteria impact host metabolism and could constitute potential pharmaceutical targets. However, this study provided evidence indicating that the shifts
in gut microbiota composition associated with host cholesterol metabolism are not
causal but a response to the latter.
Based on the data, modulations of the cholesterol metabolism by PSE are likely independent of the gut microbiome. The ability of PSE to preclude cholesterol is based on
physico-chemical interactions and bacteria have not been described as a contributing
factor for reduced cholesterol absorption (Trautwein et al., 2003). In addition, PSE
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has been reported to have an antimicrobial effect nor did they show inhibitory capacity in our in vitro assays. Therefore, it is unlikely that a direct antimicrobial effect
of PSE accounted for the significant alterations of the gut microbiota, especially the
drastic decrease of Coriabacteriaceae. The data also revealed that the fecal levels of
coprostan-3-one, coprostan-3-ol and dihydrocholesterol were not affected by dietary
PSE, and were not correlated to the metabolic improvements of the hamsters. In
contrast, fecal cholesterol showed highly significant associations with the improvements in the host lipid metabolism. Conversely, the data provided evidence that
suggest that changes in host cholesterol metabolism induced through dietary PSE
were the main drivers of the observed alteration of the gut microbiome composition.
The mechanisms in which it is envisioned that these associations happened are summarized in Figure 5.5. We propose that the intake of PSE decreased plasma and liver
cholesterol levels though an inhibition of both dietary and biliary cholesterol absorption, which consecutively increased fecal cholesterol excretion (Figure 5.5 A). In order
to maintain cholesterol homeostasis, the host compensated for the lower cholesterol
absorption by increasing cholesterol synthesis, which resulted in increased levels of
cholesterol excreted through the bile and feces. Enhanced biliary cholesterol excretion
into the intestinal lumen, together with decreased cholesterol absorption, resulted in
higher concentrations of free and esterified cholesterol in the gastrointestinal tract.
We propose that the antimicrobial action of these cholesterol derivatives inhibited
specific bacterial taxa in the gut, and thereby led to strong associations between the
gut microbiome and alterations of host metabolism (Figure 5.5 B).
There are several lines of evidence that support the model presented in Figure 5.
First, cholesterol and its derivatives have been shown to inhibit bacterial growth at
the epithelial linings of the nose and eye (Do et al., 2008, Marquart et al., 2007).
The in vitro assays performed in this study confirmed the antibacterial effect of
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Figure 5.5: Model depicting the impact of plant sterol esters on the host
lipid metabolism and on the gut microbiota. The inclusion of dietary plant
sterol esters (PSE) precludes the incorporation of cholesterol into the micelles in the
small intestine, lowering cholesterol absorption and increasing cholesterol excretion,
causing reductions of plasma non-HDL, liver weight and hepatic liver esterified cholesterol (A). The decreased cholesterol absorption is compensated by increased hepatic
cholesterol synthesis and biliary cholesterol excretion by the host. The higher concentrations of fecal cholesterol coupled with the inhibitory capacity of cholesterol result
in the decreased abundance of bacterial populations in the gastrointestinal tract,
including Coriobacteriaceae and unclassified Erysipelotrichaceae (B).

cholesteryl-linoleate on gut bacterial isolates. Although the observed inhibitory effect
by cholesteryl-linoleate in our experiments was not pronounced, in a highly competitive environment such as the GIT, this seemingly small inhibition could potentially
translate into a significant loss of fitness for the organism in the GIT.

Table 5.2: Correlations between proportions of bacterial taxa and
markers of lipid metabolism.

Whole

body

Cholesterol

Fecal
cholesterol

absorption

Fecal

Fecal

dihy-

coprostan-

drocholesterol

3-ol

excretion

choles-

Plasma

terol excretion
synthesis

(µ/day*
100g BW)

HDL

non-HDL

(µ/day*

BW)

BW)

100g

(mg/dl)

(mg/dl)

acid

excretion

cholesterol
(µ/day*100g

BW)
BW)

Plasma

total
excretion

(µ/day*100g
(µ/day* 100g

Bile
Plasma

(µ/day*

(mg/dl)

100g BW)

Phylum
Actinobacteria

r = 0.75

r = -0.69

r = -0.65

r = 0.01

r = -0.11

r = 0.68

r = 0.62

r = 0.67

r = 0.68

P<0.0001

P = 0.0003

P = 0.0010

P = 0.9347

P = 0.6226

P = 0.0005

P = 0.0022

P = 0.0006

P = 0.0005

r = -0.68

r = 0.43

r = 0.38

r = 0.05

r = -0.23

r = -0.59

r = -0.43

r = -0.61

r = -0.50

P = 0.0004

P = 0.0476

P = 0.0827

P = 0.8252

P = 0.3008

P = 0.0042

P = 0.0432

P = 0.0025

P = 0.0191

r = 0.75

r = -0.75

r = -0.68

r = -0.02

r = -0.22

r = 0.69

r = 0.64

r = 0.68

r = 0.70

P<0.0001

P<0.0001

P= 0.0005

P = 0.7268

P = 0.4956

P = 0.0004

P = 0.0012

P = 0.0005

P = 0.0003

r = -0.49

r = 0.57

r = 0.58

r = -0.41

r = -0.01

r = -0.40

r = -0.50

r = -0.35

r = -0.20

P = 0.0220

P = 0.0051

P = 0.0048

P = 0.0557

P = 0.9583

P = 0.0674

P = 0.0186

P = 0.1072

P = 0.3630

Unclassified

r = 0.50

r = -0.59

r = -0.59

r = 0.33

r = -0.03

r = 0.49

r = 0.54

r = 0.46

r = 0.26

Erysipelotrichaceae

P = 0.0169

P = 0.0038

P = 0.0040

P = 0.1284

P = 0.8969

P = 0.0196

P = 0.0089

P = 0.0308

P = 0.2348

Unclassified

r = -0.49

r = 0.58

r = 0.58

r = -0.41

r = -0.01

r = -0.40

r = -0.50

r = -0.35

r = -0.20

Eubacteriaceae

P = 0.0221

P = 0.0051

P = 0.0048

P = 0.0558

P = 0.9590

P = 0.0675

P = 0.0187

P = 0.1074

P = 0.3630

r =0.58

r = -0.64

r = -0.55

r = -0.23

r = -0.22

r = 0.54

r = 0.49

r = 0.53

r = 0.67

Firmicutes

Family
Coriobacteriaceae

Eubacteriaceae

Genus

OTUs
OTU1
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Whole

body

Cholesterol

Fecal
cholesterol

absorption

Fecal

dihy-

coprostan-

drocholesterol

3-ol

excretion

Plasma

(µmol/day*

excretion

100g BW)

(µmol/day*100g

(µmol/day*

BW)

100g BW)

HDL

non-HDL

(mg/dl)

(mg/dl)

acid

excretion
(µmol/day*

(mg/dl)

BW)
100g BW)

Plasma

cholesterol

(µmol/day*100g
(µmol/day*

Bile
Plasma

total

terol excretion
synthesis

(Eggerthella

Fecal
choles-

100g BW)

lenta
P = 0.0049

P = 0.0013

P = 0.0082

P = 0.3062

P = 0.3218

P = 0.1010

P = 0.0195

P = 0.0111

P = 0.0006

r = 0.73

r = -0.71

r = -0.72

r = 0.21

r = -0.19

r = 0.68

r = 0.63

r = 0.63

r = 0.64

P = 0.0001

P = 0.0002

P = 0.0002

P = 0.3565

P = 0.3885

P = 0.0005

P = 0.0016

P = 0.0006

P = 0.0013

r = 0.70

r = -0.62

r = -0.62

r = 0.13

r = 0.16

r = 0.71

r = 0.68

r = 0.70

r = 0.46

P = 0.0003

P = 0.0023

P = 0.0019

P = 0.5777

P = 0.4798

P = 0.0002

P = 0.0005

P = 0.0003

P = 0.0298

r = 0.59

r = -0.66

r = -0.67

r = 0.22

r = -0.20

r = 0.57

r = 0.59

r = 0.54

r = 0.54

P = 0.0040

P = 0.0008

P = 0.0007

P = 0.3216

P = 0.3829

P = 0.0058

P = 0.0040

P = 0.0090

P = 0.0088

r = 0.55

r = -0.52

r = -0.57

r = 0.20

r = 0.07

r = 0.55

r = 0.46

r = 0.56

r = 0.37

P = 0.0074

P = 0.0124

P = 0.0058

P = 0.3716

P = 0.7642

P = 0.0078

P = 0.0298

P = 0.0068

P = 0.0868

r = 0.63

r = -0.41

r = -0.50

r = 0.35

r = 0.32

r = 0.54

r = 0.64

r = 0.49

r = 0.22

P = 0.0017

P = 0.0600

P = 0.0168

P = 0.1084

P = 0.1480

P = 0.0094

P = 0.0014

P = 0.0199

P = 0.3193

r = 0.64

r = -0.68

r = -0.70

r = 0.20

r = -0.10

r = 0.65

r = 0.65

r = 0.63

r = 0.67

97%)
OTU2
(Gordonibacter
pamelaeae 93%)
OTU4
(Slackia

he-

liotrinireducens
97%)
OTU8
(Allobaculum

ster-

coricanis 91%)
OTU9
(Allobaculum

ster-

coricanis 86%)
OTU10
(Eubacterium cylindroides 87%)
OTU12
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Table 5.2 – continued from previous page
Whole

body

Cholesterol

Fecal
cholesterol

absorption

Fecal

dihy-

coprostan-

drocholesterol

3-ol

excretion

Plasma

(µmol/day*

excretion

100g BW)

(µmol/day*100g

(µmol/day*

BW)

100g BW)

HDL

non-HDL

(mg/dl)

(mg/dl)

acid

excretion
(µmol/day*

(mg/dl)

BW)
100g BW)

Plasma

cholesterol

(µmol/day*100g
(µmol/day*

Bile
Plasma

total

terol excretion
synthesis

(Allobaculum

Fecal
choles-

100g BW)

sterP = 0.0015

P = 0.0005

P = 0.0003

P = 0.3694

P = 0.6597

P = 0.0009

P = 0.0010

P = 0.0016

P = 0.0007

r = 0.59

r = -0.68

r = -0.65

r = 0.13

r = -0.38

r = 0.56

r = 0.53

r = 0.56

r = 0.64

P = 0.0040

P = 0.0005

P = 0.0010

P = 0.5682

P = 0.0773

P = 0.0062

P = 0.0118

P = 0.0072

P = 0.0015

r = 0.60

r = -0.62

r = -0.63

r = 0.20

r = -0.00

r = 0.63

r = 0.67

r = 0.59

r = 0.48

P = 0.0029

P = 0.0020

P = 0.0018

P = 0.3700

P = 0.9941

P = 0.0018

P = 0.0007

P = 0.0037

P = 0.0225

r = -0.40

r = 0.54

r = 0.53

r = -0.36

r = 0.04

r = -0.32

r = -0.42

r = -0.28

r = -0.08

P = 0.0684

P = 0.0090

P = 0.0117

P = 0.0959

P = 0.8672

P = 0.1487

P = 0.0546

P = 0.0210

P = 0.7318

coricanis 94%)
OTU13
(Eubacterium

bi-

forme 87%)
OTU15
(Clostridium

suf-

flavum 90%)
OTU16
(Eubacterium limosum 93%)
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Interestingly, although an antibacterial capacity of bile acids has been described
(Stacey and Webb, 1947) and their excretion is affected by dietary PSE (Rasmussen
et al., 2006), we determined only weak correlations between fecal bile acid concentration and bacterial groups (Supplementary Figure 5.3, despite rather high Pearson’s
r values presented in Table 5.2 and Supplementary Table 5.3). In contrast, we detected that the associations between several bacterial populations (Coriobacteriaceae,
three OTUs) with fecal biliary and cholesterol excretion showed a remarkable fit to
a mathematical model that describes dose-response relations between bacteria and
bactericidal compounds.
Although the results obtained might constitute an example of how host physiology
can impact the gut microbiota composition, other host-microbiome interactions have
been described in which a causative role of gut bacteria has been identified (Cani et al.,
2008, Bäckhed et al., 2007, Ley et al., 2005, Vijay-Kumar et al., 2010). In addition,
specific bacterial taxa have been determined to improve lipid markers in the host.
Bifidobacteria have been identified to alleviate dyslipidemia and high-fat-induced insulin resistance (Chen et al., 2011, Kondo et al., 2011, Yin et al., 2010). In addition,
combinations of probiotic lactobacilli and bifidobacteria strains have been determined
to increase plasma HDL in women (Kiessling et al., 2002, Sadrzadeh-Yeganeh et al.,
2010). Bifidobacteria had been determined to have a positive association to plasma
HDL in our previous hamster study (Martı́nez et al., 2009). However, this study
clearly suggests that interactions between the gut microbiota and host metabolism
are bi-directional.
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5.5

Conclusions

In this study we determined that PSE extensively impacted the gut microbiota composition without exhibiting antimicrobial activity. In addition, the almost perfect
fit of the associations between bacterial populations with fecal cholesterol concentrations to a mathematical model of bacterial inhibition suggest that host metabolism
can shape the gut microbiota composition. This study constitutes an important advancement of our understanding of the gut microbiome and its relation to the host,
as it identified cholesterol as an important host factor that impacts gut microbiota
composition and that might contribute to the maintenance of homeostasis in the
gut. The data further supported the notion that dysbiotic alterations of the gut microbiome associated with metabolic disease (Vijay-Kumar et al., 2010, Henao-Mejia
et al., 2012) or dietary patterns (Wu et al., 2011, Martı́nez et al., 2009) could be a
response of the metabolic phenotypes of the host. Based on the data obtained in
this study, we have to revisit our own hypothesis that Coriobacteriaceae might constitute a therapeutic target for the modulation of host cholesterol metabolism, as it
appears that this bacterial group is affected by cholesterol metabolism rather than
vice-versa. Research on the directionality of metabolic host-microbiota interactions,
such as presented here, can provide important mechanistic understanding necessary
to make informed strategies to prevent metabolic disorders by modulating the gut
microbiota.
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5.6

Supplementary materials
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Figure 5.6: Phylogenetic tree of constructed with the 16S rRNA gene tags
generated by pyrosequencing of OTUs belonging to the Coriobacteriaceae
family that were significantly affected by dietary plant sterol esters (PSE).
Representative sequences of each OTU were aligned with related type strain 16S
rRNA sequences to generate the phylogenetic tree. Consensus sequences were obtained from sequences with >97% similarity, and used as query sequences for local
blasts with a database for the tags obtained in the study. The graphs show the proportions of OTUs significantly affected by dietary PSE. ∗ P<0.05, ∗∗ P<0.01, ∗∗∗
P<0.001.
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Figure 5.7: Phylogenetic tree of constructed with the 16S rRNA gene tags
generated by pyrosequencing of OTUs belonging to the Eubacteriaceae
and Erysipelotrichaceae families that were significantly affected by dietary
plant sterol esters (PSE). Representative sequences of each OTU were aligned with
related type strain 16S rRNA sequences to generate the phylogenetic tree. Consensus
sequences were obtained from sequences with >97% similarity, and used as query
sequences for local blasts with a database for the tags obtained in the study. The
graphs show the proportions of OTUs significantly affected by dietary PSE. ∗ P<0.05,
∗∗ P<0.01.
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Figure 5.8: Associations between bile acid excretion and proportions of gut
bacterial populations. Correlations between bile acid excretion and the abundance
of Coriobacteriaceae (A), OTU1 (B), OTU4 (C), OTU13 (D), and OTU15 (E).

Table 5.3: Correlations between proportions of bacterial taxa and
markers of lipid metabolism.

Fecal
Plasma triglycerides (mg/dl)

biliary

cholesterol

ex-

cretion (µ/day*

Liver total

Liver

free

Liver esterified

cholesterol

cholesterol

cholesterol

(mg/g)

(mg/g)

(mg/g)

Liver

Liver

weight (g)

triglyc-

erides (mg/g)

100g BW)
Phylum
Actinobacteria

r = 0.69

r = -0.68

r = 0.87

r = 0.65

r = 0.70

r = 0.64

r = -0.31

P = 0.0004

P = 0.0005

P <0.0001

P = 0.0010

P = 0.0003

P = 0.0013

P = 0.1694

r = -0.59

r = 0.37

r = -0.62

r = -0.49

r = -0.50

r = -0.48

r = 0.42

P = 0.0039

P = 0.0884

P = 0.0023

P = 0.0208

P = 0.0173

P = 0.0225

P = 0.0498

r = 0.66

r = -0.75

r = 0.82

r = 0.66

r = 0.73

r = 0.65

r = -0.32

P = 0.0009

P <0.000

P <0.0001

P = 0.0009

P = 0.0001

P = 0.0012

P = 0.1440

r = -0.44

r = 0.52

r = -0.42

r = -0.37

r = -0.36

r = -0.37

r = 0.04

P = 0.0396

P = 0.0137

P = 0.522

P = 0.0867

P = 0.0983

P = 0.0928

P = 0.8463

Unclassified

r = 0.47

r = -0.55

r = 0.59

r = 0.49

r = 0.46

r = 0.49

r = -0.14

Erysipelotrichaceae

P = 0.0283

P = 0.0081

P = 0.0036

P = 0.0193

P = 0.0322

P = 0.0205

P = 0.5486

Unclassified

r = -0.44

r = 0.52

r = -0.42

r = -0.37

r = -0.36

r = -0.37

r = 0.04

Eubacteriaceae

P = 0.0397

P = 0.0137

P = 0.0524

P = 0.0869

P = 0.0985

P = 0.0930

P = 0.8479

OTU1

r = 0.51

r = -0.67

r = 0.69

r = 0.51

r = 0.63

r = 0.50

r = -0.21

(Eggerthella lenta 97%)

P = 0.0145

P = 0.0006

P = 0.0004

P = 0.0145

P = 0.0016

P = 0.0173

P = 0.3562

Firmicutes

Family
Coriobacteriaceae

Eubacteriaceae

Genus

OTUs
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Table 5.3 – continued from previous page
Fecal
Plasma triglycerides (mg/dl)

biliary

cholesterol

ex-

cretion (µ/day*

Liver total

Liver

free

Liver esterified

cholesterol

cholesterol

cholesterol

(mg/g)

(mg/g)

(mg/g)

Liver

Liver

weight (g)

triglyc-

erides (mg/g)

100g BW)
OTU2
(Gordonibacter

r = 0.66

r = -0.69

r = 0.81

r = 0.67

r = 0.64

r = 0.66

r = -0.33

P = 0.0009

P = 0.0004

P <0.0001

P = 0.0007

P = 0.0014

P = 0.0008

P = 0.1322

r = 0.62

r = -0.56

r = 0.69

r = 0.62

r = 0.81

r = 0.60

r = -0.19

P = 0.0022

P = 0.0064

P = 0.0004

P = 0.0022

P <0.0001

P = 0.0030

P = 0.3975

r = 0.60

r = -0.66

r = 0.69

r = 0.48

r = 0.72

r = 0.47

r = -0.08

P = 0.0031

P = 0.0008

P = 0.0003

P = 0.0261

P = 0.0002

P = 0.0285

P = 0.7224

r = 0.41

r = -0.49

r = 0.69

r = 0.78

r = 0.38

r = 0.79

r = -0.24

P = 0.0554

P = 0.0211

P = 0.0032

P <0.0001

P = 0.0830

P <0.0001

P = 0.2857

r = 0.39

r = -0.31

r = 0.60

r = 0.65

r = 0.39

r = 0.65

r = -0.13

P = 0.0738

P = 0.1564

P = 0.0116

P = 0.0011

P = 0.0718

P = 0.0010

P = 0.5566

r = 0.63

r = -0.69

r = 0.78

r = 0.60

r = 0.64

r = 0.59

r = -0.04

P = 0.0015

P = 0.0004

P <0.0001

P = 0.0030

P = 0.0013

P = 0.0037

P = 0.8442

r = 0.63

r = -0.70

r = 0.69

r = 0.56

r = 0.45

r = 0.55

r = -0.27

P = 0.0019

P = 0.0003

P = 0.0004

P = 0.0073

P = 0.0365

P = 0.0076

P = 0.2174

pame-

laeae 93%)
OTU4
(Slackia

heliotrinire-

ducens 97%)
OTU8
(Allobaculum stercoricanis 91%)
OTU9
(Allobaculum stercoricanis 86%)
OTU10
(Eubacterium

cylin-

droides 87%)
OTU12
(Allobaculum stercoricanis 94%)
OTU13
(Eubacterium

biforme

87%)
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Table 5.3 – continued from previous page
Fecal
Plasma triglycerides (mg/dl)

biliary

cholesterol

ex-

cretion (µ/day*

Liver total

Liver

free

Liver esterified

cholesterol

cholesterol

cholesterol

(mg/g)

(mg/g)

(mg/g)

Liver

Liver

weight (g)

triglyc-

erides (mg/g)

100g BW)
OTU15

r = 0.65

r = -0.60

r = 0.58

r = 0.57

r = 0.64

r = 0.56

r = -0.09

P = 0.0010

P = 0.0030

P = 0.0049

P = 0.0058

P = 0.0012

P = 0.0070

P = 0.6969

r = -0.35

r = 0.48

r = -0.27

r = -0.30

r = -0.34

r = -0.29

r = -0.01

P = 0.0118

P = 0.0241

P = 0.2166

P = 0.1759

P = 0.1254

P = 0.1876

P = 0.9743

(Clostridium sufflavum
90%)
OTU16
(Eubacterium
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Chapter 6
Discussion
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Diet has long been considered a major factor affecting host metabolism and a driver
of metabolic aberrations. The GM been recognized as a contributing factor to host
metabolism and metabolic aberrations. However, a large gap in knowledge exists in
terms of 1) which bacterial populations can be affected by dietary components in
humans, as most of our knowledge thus far stems from studies that used analytical
methods that target specific microorganisms, and mainly the effect of prebiotics was
investigated, 2) which bacterial populations can impact host metabolism, and 3)
the directionality of the associations between GM and health/disease. The studies
presented in this thesis address these issues. Human trials were conducted to assess
the impact of common dietary components on GM composition, resistant starches
and whole grains. Furthermore, links between the GM and metabolic markers in
humans were investigated. A series of animal experiments also helped us broaden our
understanding of the impact of diet on the GM and host metabolism in the context
of dyslipidemia, and allowed us to assess directionality between improvements in host
lipid metabolism and the GM.

6.1
6.1.1

Effect of diet on gut bacterial populations
The GM composition in humans can be extensively
altered by diet

The human trials conducted revealed that the GM composition can be substantially
altered by dietary non-digestible carbohydrates. Resistant starches and whole grains
induced GM modulations that encompassed bacterial populations from the phylum
to the species level. Numerically, the most significant compositional shifts were
prompted by the consumption of RS4, which in some subjects increased ten-fold the
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abundance of Bifidobacterium adolescentis, making it the most dominant bacterial
species during this dietary treatment for these subjects. Overall, whole grain intake
excerted milder modulations of gut bacterial populations than RS. The populations
most consistently affected by whole grains across the subjects were Eubacterium rectale and Blautia wexlerae.
The substrates investigated in these studies had differential outcomes in terms of community diversity within the host. Dietary incorporation of whole grains singificantly
increased the α-diversity of the gut ecosystem, while neither RS2 nor RS4 affected
α-diversity of the human GM. The distinct impact of the substrates on community
diversity is likely to be reflective of the food webs that these substrates generate
in the GIT. Fewer bacterial groups are likely to benefit from RS intake compared
to whole grains. First, whole grains contain a more diverse profile of non-digestible
compounds, which can potentially be degraded by a larger number of bacteria and
consequently increase diversity in the ecosystem. An alternative or complementary
possibility is that RS is more efficiently uptaken by its primary degraders, resulting
in a smaller amount of substrate available for cross-feeding, which would restrain
bacterial diversity in the GIT.
Although intake of dietary carbohydrates stimulates growth of members of the Firmicutes and reductions in Bacteroidetes (Duncan et al., 2008), the trials revealed that
these generalizations do not apply to all NDC. Intake of RS4 significantly increased
the abudance of Actinobacteria (through an increase in Bifidobacterium adolescentis)
and Bacteriodetes (mainly due to the expansion of Parabacteroides distasonis), while
significant reductions in the proportions of Firmicutes were observed. In the case of
the whole grain intervention, the increase in Firmicutes and decrease in Bacteroidetes
held true. However, in some subjects, large increases (over ten-fold) in Bacteroides
coprocola were detected.
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6.1.2

Why do we recurrently observe specific bacterial
groups being enriched by intake of non-digestible
carbohydrates?

Out of the 500-1,000 bacterial species associated with the human gastrointestinal
tract, certain species are recurrently determined to be affected by NDC. Such is the
case of bifidobacteria, Ruminococcaceae, and members of the Clostridium coccoidesEubacterium rectale group. Until recently, this could have been attributed to the
fact that taxa-specific analytical methods were used to investigate the impact of diet
on the GM (i.e.: culture, FISH, qRT-PCR). But even community-wide approaches
have determined proportions of these bacterial groups to be especially affected by
NDC intake (Abell et al., 2008, Walker et al., 2011, Davis et al., 2011). For example,
the bacteria mostly affected by RS and whole grains were Bifidobacterium adolescentis and Eubacterium rectale, respectively. Several explanations can account for
this. First, given the individuality of the human GM in terms of the member species,
changes in the abundance of ‘core’ members of the human gut microbiome are more
likely be detected when the overall effects of diet are analyzed in a population of
subjects. Both Bifidobacterium adolescentis and Eubacterium rectale have been identified as core species of the human gut microbiome. Although being a core species
is an important factor for an organism to be idientified as a ‘responder’ organism
across subjects, 60-90 gut bacterial species have been determined to be part of the
human core (Qin et al., 2010, Willing et al., 2010), which means other factors need
to be considered. A second determining factor could be the trophic level at which
the organism utilizes the substrate could potentially determine its chances of having
a significant increase in abundance. Only a subset of the species in the GIT are primary degraders of NDC (Stecher and Hardt, 2008, Ze et al., 2012), thus, if intake of
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the adequate substrate increases, it is easy to envision that this bacterial population
would expand. The impact of organisms themselves on the environment can lead to
new niches to develop. NDC utilization by primary degraders generates the release of
smaller carbohydrate units including mono- and disaccharides, which can be utilized
by secondary degraders. Because a larger number of bacteria can utilize these smaller
sized carbohydrates, the effect of the substrate becomes ‘diluted out’ at lower trophic
levels, and the abundance of these bacteria cannot be increased as easily. The same
concept is valid from the perspective of specialists and generalists. Ecological specialists have traded-off their competitive abilities in other niches to have increased fitness
in a particular niche (Kassen and Rainew, 2004). Thus, if the appropriate conditions
are met, specialists will thrive in the environment. Thus, if the right substrate is provided for a niche specialist, its population will most likely expand. On the contrary,
the fitness advantage of generalists resides on rapidly adapting to changing environmental conditions, making their populations resilient to temporal heterogeneity which
allows them to maintain more stable populations (Kassen and Rainew, 2004). The
presence of a particular substrate is not likely to induce important changes in the
population density of generalists.

6.2

Impact of diet on population dynamics

Diet induced changes in the gut microbiome were prompt, reversible and varied across
subjects.
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6.2.1

Dietary induced changes in the gut microbiota
composition occur fast and are reversible

The gut microbiota is characterized by a remarkable temporal stability (Franks et al.,
1998, Zoetendal et al., 1998). Nevertheless, the work described in this thesis and that
of other researchers has shown that GM composition in humans can be altered by
specific dietary strategies (Abell et al., 2008, Davis et al., 2011, Walker et al., 2011).
Based on our RS study, we knew that bacterial modulations can take place within
a week. In order to investigate the necessary time for dietary substrates to induce
changes in GM structure, two of the subjects that showed increases in Bifidobacterium
adolescentis in response to the RS4 treatment were followed up on a second trial in
which the same dose of RS4 (30 g) was consumed by the subjects for 10 days but
fecal sampling was performed every other instead of weekly. The results revealed
that shifts in the abundance of Bifidobacterium adolescentis occurred within 48 h
of the initiation of the treatment, indicating that bacteria can readily adapt to the
availability of the substrate in the environment (Figure 6.1).

6.2.2

Individual response to diet

Both human trials conducted revealed that modulation of the GM through diet varies
across subjects. Given that each human harbors a different collection of microbes,
this observation does not seem surprising, as in some cases the bacterium is simply
not present/detected in the subject. However, even when a species is detected, the
impact of a dietary substrate on the microbial population can be different. Several
factors could hamper the bacterial growth on a substrate: 1) the strain(s) present
in the individual do not have the enzymatic capacity to degrade the substrate, 2)
environmental conditions are not favorable for the utilization of the substrate by the
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Figure 6.1: Time-response in the increase in Bifidobacterium adolescentis
due to RS4 intake. Fecal samples from two subjects were collected every other
day during a 6-day baseline period, 10-day RS4 treatment period, and 8-day washout
period. Bifidobacterium spp. were quantified by qRT-PCR and the microbial community was profiled by DGGE.
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bacterium (i.e.: pH, limitation of other nutrients necessary for growth, etc.), or 3) the
bacterium relies on other bacteria for primary processing of the substrate and these
bacteria are not present or subjected to factors 1) or 2).
In vitro studies have indicated Bifidobacterium adolescentis is a primary degrader of
starch (McWilliam Leitch et al., 2007, Duncan et al., 2004). Therefore, it is likely
that the failure to expand this bacterial population in some subjects was due to the
enzymatic inability of the strain to utilize the substrate, or that the bacterium’s utilization of the substrate was limited by environmental factors (factors 1 and 2). In
the whole grain study, the hydrogenotrophic bacterium Blautia wexlerae was detected
in all of the subjects but enriched only in a subset of the population when WGB was
consumed. This species does not have the enzymatic capability to degrade β-glucans
itself but can use hexoses, H2 and CO2 to grow (Figure 1.1). Because Blautia spp.
is at lower trophic levels in the utilization of carbohydrates, unsuccessful enrichment
of this species is most likely to occur due to unfavorable environmental conditions,
or because microbial partners at higher trophic levels were unable to utilize the substrate.
Moreover, with approximately 160 bacterial species in an individual, there is high
competition for substrate utilization. The lack of success to stimulate a particular
bacterial species might also reside on other members of the GM being more competitive in substrate utilization, and depleting the substrate for the targeted GM
member.

6.3

Diet, health and the gut microbiome

As previously discussed, the gut microbiome is host specific, temporally stable, and
susceptible to host and environmental factors. At the same time, the gut microbiome
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and the environment affect host physiology, metabolism and the immune system (Figure 6.2). The GM has been identified as a causative factor of metabolic aberrancies in
the host (Cani et al., 2007, Bäckhed, 2011), which has prompted research to explore
how the GM can be modulated to improve host heath. One of the main goals of our
studies was to investigate how diet influenced changes in the GM composition and
host metabolism, and how these changes were interrelated.
In three of the studies presented in this thesis we had the opportunity to evaluate the associations of bacterial taxa and host metabolism. The data revealed that
dietary carbohydrates and lipids can significantly impact host metabolism. Remarkable correlations were observed between members of the families Coriobacteriaceae
and Erysipelotrichaceae with the host lipidome. Importantly, these associations have
also been determined by other researchers (Ravussin et al., 2012, Claus et al., 2011).
Moreover, we were able to determine that whole grain intake induced glycemic improvements and anti-inflammatory effects on the subject population, and that some
of these events were linked to changes in bacterial populations. From this study, we
could also conclude that the abundance of the family Ruminococcaceae is negatively
associated with several host inflammatory markers (IL-6,hs-CRP and LBP).

6.3.1

Directionality of the host-microbes interactions in
response to diet

The dietary lipid content has been shown to affect the GM in both humans and animals (Hildebrandt et al., 2009, Ravussin et al., 2012, Murphy et al., 2010, Ding et al.,
2010, Fava et al., 2012, Ley et al., 2006, Wu et al., 2011). However, because dietary
lipids induce changes in the hosts’ lipid metabolism, difficulties exist in differentiating
the effects of diet from the potential impact of host metabolism on the GM commu-
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Figure 6.2: Interactions between the host, microbiota and environment.
Diagram showing important environmental and factors affecting the gut microbiota
composition

nity. Recent research has concluded that it is mainly metabolic changes in the host
induced through a high fat diet that drive the observed bacterial dysbiosis (Ravussin
et al., 2012, Hildebrandt et al., 2009), however, other studies have determined that
it is the energy intake that shapes the GM (Murphy et al., 2010). Lack of clarity on
this issue arises due to the gap in knowledge of the mechanisms underlying the dietary fat-microbiome-host metabolism interactions. One of the main findings in this
thesis was the identification of cholesterol concentrations in the GIT as a potential
modulator of the GM through an inhibitory effect on bacterial populations.
In the human trial conducted, although directionality of the associations between
shifts in the microbiome and metabolic and inflammatory changes could not be determined, the GM alterations are likely to result from the increased NDC intake.
The bacterial taxa affected were determined to either have the enzymatic capability
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to degrade the substrates (i.e.: genes encoding for β-glucanase activity), or to feed
off by-products of bacterial fermentation of NDC.
Overall, our data suggests that while dietary non-digestible carbohydrates directly
modulate the gut microbial community dietary lipids shape the GM composition
mainly through their impact on host metabolism.

6.3.2

Manifestation of our metabolic and inflammatory
health status on the gut microbiome

The data obtained in these studies suggest that the abundance of certain bacterial
populations could be linked to the health status of the host. For instance, in both
hamsters experiments members of the Coriobacteriaceae and Erysipelotrichaceae families were associated with a dyslipidemic phenotype. Moreover, these bacterial taxa
have been recurrently identified to be altered in dyslipidemic animals or animals in
a high-fat diet (likely to have an aberrant lipid metabolism) (Claus et al., 2011,
Ravussin et al., 2012). In humans, an inverse link between the abundance of Ruminococcaceae and host inflammation was determined (measured by IL-6, LBP and
hs-CRP). Could these microbial patterns be a reflection of host health aberrancies?
Which begs another question: could altered bacterial populations serve as diagnostic
tools of metabolic disorders? Given that well characterized metabolic markers already
serve as good indicators of metabolic disease, altered bacterial patterns could be of
use if they could be observed prior to clinical manifestation of disease, a topic that
could be further investigated.
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6.4
6.4.1

Perspectives
Is our gut microbiome in permanent dysbiosis?

Dietary habits in Westernized societies greatly differ from those that we have evolved
to (Leach and Sobolik, 2010). Humans have transitioned from a diet high in legumes,
fruits, vegetables, nuts, and grains to consumption of highly refined processed foods
with little dietary fiber content. It is estimated that our hunter-gatherer ancestors
had a daily dietary fiber (including RS) intake of approximately 150-225 g, while today’s estimated dietary fiber intake ranges between 13-18 g/day (Dietary Reference
Intakes - USDA). Given the large effect of NDC in our gut microbiome, the marked
reduction in fermentable substrates is bound to affect our GM composition and community assembly. Is it possible that individuals living in Westernized societies are in
chronic dysbiosis? Differences in the GM between individuals from Westernized and
non-Westernized societies suggest this is the case (De Filippo et al., 2010, Wu et al.,
2011). Moreover, the two human trials conducted as part of this thesis used dietary
components that were greatly consumed by our ancestors, whole grains and resistant
starch (Leach and Sobolik, 2010). Their consumption led to pronounced alterations
in the GM of individuals, especially of Bifidobacteria and Eubacterium rectale. Bifidobacteria have been shown to possess anti-inflammatory capacity (Wang et al., 2011,
Gad et al., 2011, Fanning et al., 2012, Lyons et al., 2010), while Eubacterium rectale
produce butyrate in the GIT, also considered anti-inflammatory (Segain et al., 2000,
Russo et al., 2012). These observations lead us to speculate whether diet-host-microbe
interactions emerged during evolution to control inflammation.
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6.4.2

Predicting shifts in microbial composition in response
to dietary interventions

It is clear that the GM is a complex ecosystem, with a large number of members
that interact with each other, the host, and are further subjected to environmental
perturbations. In this elaborate scenario, is it realistic to predict the modulations
taking place in response to a dietary treatment?
Although researchers have been able to predict diet-induced shifts in the microbial
community structure based on the enzymatic carbohydrate utilization capacity of
organisms in simplified gnotobiotic animal models with controlled substrate supplies
(Sonnenburg et al., 2010), human trials such as ours have proved that the reality of
the gut ecosystem is too complex to allow accurate predictions to be made. Based
on our data, generalizations as to whether a certain substrate can impact a specific
gut bacterium cannot be made based solely on its enzymatic capability to degrade
the substrate. A clear example is the case of Bacteroides thetaiotaomicron, which
has the most ample repertoire of carbohydrate utilizing enzymes yet described in
a gut organism, many of which are involved in the adherence, hydrolization and
translocation of starch (Xu et al., 2003). Despite the prevalence of this organisms in
humans, in vivo studies have not reported increases in the abundance of this microbe
in dietary interventions with resistant starch (Abell et al., 2008, Walker et al., 2011).
Similar observations were drawn from in vivo human trials that analyzed the impact of
GOS on the GM (Davis et al., 2011) and in our own RS study here presented, despite
the known α-amylase activity of numerous gut bacteria (Salyers et al., 1977). These
observations reveal the need for human trials to genuinely understand the impact of
dietary strategies on the GM.
Moreover, the individuality of the GM in terms of composition and response to dietary
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interventions evidenced in these studies, indicate that generalizations as to the effect
of foods and food components cannot be accurately made across individuals. If a
specific bacterial population would be intended to be enriched in an individual, more
personalized approaches would prove more successful. For example, in vitro fecal
fermentations testing a panel of substrates could be performed to determine which
substrates can elicit the growth of a specific bacterial group, using fecal material from
that particular subject. Even this approach is not infallible, as in vitro conditions
cannot completely replicate the in vivo. Another strategy could consist of having the
individual undergo a series of dietary interventions with NDC and analyzing the GM
community to determine which substrates could have the desired impact.

6.5

Concluding remarks

The studies presented in this dissertation provided insight into the diet-microbe-host
interactions.
The use of community-wide deep sequencing techniques to characterize the GM enhanced our understanding of the effects of diet on the gut ecosystem in many regards:
1) the impact of diet on dozens of bacterial taxa and ecosytem diversity could be investigated, 2) knowledge was obtained on the interactions between bacterial members,
and among bacterial populations and host metabolism, and 3) individuality of the
response to diet and temporal dynamics could be studied.
Two human trials were conducted to evaluate the impact of different types of resistant starches (types 2 and 4) and of whole grains (brown rice and barley) on the
GM. These studies revealed individuality in the response of the subjects to the dietary treatments. Although several bacterial populations stimulated by these dietary
components were coherent across subjects, a high degree of variability was observed
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among individuals in terms of the magnitude of the changes introduced and the bacterial groups affected. The data from the human trials also enabled us to conclude that
changes in the gut microbiome composition were reversible and developed promptly
after treatment commencement.
Animal experiments in a hamster model of hypercholesterolemia provided the opportunity to evaluate the effects of dietary lipids on the GM and the host lipidome. Inclusion of grain sorghum lipid extracts and plant sterol esters greatly modulated the
GM community. Furthermore, remarkable correlations between GM compositional
shifts and host lipidome were revealed. Mathematical modeling of these interactions
suggested that some bacterial populations were inhibited by the cholesterol concentration in the GIT. Diet induced alterations in the cholesterol metabolism can therefore
shape GM composition.
In summary, these studies allowed us to conclude that while dietary non-digestible
carbohydrates are able to directly modulate the GM composition, it is likely that dietary lipids exert their effect on the GM community by affecting the host metabolism.
In particular, we determined that cholesterol concentrations in the GIT might constitute a potential mechanism by which host metabolism shapes the GM.

268

Bibliography
G.C. Abell, C.M. Cooke, C.N. Bennett, M.A. Conlon, and A.L. McOrist. Phylotypes
related to Ruminococcus bromii are abundant in the large bowel of humans and
increase in response to a diet high in resistant starch. FEMS Microbiol. Ecol., 66:
505–515, 2008.
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